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TREHALOSE-6-PHOSPHATE PHOSPHATASE 
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Boston University Graduate School of Arts and Sciences, 2019 
Major Professor: Karen Allen, Professor of Chemistry 
ABSTRACT 
Trehalose is a sugar commonly found in archaeon, bacteria, fungi, plants, and 
invertebrates. It is utilized as an energy source and upregulated during stress conditions 
such as thermal fluctuations and oxidative stress. As mammals do not synthesize trehalose, 
trehalose biosynthetic pathways have become therapeutic targets for infectious diseases. 
The enzyme trehalose-6-phosphate phosphatase (T6PP) catalyzes the dephosphorylation 
of trehalose 6-phosphate to form trehalose. In its absence, the viability and virulence of 
bacteria, fungi, plants and nematodes are decreased. Hence T6PP is the focus of this study 
as a target for therapeutics of the diseases tuberculosis and lymphatic filariasis.  
T6PP is a phosphohydrolase in the haloalkanoic acid dehalogenase superfamily. To 
identify the determinants for substrate specificity needed to guide structure-aided inhibitor 
design for therapeutics, atomic-resolution crystallographic information on the Michaelis 
complex is of great importance. Toward this goal, the structure of T6PP from 
Mycobacterium marinum was determined via X-ray crystallography in an unliganded form 
and the structure of T6PP from Salmonella typhimurium (St) was determined in the apo 
form, bound to the substrate analog, trehalose 6-phosphate, the product, trehalose, and the 
 vii 
inhibitor, 4-n-octylphenyl α-D-glucopyranoside 6-sulfate. The enzyme confers specificity 
via hydrogen bonding to the phosphate and glucosyl group proximal to the phosphate. 
Specifically, the conserved residues Glu123, Lys125 and Glu167 form hydrogen bonds to 
the hydroxyl groups of the proximal glucose. However, the distal glucose binding sub-site 
can tolerate new chemotypes.  
To further aid inhibitor design, the two inhibitors of Brugia malayi T6PP 
discovered via screening the Johns Hopkins library of FDA-approved drugs, 
Cephalosporin C and Closantel, were computationally docked into StT6PP. The 
Cephalosporin C scaffold was optimized to provide an inhibitor with a KI of 20 µM that 
comprises a 5,6-indole scaffold to afford hydrogen bonds to the Glu/Lys/Glu motif and a 
computationally discovered phosphate mimic tetrazole. Closantel acts as a slow-binding 
inhibitor and a series of analogs were synthesized to increase potency. Two analogs show 
enhanced efficacy relative to Closantel with IC50 values near 60 µM. Future efforts will 
aim to optimize these scaffolds for inhibition of T6PP to develop therapeutics for 
tuberculosis and lymphatic filariasis.  
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 THE IMPORTANCE OF TREHALOSE BIOSYNTHESIS AND USAGE IN 
MYCOBACTERIA, PATHOGENIC FUNGI, AND PARASITIC NEMATODES 
Abstract 
Trehalose is an 1,1-a-D-glucopyranosyl a-D-glucopyranoside commonly found in 
archaea, bacteria, fungi, plants, and invertebrates [1]. It can be utilized as an energy source 
and is upregulated during stress conditions such as thermal fluctuations and oxidative 
stress. In some organisms there are a number of trehalose biosynthesis pathways, others 
utilize only a single pathway; mammals do not synthesize trehalose [1]. Thus, trehalose 
pathways have become therapeutic targets for infectious diseases. In this Chapter, I will 
discuss trehalose biosynthetic production and utilization, as well as identify therapeutic 
targets for the infectious agents mycobacteria, fungi, and nematodes.  
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Figure 1.1: Biosynthesis and utilization of trehalose. Pathways in black are found in 
mycobacteria, fungi, and nematodes. Enzymes in blue are found only in mycobacteria, 
while those in red are found only in fungi.  
 
1.1. Mycobacteria 
Mycobacteriaceae is a family of actinobacteria that contains many pathogens 
causing human diseases such as tuberculosis (Mycobacterium tuberculosis), leprosy 
(Mycobacterium leprae), and aquarium granuloma (Mycobacterium marinum). Trehalose 
can be synthesized by up to three different pathways in mycobacteria. The disaccharide is 
utilized for energy, during stress conditions, and to generate virulence factors such as 
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mycolic acid. Virulence factors enable pathogens to colonize hosts and evade immune 
response. Inhibition of the trehalose pathway may prevent mycobacterial infection by 
decreasing virulence and stress tolerance.  
 
1.1.1 Trehalose Biosynthesis  
The three biosynthetic pathways of trehalose identified in mycobacteria are called 
OtsAB, TreYZ and TreS. Each is discussed in the following sections.  
 
OtsAB Pathway  
The osmoregulatory trehalose synthesis (OtsAB) pathway consists of the genes 
otsA and otsB [2] encoding trehalose-6-phosphate synthase (T6PS) and trehalose-6-
phosphate phosphatase (T6PP), respectively [3]. T6PS catalyzes the condensation of 
glucose 6-phosphate and UDP-glucose into trehalose 6-phosphate (T6P), followed by 
dephosphorylation to form trehalose catalyzed by T6PP. M. smegmatis (Ms), a common 
mycobacterial model, contains a single gene for otsA and otsB. However, M. tuberculosis 
(Mt) contains an otsA and two predicted otsB genes (otsB1 and otsB2) [4]. The amino-acid 
sequences from otsB1 and otsB2 are 25% similar, but the protein product of otsB1 does not 
display T6PP activity and its function remains unknown [5]. Therefore, it is unsurprising 
that gene knockout models of otsB1 result in the same phenotype as wild-type cells. 
Functional T6PP is encoded by otsB2 and gene knockout models prevent growth. So, the 
otsB2 gene product in Mt is responsible for T6PP activity [6].  
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TreYZ Pathway 
A second pathway converts the terminal a(1,4)-linkage of unbranched glycan 
polymers to a(1,1) linkages via maltooligosyltrehalose (MOT) synthase encoded by the 
treY gene (glycogen debranching is catalyzed by an a-amylase encoded by treX [7]). Next, 
the terminal disaccharide is cleaved by the MOT trehalohydrolase encoded by treZ to 
generate free trehalose [8–10]. MOT synthase and trehalohydrolase have been 
characterized in Rhizobium sp. and Arthrobacter sp. Although Mt, Ms, and M. leprae (Ml) 
contain genes homologous to treY and treZ, they remain uncharacterized in these organisms 
[4, 11]. Additionally, the Ml treY and treZ genes contain frameshifts and stop codons 
indicating they are pseudogenes [4].  
 
TreS Pathway 
Trehalose synthase (TreS) interconverts trehalose and maltose. TreS was originally 
thought to be part of a redundant trehalose synthesis pathway in Ms [11], but later MsTreS 
was shown to utilize trehalose or maltose as substrates with similar efficiencies (0.75 x 103 
and 2.4 x 10-3 M-1s-1, respectively), indicating the direction of isomerization is equilibrium 
controlled based on the concentration of trehalose and maltose [12]. When MtTreS is 
incubated with 10 mM trehalose or maltose, the in vitro equilibrium established by 
isomerization is 2.2:1 trehalose:maltose (equilibrium varies  slightly between Ms and Mt 
TreS). Additionally, overexpression of MtTreS decreases the concentration of cellular 
trehalose [13]. These results indicate that at equilibrium, the trehalose concentration is 
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substantially higher than that of maltose and therefore the biological function of 
mycobacterial TreS is degradation, not synthesis of trehalose.   
 
1.1.2 Trehalose Utilization 
Trehalose constitutes 1.5-3.5% of the dry weight of Ms cells during both 
logarithmic growth and stationary phases and it is rapidly utilized and remade [14]. The 
high concentrations and quick turnover of free trehalose, in addition to the redundant 
biosynthetic pathways, are consistent with the concept that trehalose is an important 
metabolite for mycobacterial survival.  
Trehalose is an osmolyte in archaeon, bacteria, fungi, and plants [15] which 
maintains fluid balance during stressful conditions such as heat, desiccation, or extreme 
cold. A trehalose knockout strain of Ms lacking the genes OtsA, TreY and TreS (MsTre-) is 
temperature sensitive; the cells are less viable when incubated at 18 °C and 43 °C. 
Additionally, growth of MsTre- cells is not rescued by the presence of trehalose in the 
growth media indicating endogenous trehalose synthesis is necessary for thermoprotection 
in mycobacteria [11]. Thus, trehalose is important for mycobacterial growth in stressful 
conditions such as a human host. Moreover, tuberculosis patients can contract latent 
tuberculosis which is caused by a small number of Mt cells surviving and replicating in the 
host, but not causing illness. The latent cells are under great stress by the host’s immune 
system and inhibiting trehalose production may provide a means to eliminate latent 
tuberculosis. However, additional work is necessary to understand if trehalose is required 
for the survival of these latent tuberculosis cells. 
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Trehalase is an enzyme that cleaves the glycosidic bond of trehalose generating two 
glucose molecules. Ms trehalase is phosphate and magnesium dependent and is highly 
specific for a,a-trehalose [16]. The glucose molecules produced from trehalose 
degradation are then used in glycolysis. Additionally, the isomerization of trehalose to 
maltose by TreS can be utilized in the biosynthesis of glucan which is initiated by the 
conversion of maltose to maltose 1-phosphate by GlgE. Glucans can be converted back to 
trehalose using the TreYZ pathway, or the terminal glucose can be cleaved to replenish 
glucose supplies [17].  
Lastly, trehalose is utilized in the generation of mycolic acid, a lipid in 
mycobacterial cell walls. Mycobacterial cell walls are thicker than typical bacterial walls. 
The majority of bacteria contain a peptidoglycan layer in the cell wall; mycobacterial cell 
walls have additional mycolic acid and polysaccharide layers. The mycolic acid layer is 
extremely hydrophobic and enables cording, a phenomenon in which mycobacteria grow 
end to end that enhances virulence of the bacteria. Trehalose is linked to a-alkyl b-
ketoacids with 60-90 carbon units by the enzyme polyketide synthase (Pks13). Then 
Corynebacterineae mycolate reductase A (CmrA) reduces the keto moiety forming 
trehalose monomycolate (TMM) which is then transported from the cytoplasm to the 
periplasm. In the periplasm, TMM can be converted to the cell-wall components 
mycolylarabinogalactan (mAG) or trehalose dimycolate (TDM, cord factor) by different 
subunits of antigen 85 complex (Ag85s). In either pathway, a trehalose molecule is released 
and transported to the cytoplasm by LpqY-SugA-SugB-SugC for recycling [17]. 
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1.1.3 Identifying Therapeutic Targets in Trehalose Biosynthesis for Tuberculosis 
The trehalose biosynthetic pathway has been shown to play crucial roles in the 
viability of mycobacteria under stress condition and for pathogenicity in mouse models [6]. 
Hence, interest has developed in preventing the formation of trehalose as a means to treat 
mycobacterial-borne infections. There have also been attempts to inhibit the usage of 
trehalose by targeting GlgE, Pks13, and CmrA, reviewed by Thanna and Sucheck [17]. 
Preventing the formation of trehalose is a more direct approach for therapeutic design and 
thus, I will discuss the evidence supporting targeting of trehalose biosynthesis enzymes to 
generate non-viable mycobacteria in human hosts. 
The Robertson lab identified three trehalose biosynthetic pathways in Mt [4] and 
determined that the OtsAB pathway was the dominant pathway. Murphy et al. generated 
Mt gene knock-out strains of otsA, otsB1, treY, and treS. The DotsB1, DtreY, and DtreS 
strains were phenotypically the same as wild-type with normal growth. The DotsA variant 
showed slow growth in media and agar plates, while DotsB2 variants could not be isolated. 
Disruption of the TreYZ and TreS pathways yielded no consequences to bacterial growth; 
therefore, the TreYZ and TreS pathways are not good targets for therapeutic intervention 
of tuberculosis. However, the disruption of the OtsAB pathway caused growth impairment 
of Mt, indicating trehalose is necessary for bacterial growth and that OtsAB is the dominant 
trehalose biosynthetic pathway [6].  
The OtsAB pathway, consisting of the enzymes T6PS and T6PP, may be a 
therapeutic target as the lack of T6PS not only stunted growth of Mt cells in media, it also 
prevented the growth of cells in mouse models. Mice infected with DotsA Mt survived for 
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10 months after infection, while the control group treated with wild-type Mt were dead in 
less than 6 months. Thus, without T6PS, Mt becomes non-virulent in a murine infection 
model and T6PS could provide a useful target to prevent the virulence of the tuberculosis 
pathogen [6].  
To ensure the non-viability of the DotsB Mt variant was caused by the lack of T6PP, 
Murphy et al. generated a diploid strain with two copies of otsB2. When the original coding 
region of otsB2 was subsequently removed, the resulting cells were viable [6]. Korte et al. 
confirmed this result using allelic exchange to knock-in a tetracycline-dependent promotor 
region upstream of otsB2. In the absence of tetracycline, otsB2 was silenced and the cells 
were not viable [18]. In mouse models, Mt with a silenced otsB2 gene were not able to 
establish an infection. However, if otsB2 silencing was induced after the infection was 
established (28 days), similar bacterial loads were seen in the lung and spleen as in wild-
type treated mice. The similar bacterial load could be due to inefficient silencing of the 
otsB2 in vivo. Furthermore, in vitro double knockout variants of DotsA/DotsB2, generate a 
viable, yet slow growing variant similar in phenotype to that of DotsA [18]. The DotsA and 
DotsA/DotsB2 knockout variants prevent the production of T6P and trehalose, while the 
DotsB2 knockout variant accumulates T6P and prevent trehalose synthesis. As the lack of 
trehalose in nonlethal, it can be concluded the toxicity in the otsB2 knockdown strain is 
cause by the accumulation of T6PP substrate, T6P. T6PP is a therapeutic target to decrease 
the viability of Mt.  
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1.2 Pathogenic Fungi 
Mycoses, cryptococcosis, candidiasis, and aspergillosis are fungal infections that 
cause illness in humans, especially in those with compromised immune systems. Trehalose 
supports life during sporulation and stressful conditions in fungi. Saccharomyces 
cerevisiae (Sc), has been used as a fungal model system to study trehalose-related systems.  
1.2.1 Trehalose Biosynthesis  
In fungal species, there is only one known trehalose biosynthetic pathway, the 
trehalose phosphate synthesis (TPS) pathway (equivalent to OtsAB in mycobacteria). This 
pathway encodes the enzymes T6PS and T6PP via the genes tps1 and tps2, respectively. 
Some fungi (e.g. Candida albicans (Ca), Cryptococcus neoformans, Aspergillus nidulans) 
have one copy of each gene, while others (A. fumigatus, A. niger) have two copies of tps1 
and one copy of tps2 [19]. In Sc, trehalose is produced in a complex containing T6PS, 
T6PP, and a regulatory enzyme encoded redundantly by TPS3 and TSL1 [20]. To date, a 
regulatory subunit in other organisms has not been confirmed indicating Sc may be a poor 
model for TPS pathway of pathogenic fungi.  
 
1.2.2 Trehalose Utilization in Fungi 
Trehalose can be used as an energy source and stress protection molecule in fungi. 
Spores of the mold Neurospora tetrasperma contain up to 10% dry weight trehalose [21] 
and quiescent Sc contain up to 20% trehalose [22]. These trehalose stores are rapidly 
depleted and used as an energy source during germination or entry into the growth cycle 
[1]. In fungi, there are two classes of trehalases that optimally cleave trehalose into two 
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glucose molecules at different acidities, neutral trehalase (NTH1 (also known as NTC1) 
and NTH2) and acid trehalase (ATH1 (also known as ATC1)) [23]. Neutral trehalase is 
found in the cytosol, while ATH1 is membrane bound [24] and catalyzes the cleavage of 
trehalose outside the cell wall to increase uptake of glucose [25].  
Sc stores glucose as trehalose in higher concentrations than glycogen [22]. Storing 
energy as trehalose during times of low cellular activity is advantageous due to the stress 
protection capabilities of trehalose. Trehalose stabilizes unfolded proteins preventing 
aggregation and allowing chaperones to assist refolding [26]. Heat-shock treatment of Sc 
causes an accumulation of trehalose (up to 0.5 M) indicating trehalose biosynthesis is 
upregulated during thermal stress [1]. Additionally, cells with increased concentrations of 
trehalose resulting from a 30 minute heat shock at 38 °C are able to survive exposure to 
oxygen radicals (H2O2/iron) 40% better than cells with basal trehalose levels [27].  
 
1.2.3 Identifying Therapeutic Targets in Trehalose Biosynthesis for Fungal Infections  
As described above, Sc is used as a fungal model where trehalose biosynthesis 
occurs in a complex containing T6PS, T6PP, and TPS3 (encoded by TPS3 or TSL1). 
Double knockout models of TPS3 and TSL1 reduce T6PS and T6PP activity by 5- and 6-
fold, respectively, causing a 60% decrease in trehalose production [20]. Although this 
binding protein enhances trehalose production, it is not a good therapeutic target as 
homologues have not been found in other species. Knockout models of tps1 in Sc abolish 
trehalose production [20], prevent growth using glucose as the carbon source (however, 
Dtps1 grows on galactose), and decrease sporulation [28]. The Dtps2 variants in Sc 
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accumulate T6P and are thermosensitive, lacking growth at temperatures above 34 °C [28]. 
The accumulated T6P can inhibit hexokinase with an inhibition constant (KI) of 40 µM 
[29]. Based on the data gathered for Sc, both T6PS and T6PP could be therapeutic targets 
to decrease the survivability of fungi in stress conditions. However, knockout models of 
tps1 and tps2 in other fungi show phenotypes different to variant Sc which could be due to 
the coupling of T6PS and T6PP activity in the trehalose biosynthetic complex (T6PS, 
T6PP, and TPS3), confirmed only in Sc. In A. niger and A. nidulans, lack of T6PS does not 
affect growth on glucose [28] and the mold remains virulent in a mouse model. In Ca, 
growth on glucose was temperature dependent (did not grow at 42 °C; normal growth 
temperature is 30 °C), but not on galactose or glycerol. However, this sensitivity decreased 
Ca infectivity in mice [30]. In Cryptococcus neoformans (Cn) and Cryptococcus gattii, 
Dtps1 strains have decreased growth at 37 °C and are not viable in a murine model [23]. 
These results indicate that T6PS may be a target for therapeutic intervention of fungal 
infections. However, studies must be undertaken in each fungal species to ensure inhibition 
of T6PS results in non-virulence.  
The Dtps2 variant in Ca, and A. nidulans resulted in the accumulation of T6P and 
a temperature-sensitive phenotype (with cell death at ~42 °C) [28]. This temperature 
sensitivity indicates the fungus may not grow at the body temperature of a human host. In 
fact, it has been shown in Ca and Af that Dtps2 variants are non-virulent in mouse models 
[23]. Prevention of T6PP function in all fungi studied to date causes a decrease in viability 
at human physiological temperatures, therefore T6PP is a possible therapeutic target.  
 12 
1.3 Parasitic Nematodes 
Parasitic nematodes cause a wide range of human diseases such as hookworm, river 
blindness and lymphatic filariasis. Additionally, many plant infections are caused by 
parasites which can lead to low crop yields and famine. Trehalose is implicated in 
embryogenesis and may be used as a blood sugar in nematodes. Therefore, the inhibition 
of trehalose biosynthesis has become of interest for antihelminthics. Caenorhabditis 
elegans (Ce) is often used as a non-pathogenic model to study nematodes.  
 
1.3.1 Trehalose Biosynthesis  
Like fungal species, nematodes only have one biosynthetic pathway for trehalose 
production. They utilize T6PS and T6PP to generate trehalose from glucose 6-phosphate 
and UDP-glucose. The enzymes in this pathway were characterized in the nematodes 
Aphelenchus avenae and Aacaris suum (As) by 1980 [31], but the genes encoding T6PS 
and T6PP were not identified until 2005. First, two putative T6PS genes (tps) were 
identified in Ce which aided in the identification of the homologous tps gene (single copy) 
in Brugia malayi (Bm) and Onchocerca volvulus (the causative agents for lymphatic 
filariasis and for river blindness, respectively). The T6PP gene was serendipitously 
discovered while investigating several genes that when mutated lead to gut obstruction in 
nematodes, arresting larval development at the L1 stage. Hence, the T6PP gene in 
nematodes is named gob-I (gut obstruction I) 
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1.3.2 Trehalose Utilization in Helminths 
Trehalose in nematodes is used as an energy storage and stress protectant molecule. 
Trehalose is found in high concentrations relative to glucose in the haemolymph of As 
indicating trehalose may be the primary circulatory sugar in nematodes [31]. During 
gradual desiccation, A. avenae, Ditylenchus dipsaci, and Anguina tritici increase trehalose 
stores. A. avenae converts glucose, glycogen and lipid reserves to trehalose and glycerol 
[31]. As shown in Heterorhabditis bacteriophora, entomopathogenic nematodes 
accumulate trehalose, increase T6PS and T6PP activity and decrease trehalase activity 
upon exposure to heat (35 °C) and cold (10 °C) [32]. These studies indicate trehalose 
stabilizes proteins and lipids membranes to aid survival during thermal fluctuations.  
Trehalose is found in concentrations of up to 0.5 M in the eggs of nematodes such 
as Ascaris, Globodera rostochiensis, Nematodirus battus, Heterodera schachtii, H. 
goettingiana and H. contortus. The majority of trehalose in ova is found in the zona 
pellucida, a protective layer at the cell membrane [31]. Prior to fertilization, the high levels 
of trehalose possibly help the cell survive osmotic stress, temperature changes, and 
desiccation. After fertilization, the trehalose stores are depleted for use as an energy source 
[31].  
 
1.3.3 From Enzyme to Target 
In Ce, RNA interference (RNAi) was used to prevent the transcription of the tps 
and gob-I genes. The tps knockdown variant does not cause a change in phenotype, 
indicating T6PS is not a target for therapeutics to treat lymphatic filariasis. However, 
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knockdown of gob-I, as previously mentioned, causes gut obstruction and death in larvae 
[33, 34]. Additionally, adult nematodes of Bm treated with siRNA of the gob-I gene for 48 
hours were 75% less viable and females produced 75% fewer microfilariae than control 
nematodes. The RNAi of the gob-I gene prevented normal embryogenesis and caused 68% 
of released microfilariae to die within 48 hours compared to 24% for untreated cells [35]. 
Due to the detrimental effects of silencing the gene encoding T6PP to all levels of nematode 
development, T6PP is a prime target to kill nematodes.  
 
1.4 Conclusions 
Trehalose is synthesized in numerous organisms that cause human illness. 
Although the number of biosynthetic pathways varies amongst the species, all domains of 
life include organisms that utilize the activity of T6PS and T6PP to generate trehalose. 
Gene knock-out models encoding T6PP impair or prevent viability of mycobacteria, fungi, 
and nematodes. Therefore, T6PP is a prime target for small-molecule inhibition to prevent 
pathologies such as tuberculosis, fungal infections, and lymphatic filariasis. 
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Abstract 
Phosphotransferases catalyze reactions on chemically diverse molecules in 
organisms from all domains of life. The haloalkanoate dehalogenase superfamily (HADSF) 
is a model system for phosphoryl transfer enzymes as members catalyze phosphoester 
hydrolase, phosphonate hydrolase, and phosphomutase reactions from sugars, lipids, 
nucleotides and peptides. Because these reactions are fundamental to essential metabolic 
transformations, understanding the mechanism and determinants of substrate specificity in 
the HADSF is critical. Structure/function relationships in the superfamily have also been 
leveraged in the development of methodologies for the assignment of enzyme function. 
Enzyme complexes with substrate, product, and analogs of the ground state or 
intermediate/transition state can be studied via high-resolution macromolecular 
crystallography to provide insight into the relative locations of residues and ligands, as well 
as associated enzyme conformational states. This knowledge can provide insight for 
inhibitor design of phosphohydrolase reactions and target-specific therapeutics. Here we 
describe experimental approaches to capture liganded X-ray crystallographic structures of 
HADSF members. A number of these methods can be employed generally, including for 
other families of phosphohydrolases and enzymes catalyzing phosphoryl transfer. 
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2.1 Introduction 
Phosphohydrolases are vital to the cellular processes of signal transduction, 
regulation, and primary and secondary metabolism. Hence, the enzymes that catalyze 
phosphohydrolase reactions are ubiquitous and catalyze phosphoryl transfer from 
chemically varied molecules including proteins, nucleotides, carbohydrates and lipids [1]. 
The necessity for Nature to have evolved such catalysts is underscored by the 
extraordinarily slow rate of uncatalyzed phosphate monoester hydrolysis at 2 x 10-20 s-1 [2]. 
Therefore, understanding the catalytic and chemical mechanisms of phosphoryl transfer is 
of significant interest. To lend mechanistic insight, a primary approach is the use of X-ray 
crystallography to visualize the Michaelis complex or its analogs (including product 
complexes) to provide the active-site residue positions relative to bound substrate. Insights 
from such “ground-state” complexes are often extended by obtaining 
intermediate/transition-state analog complexes to visualize interactions integral to 
catalysis. Using these approaches together with evaluation of steady-state kinetic constants 
and site-directed mutagenesis provides significant insight into the contribution of enzyme 
residues to chemical steps, to substrate binding, and to stabilization of the transition state. 
Additionally, identifying substrate specificity determinants can aid inhibitor design for 
therapeutics. Herein, we discuss the design and technical aspects of experiments to 
determine the liganded structures of phosphatases with substrate, substrate mimics, 
intermediate and transition-state analogs, products, and inhibitors.  
Throughout this chapter, the haloalkanoate dehalogenase superfamily (HADSF) 
will be used as a model system for phosphohydrolases. The HADSF is the largest family 
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of phosphatases, consisting of ~120,000 members from all domains of life and comprises 
mostly enzymes that perform reactions at phosphorus (99% of annotated members) [3, 4]. 
The many liganded structures deposited in the Protein Data Bank (PDB) (>114 unique 
liganded structures at the time of writing) make it an ideal superfamily for describing a 
variety of methods for obtaining enzyme-ligand complexes via crystallography. HADSF 
members are composed of a Rossmann-fold containing a core domain and an accessory 
cap domain, which closes onto the core completing the solvent excluded active site at the 
interface between cap and core (Figure 2.1a) [3]. The major cap types (C0, C1, C2a/C2b) 
are named for the location of the cap insertion into the Rossmann core domain and by the 
size and secondary structure topology of the domain. Irrespective of cap type, the active 
site is found at the interface of the core and cap domain. The cap domain and its dynamics 
with respect to the core typically determine substrate specificity/promiscuity [5, 6].  
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Figure 2.1. A. Ribbon diagram of the structure of trehalose phosphate phosphatase in the 
unliganded, open conformation (light grey) and in the substrate-bound, closed 
conformation (dark grey). Magnesium is shown as a pink sphere and substrate is shown as 
ball and stick. The active site loops 1-4 are colored as in panel b. B. The common active 
site of HADSF members. Note that the substrate specificity loop 5 is a simplification to 
denote one or more secondary structural elements that provide residues to bind the substrate 
leaving group. 
 
The mechanism of catalysis in the HADSF involves a divalent magnesium ion 
cofactor, nucleophilic aspartate (Dn), and a general acid/base aspartate located two residues 
toward the C-terminus in the primary structure (Dn+2) (Figure 2.1b). The reaction scheme, 
shown in Figure 2.2, proceeds through a trigonal bipyramidal phospho-enzyme 
intermediate/transition state [7–9]. The substrate undergoes a nucleophilic attack by 
aspartate, Dn, cleavage of the bond to the substrate leaving group, and formation of the 
phosphoaspartyl intermediate. The second half reaction comprises hydrolysis of the 
phosphoenzyme and regeneration of the nucleophilic aspartate, releasing inorganic 
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phosphate as a second product [10]. Each step along the reaction coordinate can be 
analyzed structurally via well-designed crystallographic studies. In this chapter, we 
describe methods to determine the structure of enzyme complexes revealing the ground-
state and transition-state geometries using substrates, substrate analogs, products, 
phosphoryl mimics, and inhibitors.  
 
Figure 2.2 General mechanism of HADSF members. 
  
Ligands can be introduced to proteins prior to crystal formation endogenously from 
ligands carried through purification, or exogenously introduced by co-crystallization. 
Alternatively, ligand addition after protein crystals have formed is accomplished via 
soaking. It is important to consider the benefits and drawbacks of each method for every 
protein system as the best approach may vary depending on the HADSF member. Co-
crystallization is advantageous when the protein requires a significant conformational 
change for productive ligand binding, which is common among HADSF members. Ligand 
binding with induced fit often leads to protein stabilization, which has the added benefit of 
promoting crystallization; however, co-crystallization often requires extensive 
optimization for each ligand. As soaking requires a pre-formed crystal, the crystal contacts 
must allow the protein to adopt a conformer amenable to ligand binding, and the ligand 
size (usually < 500 Daltons) must allow diffusion through the solvent channels to the 
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binding site. In general, soaking is enabled by the high solvent content in protein crystals 
(at present 86% of protein X-ray crystallographic structures in the PDB are 35-65% 
solvent). Thus, if the crystal lattice can adopt a productive conformer, and if ligands are 
small and soluble, then protein-ligand complexes can be determined via soaking without 
laborious optimization of the crystallization condition. Utilizing the soaking method can 
lead to rapidly obtaining structures of numerous enzyme-ligand complexes.   
In both soaking and co-crystallization methods, the concentration of the ligand must 
be optimized to have > 90% of the protein molecules bound as crystallographic electron 
density is obtained from averaging all molecules exposed to the X-ray source. We suggest 
a protein: ligand ratio of 1:1.2 to supply excess ligand while preventing non-specific ligand 
binding. Non-specific binding can cause heterogeneity, disrupt crystal contacts and prevent 
crystallization, or degrade crystal quality and lead to a decrease in resolution. Additionally, 
considerations for the binding affinity should be made to ensure homogeneity; the ligand 
concentration should ideally be at least 5-10 times greater than the dissociation constant 
(KD). Practically, the Michaelis constant (KM), inhibition constant (KI), and the half-
maximal inhibitory concentration (IC50) can be used as estimates for KD. Both soaking and 
co-crystallization approaches have proven successful for members of the HADSF. 
Considerations for experimental design, reagents, and methods are described in this 
Chapter.  
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2.2 Substrate and Product Complexes 
2.2.1 Substrate soaking 
Optimally, a crystal structure of the enzyme-substrate complex in the catalytically 
competent conformation with the residues aligned for catalysis (i.e. the Michaelis complex) 
is desired. Unfortunately, using standard single-crystal macromolecular X-ray 
crystallographic approaches, data collection is not rapid enough to capture this complex 
prior to catalysis. Therefore, catalysis occurs and the product(s) either diffuse out of the 
active site, leading to an unliganded structure, or remain bound resulting in determination 
of the enzyme-product complex. However, based on the equilibrium between substrate and 
product(s), the enzyme conformation, and the rate of turnover in crystallo, catalysis may 
not occur or occur on a time scale slow enough to trap the Michaelis complex. Hence, we 
suggest attempting to soak crystals with the substrate. The resulting data must be closely 
analyzed to determine which species is bound: the substrate, the product(s), buffers, salts, 
or precipitants from the crystallization milieu, solvent, or any combination thereof. The 
population of any one bound species must be greater than 10-20% of the ensemble 
(depending on the resolution and ligand motion), otherwise the corresponding electron 
density may be weak or unobservable [11]. The occupancies and B-factors of 
solvent/ligands are correlated at the resolutions commonly observed for protein complexes 
(< 2.5 Å) [12] and should be used to identify bound species. If multiple species are bound, 
all ligands should be modeled and B-factors and occupancies refined for appropriate 
interpretation of the data (for an example of refinement of multiple species Kyle M. Stiers 
and Lesa J. Beamer [13]). 
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Alternative to the soaking with substrate alone, shifting the equilibrium towards 
substrate by the addition of products can prevent catalysis. This approach was applied in 
determining the complex of D-glycero-D-manno-heptose-1,7-bisphosphate phosphatase 
(GmhB) from Escherichia coli (Ec) with D-glycero-D-manno-heptose 1,7-bisphosphate 
(PDB ID: 3L8G). The crystals were soaked with a 1:1 ratio of substrate to product, shifting 
the equilibrium towards bound substrate [14].  
An additional aspect in substrate soaking exists in that flexible enzymes may 
crystallize in a conformation that is not catalytically competent. In the HADSF, the cap 
domain must close over the core, providing a solvent exclusive environment and 
maintaining electrostatic control of the active site, to promote catalysis [15–18]. Thus, if 
the enzyme crystallizes in the cap open conformer, soaked substrate may bind to either the 
core or cap domain alone precluding identification of all binding and catalytic 
determinants, as has been seen with Mycobacterium tuberculosis (Mt) trehalose-6-
phosphate phosphatase (T6PP)  [19] and Homo sapiens (Hs) phosphomannomutase 1 
(PMM1) (PDB ID: 2FUE)  [20]. As the MtT6PP structure shows interactions of the 
substrate with only the core domain, interaction with catalytic residues (Dn and Dn+2) and a 
subset of substrate-binding determinants (for the most part those involved in binding the 
phosphoryl group) can be identified. In contrast, D-mannose 1-phosphate is bound solely 
by residues of the cap domain of HsPMM1, and therefore, only interactions with the 
substrate leaving group are identified.  
In the MtT6PP and HsPMM1 examples, the crystal contacts preclude large 
conformational change necessary for reach the transition state. However, it is possible that 
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even in a domain-domain closed conformation, small, but necessary, changes to reach the 
transition state are prevented by decreased mobility in the crystalline form, causing the 
catalytic rate of the enzyme to be lower than that of enzyme in solution. For example, the 
turnover rate (kcat) of aldolase is two times slower in crystallo than in solution [21]. Thus, 
a short soak (1 - 5 minutes) prior to flash freezing could yield a substrate-bound structure 
for an enzyme that is slow (kcat < 1 s-1) with a natural substrate or a poor substrate (kcat/KM 
< 103 M-1s-1). The success of a quick soak depends on three characteristics of the crystalline 
enzyme: the viscosity of the mother liquor, the crystal morphology, and the kcat of the 
enzyme. The viscosity of the mother liquor determines the diffusion rate of the ligand. For 
example, a system with a viscous mother liquor or soaking solution and a larger ligand will 
have a slower diffusion rate. The crystal morphology also determines the rate at which a 
ligand fully diffuses into a crystal. Small, thin crystals (plates, microcrystals, etc.) with 
high surface to volume ratios equilibrate with the substrate faster than large, thick crystals 
(cubic, pyramidal, etc.). This rate has been estimated in our laboratory empirically by 
measuring the time for a Coomassie-based or other dye (e.g. Izit Dye (Hampton Research)) 
to color the crystal. Alternatively, the time for diffusion into the crystal can be calculated 
using the binding affinity of the ligand for the enzyme and physical and chemical properties 
of the protein crystal and ligand [22]. Initial ligand-soaking experiments can be planned 
using the estimated rate for guidance. Experimental trial and error is necessary to optimize 
the amount of time the substrate is soaked with the crystal. Once the crystal is cryo-cooled, 
it is assumed that the catalytic reaction is terminated.  
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A structure of the Michaelis complex may be obtained by simply soaking a pre-
formed crystal with substrate. But, one must consider the species present at equilibrium, 
the conformation of enzyme in crystallo and soaking time. Section 2.2 provides 
experimental procedures for ligand soaking.  
 
2.2.2 Ligand soaking experiments  
 
2.2.2.1 Equipment 
§ Crystal trays (i.e. 24 well Hampton Research VDX plate) 
§ Siliconized cover slips (Hampton Research) 
§ Stereo-Microscope (eg: Olympus SZX12) 
§ CryoLoopsä (Hampton Research) 
 
2.2.2.2 Buffers and reagents 
§ Pre-grown crystals (> 0.7 mm on a side tend to be more fragile than smaller 
crystals) 
§ Components of crystallization solution 
§ Ligand stock solution (as concentrated as allowed by solubility) 
§ Cryo-protectant  
 
2.2.2.3 Procedure 
1. Select crystals for soaking. 
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2. Create a soaking solution of mother liquor with at least a 5-20% increase in 
precipitant (i.e. polyethylene glycol (PEG), ammonium sulfate, etc.) and ligand of 
interest at a concentration such that a final molar ratio of 1.2:1 ligand: protein (using 
the total concentration of protein in the drop) or 10 x KD is reached (whichever is 
larger).  
3. Carefully transfer crystals from original drop to soaking drop using a loop large 
enough to allow for collection of multiple crystals (if applicable), seal the well, 
observe under a microscope for any immediate crystal cracking/decay. Visible 
signs of crystal decay include crystal dissolution, precipitation, phase separation, 
and crystal cracking. Occasionally, crystals will appear solid, but upon disturbance, 
they crack and dissolve. Additionally, crystals may lose diffraction upon soaking. 
4. Allow for crystal to equilibrate (soak) in ligand-containing drop prior to 
cryoprotection and cryocooling for data collection.    
 
2.2.2.4 Notes and examples 
§ The soaking drop size can vary between 2-20 μL and is generally larger than the 
crystallization drop. We prefer a 5 μL soaking drop (increased with respect to a 
typical 2 μL crystallization drop). One advantage to a larger drop is that it will not 
dry out as quickly under the microscope during manipulation for crystal mounting.   
§ The suggested concentration of ligand for soaking is a minimum and greater 
concentrations may be necessary and should be empirically determined. 
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§ Initial soak time is typically determined as described in section 2.1 then optimized 
via trial and error depending on resulting diffraction quality and achievement of the 
desired bound complex. 
§ If possible, it is best to introduce the cryo-protectant in the soaking solution to 
decrease the number of crystal transfers and damage to the crystal. This can be 
accomplished by adding glycerol, ethylene glycol, or other cryo-protectants to the 
mother liqueur solution [23]. 
§ To shift the equilibrium towards bound substrate Nguyen and colleagues added 
product to a soaking solution (e.g. the GmhB structure (see section 2.1)) [14]. In 
this case the crystal was transferred to a drop of well solution containing an 
additional 5% PEG3350 and equal concentrations of substrate and product (30 μM).  
 
2.2.3 Mutation of the catalytic residue(s) 
Point mutations are utilized in crystallography to decrease surface entropy, add 
crystal contacts, and introduce residues necessary for experimental phasing [24–26]. 
Mutating an amino acid essential to enzyme catalysis but not to substrate affinity oblates 
activity but generates a substrate-binding protein. In the HADSF, the Dn is often mutated 
to obtain substrate-bound crystal structures [17, 27–29]. Point mutations have varying 
effects on the production, stability and crystallization of the resulting protein. Mutating 
residues on the solvent-exposed surface of the protein may disrupt or promote crystal 
contacts, while changing amino acids on the protein interior can affect the structural 
stability. It has been shown that replacing a polar residue with a non-polar equivalent in 
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the enzyme active site can stabilize the protein [30] and consequently lead to higher quality 
crystals and enhanced resolution. As the active site of the HADSF is at the cap-core 
interface, the residues can be either solvent exposed or solvent excluded. Therefore, 
mutations at the active site can shift the equilibrium between the open and closed 
conformers.  
Taking into account these considerations, a conservative mutation of an active site 
residues is recommended; for instance, a mutation of the nucleophilic Asp (Dn) to Asn has 
most commonly resulted in stabilization of the Michaelis complex for HADSF members 
[17, 27, 28]. Even with this conservative approach, results from mutation of the active site 
have varied. For instance, in the structure determination of Mus musculus (Mmus) cytosolic 
5¢(3¢)-deoxyribonucleosidase (cdN), the nucleophilic Asp (Dn) to Asn mutation had little 
effect on the stability of the enzyme (PDB IDs: 2JAR, 2JAO) [27]. Variant protein was 
expressed, purified, and crystallized under the same conditions as wild type, and then 
simply soaked with substrate. However, co-crystallization of the Dn11N variant of 
Methanocaldococcus jannaschii (Mj) phosphoserine phosphatase (PSP) with 
phosphoserine (PDB ID: 1L7P) required optimization of the crystal conditions [17]. After 
success determining the structure of wild-type Candida albicans (Ca) T6PP bound to a 
substrate analog (PDB ID: 5DXI), co-crystallization of the Dn559N variant with substrate 
yielded no crystals. A structure with substrate bound was instead determined for the 
Dn704N variant of T6PP from Cryptococcus neoformans (Cn) (PDB ID: 5DX9) [28].  
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Although Asp (Dn) to Asn mutation has proven successful for HADSF enzymes, a 
different tactic was taken in the case of Bacillus cereus (Bc) phosphonatase, where the 
nucleophilic Asp was mutated to Ala. Whereas the wild-type structure was determined to 
3.0 Å resolution (PDB ID: 1FEZ) [31], this mutation afforded an unliganded structure with 
increased resolution (2.3 Å) (PDB ID: 1SWV), as well as a substrate-bound 
(phosphonoacetaldehyde) structure refined to a resolution of 2.55 Å (PDB ID: 1SWW) 
[29]. It should be noted that the absence of the Dn side chain in this position caused the 
substrate phosphoryl group to move into the position usually occupied by the aspartyl 
carboxylate. 
 
2.2.4 Exchange metals  
In phosphoryl transfer reactions the magnesium ion acts to stabilize both the leaving 
group of the substrate and the oxygens of the phosphoryl group in the transition state [32] 
and indeed, HADSF members that catalyze phosphoryl transfer have an absolute 
requirement for a divalent magnesium ion cofactor. Thus, when magnesium ion is replaced 
with another divalent metal, activity is either abolished as is the case with calcium ion or 
significantly decreased as is the case for cobalt ion and some other period 4 elements [33]. 
In systems with metal dependent catalysis, it is possible to exchange the metal to prevent 
turnover and capture substrate-bound structures. Furthermore, in the HADSF, the catalytic 
magnesium ion is not typically essential for proper folding and stability, so it may be 
removed altogether.  
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One method to allow for calcium or cobalt ion binding in place of magnesium ion 
is simply to increase the concentration of the alternative divalent metal chloride in the 
mother liquor solution, as is the case in HsPSP (PDB ID: 1NNL) [33]. The Ca2+-substituted 
structure of HsPSP provides evidence that the loss of activity with calcium ion is due to 
the differing coordinate bonds between the calcium and magnesium ions. The calcium ion 
prevents the placement of phosphoserine in a catalytically competent orientation [33]. The 
structure of Haemophilus influenza (Hi) 3-deoxy-D-manno-octusonate 8-phosphate 
phosphatase (KDO8PP) was determined with cobalt ion in place of magnesium ion by 
omitting magnesium from the crystallization buffer and adding 10 mM cobalt (II) chloride 
to the drop solution (PDB ID: 1K1E) [34]. Although these metal swaps were not performed 
to obtain substrate-bound structures, the procedures show a valid means of replacing the 
catalytic magnesium with an alternative divalent metal.  
Substrate-bound structures may also be determined by removing the magnesium 
from the active site, by chelation via soaking of the crystal in ethylenediaminetetraacetic 
acid (EDTA) and substrate. This is exemplified by the structure of Synechocystis sp PCC 
6803 (Ss) sucrose phosphatase (SPP) with substrate. Sucrose 6-phosphate (Suc-6-P), was 
bound (PDB ID: 1U2T) in an orientation that is consistent with a Michaelis complex, but 
electron density consistent with that of a water molecule was observed in the binding site 
for the magnesium cofactor. Thus, in the absence of magnesium, it is expected that water 
binds in the metal-binding site, affording hydrogen bonds in place of coordinate bonds to 
the phosphoryl group of the substrate. Notably, SsSPP crystals grown under the same 
condition and soaked in a solution containing Suc-6-P (no EDTA), allows for turnover in 
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crystallo of substrate and produces a structure of SPP with sucrose and phosphate bound 
(PDB ID: 1TJ5) [35]. This confirms that removal of magnesium via chelation by EDTA in 
crystallo may not destroy the crystal but can prohibit turnover, enabling comparison of 
substrate and product complexes using the same crystal form.  
The necessity of the metal cofactor should be considered as it varies substantially 
in the HADSF. In some members, such as Bc phosphonatase, the protein is destabilized 
and unfolds upon magnesium removal  [29]. In contrast, Salmonella typhimurium (St) 
T6PP has a low affinity for magnesium; soaking with 50 mM magnesium chloride prior to 
cryo-cooling does not provide full occupancy of the magnesium ion in the active site 
(unpublished observation). Lastly, magnesium salts prevent the crystallization of Mmus 
magnesium-dependent phosphatase-1 (MDP-1). Even soaking crystals in magnesium alone 
did not allow for cofactor binding. However, MmusMDP-1 crystals grown in the absence 
of magnesium and then soaked in a solution containing both sodium tungstate (as a 
phosphate analog) and magnesium resulted in full occupancy of the magnesium- and 
phosphate- binding sites (PDB ID: 1U7P)  [36]. The tungstate itself, provides one 
coordinate bond to aid in completion of the magnesium ion coordination sphere, 
synergizing tungstate and magnesium-ion binding.  
The metal cofactor of the HADSF may be removed or replaced by another divalent 
metal before or after crystallization to generate a non-catalytic enzyme. As the affinity for 
the magnesium ion and the necessity of the magnesium ion for protein structure is different 
for each member of the superfamily, perturbation of the ion will have varied effects on 
enzyme structure and ion binding.  
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2.2.5 Phosphate Binding 
The location, coordination state, and geometry of phosphate in the active site of 
phosphatases act as a both substrate-bound and product-bound complexes. Oftentimes, 
structures containing phosphate are a result of in-crystal hydrolysis of soaked substrate. In 
the case of Bordetelia bronchiseptica (Bb) GmhB and EcGmhB, the alternate substrates 
imidodiphosphate and fructose-1,6-bisphosphate were soaked in crystals for five minutes 
prior to cryo-cooling. The ligand density in both structures clearly shows only phosphate 
bound in the phosphoryl transfer site of the active site (PDB IDs: 3L8F & 3L8H, 
respectively) [14].  
As phosphate is such a common precipitant in crystallization buffers, it is possible 
for phosphate to co-crystallize with the enzyme. This is observed in the structure of MjPSP 
(PDB ID: 1L7M) with phosphate bound [17]. In this case, phosphate was not separately 
added to the protein or soaked into the crystal but the crystallization conditions included 
0.5 M sodium phosphate dihydrate. These phosphate-bound structures corroborate the 
location of the phosphoryl binding site and provide details about coordinate bonds to 
magnesium. The position of phosphate can also act as a valuable “anchor” for 
computational positioning of substrates and phosphoryl- or phosphoryl mimic- bearing 
ligands via superposition.  
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2.3. Ground-state, Intermediate, and Transition-state Mimic Complexes  
Using structural information of the Michaelis complex, transition state mimics, and 
intermediates, the overall mechanism of catalysis and determinants of ligand binding can 
be better understood to guide efforts in rational inhibitor design as therapeutics and as 
probes in chemical biology. In phosphatases, this is typically accomplished using 
phosphate analogs to mimic either the ground state (tetrahedral geometry) or transition 
state (trigonal bipyramidal geometry) (Figure 2.3). Vanadate and tungstate, the most 
commonly used phosphate analogs, may adopt either the tetrahedral or trigonal 
bipyramidal geometries, because they are flexible in the number of coordinate bonds in 
which they participate [37]. Orthovanadate (VO43-) and orthotungstate (WO42-) are 
tetrahedral and mimic the ground state geometry. In HADSF members, the ground state 
species include the substrate-bound, product-bound and phospho-enzyme complexes. We 
include the phospho-enzyme as a ground state because of its relative stability, varying 
between family members but exemplified by the fact that the phospho-enzyme can be 
isolated [38]). Metavanadate (VO3-), in the absence of additional coordinate bonds from 
the enzyme or waters, is trigonal planar. Pentacoordinate forms of tungstate and vanadate 
exhibit trigonal bipyramidal geometries, mimicking the transition state, and can include 
coordinate bonds donated by substrate, water and/or oxygen from the nucleophilic 
aspartate, Dn [8, 39–41]. As pentacoordinated tungstate is less frequently observed in 
complex with phosphatases [8, 42] than vanadate, the versatility in coordinate-bond 
formation makes vanadate most appealing for mimicking transition-state geometry [37]. 
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Sulfate and some metal fluoride complexes, such as aluminum trifluoride (AlF3) and 
beryllium trifluoride (BeF3-), mimic the ground state geometries; therefore, when added 
together with the leaving group they can simulate enzyme-substrate complexes [41, 43, 44] 
Notably BeF3- with one coordinate bond from Dn resembles the phosphoenzyme. In 
following sections, we describe how the use of phosphate mimics in the presence and 
absence of the leaving group product can serve as ground-state, intermediate and transition-
state complex analogs for phosphatases in the HADSF. 
 
Figure 2.3 Transition state and ground state geometries as represented by 4HGO(A), 
1J97(B), 2RB5(C), and 2RAV(D). A. The trigonal bipyramidal transition state mimic. The 
apical positions are occupied by the oxygens of KDN and Dn. B. BeF3, forming a coordinate 
bond with Dn acts as a mimic of the phosphoaspartyl intermediate. C. A trigonal 
bipyramidal geometry formed with tungstate with the apical positions occupied by Dn and 
a water molecule illustrating the second half reaction, hydrolysis of the phosphoaspartyl 
intermediate. D. Tungstate bound structure in a tetrahedral geometry. Dn is not coordinated 
to the tungstate, showing the product bound complex. Magnesium ion is shown as pink 
sphere, and water molecules as red spheres. Dn+210A denotes a point mutation of aspartate 
to alanine. 
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2.3.1 Intermediate bound complexes 
In the example of Lactococcus lactis (Ll) β-phosphoglucomutase (β-PGM), Lahiri 
et al. were able to successfully observe the pentavalent bisphosphorane intermediate (PDB 
ID:1O03 & 1O08). This was accomplished through equilibration of crystals with 
magnesium and either glucose 1-phosphate (Glc-1-P) or glucose 6-phosphate (Glc-6-P) 
[7]. In mutases, isomerases, and racemases (enzymes with a single substrate and single 
product), equilibration of a crystal or co-crystallization with either substrate or product at 
concentrations greater than the KM, results in observation of the species that predominates 
at equilibrium [45]. The structure clearly shows the apical groups belonging to the 
nucleophilic oxygen of aspartate - Dn8 and the oxygen of the substrate leaving group [7]. 
By gaining insight into intermediate-bound structures, such as the bisphosphorane, one can 
discern important contributions to catalysis. For instance, the position of the Dn+2 that forms 
a hydrogen bond to the bridging oxygen in this structure supported its identification as the 
general acid-base and highlighted the change in conformation the residues undergo 
between the intermediate/transition state and unliganded structures. This conformational 
change is a key component of the mechanism by which the enzyme discriminates between 
substrate hexose sugar and water, allowing mutase over phosphatase activity [46].   
 
2.3.2 Ground-state mimic complexes 
Phosphoryl mimics in the absence of additional ligands in the active site resemble 
the ground-state, by taking on a tetrahedral geometry. Structures with tetrahedral 
phosphoryl mimics (any discussed in section   
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2.3. Ground-state, Intermediate, and Transition-state Mimic Complexes) can aid in 
the identification of binding determinants for the phosphate moiety.  
For the four HADSF sulfate-bound structures deposited in the PDB at the time of 
writing, in all cases the sulfate ligand was introduced from the crystallization milieu 
(examples: PDB IDs: 3R4C, 3QUB, 3QUC, and 1YMQ). These structures allow for 
identification of the phosphoryl-binding site and the relative placement of catalytic 
residues.  
The fluoro phosphoryl mimics, such as beryllium fluorides, are exemplified in 
structures of MjPSP [43] and calcium ATPase from Oryctolagus cuniculus (Oc) (PDB ID: 
2ZBE) [41, 44]. Cho et al. observed BeF3- complex formation using 1H-15N FHSQC spectra 
to identify the necessary ratios of sodium fluoride, beryllium chloride, and magnesium 
chloride to form BeF3-. Sodium fluoride, beryllium chloride, and magnesium chloride at 54 
mM, 10.8 mM and 90 mM, respectively, were added to MjPSP prior to crystallization. In 
the resulting MjPSP structure (PDB ID: 1J97), there is an oxygen-beryllium bond (1.55 Å) 
observed with the oxygen of the nucleophilic aspartate (Dn11) completing the tetrahedral 
geometry and mimicking the phosphoenzyme [43].  
The Oc calcium ATPase bound to tetrafluoromagnesate (MgF42-) (PDB ID: 1WPG) 
mimics the phosphate bound product complex with the MgF42- species exhibiting 
tetrahedral geometry [41]. This geometry affords insight into the conformation of enzyme 
during the second half-reaction prior to product release.   
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2.3.3 Transition-state mimic complexes 
As described in section 3, the choice of phosphate mimic can dictate whether the 
ground-state (tetrahedral) or transition-state (trigonal bipyramidal) geometry is captured. 
Using tungstate or vanadate as the phosphoryl mimic is advantageous in obtaining a 
transition-state-like complex as they can make more than four coordinate bonds. Structures 
of the bacterial homologs, Bacteriodes thetaiotaomicron (Bt) 2-keto-3-deoxy-D-glycero-
D-galacto-nononate 9-phosphate phosphatase (KDN9PP) (PDB ID: 4HGO) and 
HiKDO8PP (PDB ID: 4HGP), in the presence of vanadate and product 2-keto-3-deoxy-D-
glycero-D-galacto-nononic acid (KDN) or 3-deoxy-D-manno-octulosonic acid (KDO), 
respectively, adopt transition-state-like geometry through vanadium participating in five 
coordinate bonds. The equatorial positions are occupied by three oxygens coordinated to 
vanadium, and the carboxylate of the nucleophilic aspartate and the C9O (KDN) or C8O 
(KDO) of the substrate are in the apical positions, completing the trigonal bipyramidal 
geometry. This complex mimics the first step of phosphoryl transfer, in which the 
nucleophilic aspartate attacks the phosphoryl group of the substrate and provides further 
evidence of an in-line, backside displacement mechanism [39].  
Notably, several crystals of BtKDN9PP grown in a condition containing sodium 
acetate did not yield liganded structures. In these structures, acetate binds in the subsite of 
the active site where the carboxylate moiety of the sialic acid leaving group of the substrate 
would bind. This problem was circumvented by soaking the crystals in a solution 
containing the ligands of interest with an increased concentration of PEG (5%) in the 
absence of acetate. This allowed for the ligand of interest, in this case an alternate substrate, 
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5-N-acetyl-β-D-neuraminate (Neu5Ac), and vanadate, to outcompete any bound or 
remaining acetate, yielding a transition-state complex structure (PDB ID: 3E81)  [40].  
In the case of Bt hexose-phosphate phosphatase (BT4131), the trigonal bipyramidal 
geometry was observed in a structure with tungstate bound (PDB ID: 2RB5) as well as 
with vanadate bound (PDB ID: 2RBK). Three W-O coordinate bonds are in the equatorial 
positions, and the apical positions are occupied by the fourth W-O coordinate bond and the 
carboxylate oxygen of Dn8. Additionally, the apical oxygen is hydrogen bonding with the 
carboxylate of Dn+210. This structure mimics the transition state of phosphoenzyme 
hydrolysis - the second half-reaction of phosphoryl transfer. The same pentacoordinate 
geometry is assumed by vanadate in the BT4131 active site; these structures support the 
role of the enzyme active site in stabilizing this geometry along the normal reaction 
coordinate.   
Notably, in a structure of a variant of BT4131 with the Dn+210 replaced by alanine, 
VO3- is bound as a tetravalent complex with the Dn8 supplying the fourth coordinate bond 
(PDB ID: 2RAR). This complex displays distorted tetrahedral geometry in which the bond 
angles to the non-bridging oxygens are close to 90° (the VO3- moiety is close to planar) 
and the tetravalent Dn8-vanadate adduct is a mimic of the aspartylphosphate intermediate 
and not the pentavalent trigonal-bipyramidal transition state. This tetrahedral geometry 
illustrates the importance of the Dn+2 in observing the trigonal-bipyramidal geometry, 
further supporting the general base mechanism of phosphoryl transfer in the HADSF [8].  
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Toyoshima et al. generated AlFx, ADP,– Oc calcium ATPase complexes by co-
crystallizing with ADP and adding aluminum (III) chloride and sodium fluoride directly to 
the mother liquor prior to crystallization (PDB ID: 2ZBD). It was not possible to identify 
from the electron density whether AlF3 or AlF42- was present in the structure  [41]. 
However, it is obvious that aluminum forms at least 6 coordinate bonds:  the three (or four) 
equatorial positions are fulfilled by the fluoride ions, with carboxylate of Dn8 in one of the 
apical positions and an oxygen from ADP in the second apical position. The AlFx displays 
a trigonal (or tetragonal) bipyramidal geometry resembling the transition state [41].  
Whether the reaction mechanism is elimination-addition (dissociative), addition-
elimination (associative) or concerted, the intermediate/ transition state takes on a trigonal 
bipyramidal geometry. Any transition-state/ intermediate analog should mimic that 
geometry. Previously, it has been noted that although the complexes of HADSF members 
with AlFx and VO43- provide evidence for the trigonal bipyramidal geometry of the 
transition state, they do not rigorously test the ability of the enzyme active site to play a 
role in the formation and stabilization of the trigonal bipyramidal complex [8]. Tungstate 
provides a better probe as pentavalent trigonal bipyramidal geometry is rare for tungstate 
in the active site of phosphotransferases [8, 42, 47]. Notably, in the case of BT4131, 
comparison of the structure of the enzyme-tungstate complex reveals the same pentavalent 
trigonal bipyramidal geometry and stabilizing hydrogen-bond interactions as are observed 
for the vanadate complex. In BT4131, the ~130-fold lower affinity of tungstate to vanadate 
is considered to reflect the amount of binding energy required to stabilize this higher 
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valency state of tungstate [8]. But the extent to which any of these complexes mimic the 
transition state cannot be determined solely by crystallographic structure determination or 
binding affinity to wild-type enzyme. Instead, the relationship between catalytic activity 
and affinity for a series of site-directed variants has been used to show mimicry of the 
transition state. Indeed, such correlations show that vanadate is not a true transition-state 
analog for protein-tyrosine phosphatase [48], and that tungstate is a mimic for the transition 
state properties of alkaline phosphatase [42]. 
These complex structures together provide evidence useful for defining the 
catalytic and chemical mechanism of phosphohydrolase and phosphomutase activity of 
HADSF members. Coordination of the nucleophilic aspartate and the leaving group to 
vanadium completes the trigonal-bipyramidal geometry and allows visualization of the 
transition-state analog complex of the first half reaction. Coordination of the nucleophilic 
aspartate and water to vanadium or tungsten allows visualization of the transition-state 
analog complex of the second half reaction. Rational inhibitor design should take 
advantage of the hydrogen bonds formed to the equatorial oxygens and oxygens bridging 
to the leaving group as these are expected to be optimized in the transition state.  
 
2.3.4 Activation of sodium orthovanadate 
The activation of vanadate for use in forming ground state or transition state analogs 
in kinetics is essential to preventing the polymerization into decavanadate polyanion. 
Sections 3.4.1-3.4.4 describe our method for activation of sodium orthovanadate at pH 10 
to be used for crystallization purposes.  
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2.3.4.1 Equipment 
§ pH probe, calibrated 
§ hot/stir plate 
§ 3.4.2 Buffers and reagents 
§ 6 M hydrochloric acid 
§ 10 M sodium hydroxide 
§ sodium orthovanadate (CAS 13721-39-6)  
 
2.3.4.3 Procedure 
1. Add sodium orthovanadate (3.6782 g) to Millipore water (20.0 mL, half final 
volume) in a heat-resistant container (eg. a 100 mL pyrex bottle).  
2. Add 6 M hydrochloric acid to reach pH 10 in 100-200 μL aliquots (solution will 
turn yellow with addition of acid due to the formation of decavanadic acid).  
3. Cover container with aluminum foil and boil on a hot/stir-plate until colorless (~15 
minutes). Then, cool to room temperature. 
4. Measure pH and add either 6 M hydrochloric acid or 10 M sodium hydroxide until 
the solution reaches pH 10. 
5. Repeat steps 3-4 until the pH stabilizes at pH 10. 
6. Add Millipore water to achieve the desired final volume (40 mL). 
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2.3.4.4 Notes 
§ Detailed protocol is for making a 40 mL, 500 mM sodium orthovanadate stock 
solution. 
§ 250-500 mM stocks are ideal for minimizing volume change due to the addition of 
ligand. 
§ For a 40 mL solution, add acid/base in roughly 200-500 μL aliquots. 
§ Aliquots of ~1.5 mL in Eppendorf tubes can be stored at -20°C. Samples may 
withstand 2-3 freeze-thaws. If solution is no longer colorless (begins to turn 
yellow), then the sample should be discarded.  
  
 47 
2.4. Inhibitors 
2.4.1 Substrate mimics as inhibitors 
Another means of obtaining information about the residues comprising the 
substrate-binding site in phosphatases is to utilize a non-hydrolyzable substrate mimic. 
Because phosphoryl transfer is not possible, these molecules are likely to compete for the 
active-site, and as such, affinity can be found through measurement of KI. One option is to 
use the sulfonate- or sulfate-substituted version of the phospho-substrate. Trehalose 6-
sulfate is a 180 μM inhibitor of StT6PP  [49] and was used to mimic the Michaelis complex. 
This approach was utilized for Bc phosphonoacetaldehyde hydrolase, as well (see 
phosphonoacetaldehyde hydrolase-vinyl sulfonate complex, PDB ID: 1RQL)  [50]. 
Alternatively, for phosphatases, substituting the substrate phosphate group with a 
phosphonate group removes the leaving group and prevents turnover. For HsPSP, the 
inhibitor 2-amino-3-phosphonopropionic acid which lacks the bridging oxygen to 
phosphorous, was used as a substrate mimic with an IC50 of 1.4 mM (PDB ID: 1L8L) [51]. 
The leaving group of the substrate can be used to study the binding determinants of 
substrate binding. However, in the HADSF, in general, the leaving group does not bind 
tightly. Therefore, inhibitors that resemble only parts of the original substrate can be used. 
For sugar phosphatases, other sugars can be used as inhibitors. For instance, structures of 
SsSPP were determined with the inhibitory disaccharides cellobiose, maltose, and 
trehalose, which have poor affinity with KI values of 101, 100, and 26 mM, respectively 
(PDB IDs: 2BIR, 2D2V, and 2BIQ) [52]. Additionally, α-galactose-1-phosphate (Gal-1-
P) acts as a substrate mimic of the phosphorylated enzyme or a 30 μM inhibitor of Llβ-
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PGM. Gal-1-P was co-crystallized with Llβ-PGM to reveal structural insight into the 
overall mechanism of catalysis (PDB ID: 1Z4O) [53].  
Fortunately, most mimics of phosphatase substrates will be polar and therefore 
soluble in water. However, the ultimate goal of many projects is small molecule drug 
design that requires molecules to permeate the cell membrane. Cell permeable drugs are 
not highly polar and rarely charged  [55]; thus, they often have limited solubility in water. 
As crystallization requires high concentrations of protein (generally ~300 µM), high 
concentrations of inhibitors in crystallization buffer are necessary to achieve equimolar 
solutions. In Section 2.4.2, we describe methods to test protein and crystal stability in the 
presence of solvents and inhibitors and strategies to increase stability, if necessary.  
 
2.4.2 Protein and crystal stability in the presence of inhibitors/solvents 
 
2.4.2.1 Determining protein stability 
 
2.4.2.1.1 Equipment 
§ White PCR strips or plates 
§ Real-time Thermocycler 
 
2.4.2.1.2 Buffers and reagents 
§ Solvents of interest 
§ Protein (10 µL of 20 µM per sample) 
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§ SYPRO® Orange Protein Dye (5,000 x; Thermo-Fisher catalog number S-6650). 
2.4.2.1.3 Procedure 
1. Prepare solvent of interest in protein buffer. Example: Prepare 2.5, 5, 10 and 20% 
dimethyl sulfoxide (DMSO) solutions in buffer containing HEPES pH 7.0 and 50 
mM NaCl. Add 10 µL of solvent mix to a well in a white PCR plate. Repeat for 
each solvent and concentration to be tested. Use 10 µL of protein buffer as a control.  
2. Add SYPRO® Orange dye to 20 µM protein solution at 1:500 dilution.  
3. Add 10 µL protein with SYPRO® Orange dye to each solvent mix.  
4. Cover wells with clear plastic.  
5. Record the fluorescence at 520 nm while temperature is increased from 20 to 95 at 
1 °C per minute.  
6. Analyze data: Raw data will show an increase in fluorescence as the protein unfolds 
and the SYPRO® Orange dye binds to exposed hydrophobic residues. The inverted 
derivative of the fluorescence signal will result in peaks corresponding to the 
melting temperature (Tm). Select solvents at concentrations that minimally decrease 
the Tm (≤ 5 °C).  
 
2.4.2.1.4 Notes 
§ Centrifuge prepared PCR strip/plate to remove bubbles if necessary.  
 
  
 50 
2.4.2.2 Optimizing crystal stability 
 
2.4.2.2.1 Equipment 
§ Crystal trays 
§ Siliconized cover slips 
§ Stereo-Microscope 
 
2.4.2.2.2 Buffers and reagents 
§ Pre-grown crystal 
§ Solvent  
 
2.4.2.2.3 Procedure 
1. Follow procedures in section 2.2.3 for soaking crystals. If ligand is precious, test 
using solvent.  
2. Monitor crystal decay over time at various time points such as 5 min, 30 min, 1 
hour, 2 hours, 6 hours, and overnight (see Section 2.2.3 for discussion of decay). 
3. If crystals are stable, cryo-protect and cryo-cool for data collection. If not, try 
crosslinking  [56] or the use of alternative solvents or mixtures of solvents as 
described in [57, 58].  
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2.4.2.2.4 Notes 
§ Prepare soaking solutions with varying concentrations of solvent (if material is 
precious) or inhibitor in solvent. Limiting the solvent content to less than 10% V/V 
is preferable.   
§ The stability of protein solution and crystals to the same solution may vary. In 
solution, StT6PP is stable with up to 20% DMSO, but crystals rapidly decay as 
assessed macroscopically with >5% DMSO. 
§ When crosslinking, we use 5 µL of 8% glutaraldehyde on a microbridge in the 
crystallization well incubated for 5 minutes. During the first trial, monitor crystals 
every 5 minutes for signs of crystal decay.  
§ Molecular Dimensions sells the CryoSol kit (catalog number MD1-90) of 
multicomponent solutions for solubilizing hydrophobic ligands and for 
cryoprotection.  
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2.5. Summary and Conclusion 
In this chapter, we have described various techniques using single crystal X-ray 
crystallography to gain mechanistic insight into the HADSF of phosphatases. Using 
procedures such as site-directed mutagenesis and metal exchange, we demonstrate how one 
can capture a substrate-bound structure and decipher the binding determinants for 
substrate, affording mechanistic understanding and insight for inhibitor design. Phosphoryl 
mimics, such as vanadate, tungstate, sulfate, aluminum fluoride, and beryllium fluoride, 
allow for structural characterization of both half-reactions in the overall mechanism of 
catalysis:  nucleophilic attack producing the phospho-enzyme intermediate, and hydrolysis 
to release an inorganic phosphate and regenerate the enzyme. Lastly, characterization of 
substrate-like inhibitors can provide additional support for hypotheses regarding the 
binding determinants and mechanism of catalysis. 
The methods described can be applied to other phosphatase families or generally to 
protein-ligand complexes. The methods for soaking substrate into crystals in section 2.1 
and 2.2 may be useful for any ligand-binding protein. Sections 2.3-2.5 are applicable to 
other families of phosphatase. Mutagenesis of analogous residues important for catalysis 
or removal/replacement of the metal cofactor will oblate activity and enable substrate 
binding. Additionally, co-crystallization with phosphate allows one to pinpoint the active 
site. In section 3, the information about phosphate mimics can be leveraged in other 
phosphoryl transfer enzymes to capture various snapshots of the catalytic mechanism. 
Finally, the concepts and methods to determine an inhibitor bound structure in section 4 
can be used for any protein. These methods highlight complications in attaining liganded 
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structures from the presence of competing ions introduced by the crystallization milieu and 
of poor solubility of ligands and some approaches that circumvent these problems. The 
HADSF therefore acts as a testbed for phosphoryl mimics, with particularly strong 
applications to phosphoryl transferases that go through a covalent intermediate.  
Ta
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  STRUCTURE AND BINDING DETERMINANTS OF TREHALOSE-6-PHOSPHATE 
PHOSPHATASE 
Abstract  
T6PP is a member of the haloalkanoic acid dehalogenase superfamily and a target 
for therapeutics of human illnesses caused by bacteria, fungi and parasitic nematodes. 
T6PP catalyzes the dephosphorylation of trehalose 6-phosphate (T6P) to form trehalose. In 
the absence of T6PP, the viability and virulence of bacteria, fungi, plants and nematodes is 
decreased. To identify the substrate binding determinants, the structures of T6PP from 
Mycobacterium marinum and Salmonella typhimurium (St) were determined via X-ray 
crystallography. Additionally, the structure of StT6PP was determined in the presence of 
the substrate analog trehalose 6-sulfate, the product trehalose and an inhibitory probe. Our 
analyses show the enzyme confers specificity via hydrogen bonding to the phosphate and 
to the glucosyl group proximal to the phosphate. Specifically, the conserved residues 
Glu123, Lys125 and Glu167 form hydrogen bonds to the hydroxyl groups of the proximal 
glucose. The importance of the phosphate and glucose moieties was probed via the 
competitive inhibitor, 4-n-octylphenyl α-D-glucopyranoside 6-sulfate (OGS), which has an 
inhibition constant of 56 µM for StT6PP. This inhibitory probe bears a sulfate group in 
place of the substrate phosphoryl group and the glucosyl ring distal to the phosphate has 
been replaced with an octylphenyl moiety. The T6PP/OGS structure shows that the 
hydrogen bonding in the phosphate and proximal site is retained but the distal sub-site 
binds the octylphenyl moiety in a unique manner, showing that this subsite can tolerate 
various chemotypes. 
3.1 Introduction 
Trehalose-6-phosphate phosphatase (T6PP) is a member of the haloalkanoic acid 
dehalogenase superfamily (HADSF). This superfamily of phosphatases, phosphomutases, 
and dehalogenases is characterized by two domains: a conserved core domain with a 
Rossmann-like fold, and a cap domain which varies in fold [1]. The active site is situated 
between the domains with the phosphoryl moiety binding in the central pocket of the core 
domain. The phosphoryl-transfer site within the active site comprises loops I-IV and a 
magnesium ion cofactor to stabilize the charge of the phosphate group and catalyze 
phosphoryl transfer. A nucleophilic aspartate (Dn) on loop I attacks the phosphorous 
creating the aspartylphosphate intermediate whereas the aspartate two residues removed 
(Dn+2) is proposed to protonate the leaving group. Phosphoryl-group transfer to water 
regenerates the enzyme [2]. The cap domain of HADSF members typically confers the 
specificity for substrates and excludes solvent during catalysis [3]. There are three cap-
types in HADSF members: C0 type caps consist of a minimal loop or beta strand, C1 type 
caps are alpha helical domains inserted after the first b-strand of the Rossmann-like fold, 
and C2 type caps contain alpha helices and beta strands inserted after the second b-strand 
of the Rossmann fold. Furthermore, C2 caps may be type a or b with parallel or antiparallel 
beta strands, respectively [1]. T6PP has a C2b type cap.  
T6PP catalyzes the dephosphorylation of trehalose 6-phosphate (T6P) to trehalose, 
the final step of the primary two-step trehalose biosynthetic pathway (Figure 3.1). This step 
follows the condensation of glucose and UDP-glucose to form T6P, catalyzed by trehalose-
6-phosphate synthase (T6PS) [4]. Trehalose is mainly produced under stress conditions, 
such as desiccation and extreme temperatures, in many bacteria, fungi, nematodes and 
plants, but not mammals. Trehalose can also be utilized as a carbon source and metabolic 
regulator [5]. Experiments using gene knock-out strains of T6PP or T6PS in 
Mycobacterium tuberculosis and Saccharomyces cerevisiae and RNA interference of T6PP 
or T6PS in Caenorhabditis elegans (Ce) have shown that the accumulation of T6P is toxic, 
leading to organismal death or impaired growth [6–8]. T6P toxicity is possibly due to the 
inhibition of hexokinase, as is observed in fungi [9], but other etiologies such as phosphate 
starvation are possible. This toxicity makes T6PP an alluring target for antibiotic, 
antifungal and antihelminthic therapeutics. 
 
Figure 3.1 Biosynthesis of trehalose. 
 
X-ray crystallographic structures of T6PP have previously been determined from 
the nematode Brugia malayi (Bm) [10], the bacteria M. tuberculosis (Mt) [11] and 
Pseudomonas aeruginosa (Pa) [12], the archaeon Thermoplasma acidophilum (Ta) [13], 
and the fungi Cryptococcus neoformans (Cn), Candida albicans (Ca), and Aspergillus 
fumigatus (Af) [14]. All T6PP orthologs share the architecture of the HADSF with the 
active site at the interface of a conserved Rossmann-like core domain and a variable cap 
domain [15]. The Bm, Mt and fungal T6PP orthologs possess an additional domain at the 
N-terminus that that varies in size and structure, for which the function is not known [10, 
11, 14].  
To probe the active site of T6PP, substrate-analogs that act as reversible inhibitors 
have been designed using structure-activity relationships [16, 17]. The design approach 
divided the substrate, trehalose 6-phosphate, into three moieties: the phosphoryl group, the 
glucosyl group proximal to the phosphoryl group, and the glucosyl group distal to the 
phosphoryl group. Each moiety was replaced with similar function groups to establish its 
importance in substrate binding. First, the phosphate group was replaced with sulfate, 
phosphonate, monofluorophosphonate and boronate. Sulfate was the best phosphoryl 
analog with trehalose 6-sulfate inhibiting BmT6PP with an inhibition constant (KI) of 180 
μM [16]. Next, each glucosyl group was replaced with a phenyl and tested for inhibition. 
Replacing the glucosyl group distal to the phosphate generated an inhibitor with higher 
affinity than the molecule with the proximal glucosyl group. Nonpolar substituents were 
place on the phenyl ring of glucopyranoside 6-sulfate to create a competitive inhibitor with 
a KI of 5.3 μM for BmT6PP [17]. This inhibitor, 4-n-octylphenyl α-D-glucopyranoside 6-
sulfate (OGS), replaces the phosphoryl group of trehalose with a sulfate and the distal 
glucosyl ring with an octylphenyl moiety. In this Chapter, I show X-ray crystallographic 
evidence for the binding mode of OGS within the T6PP active site to aid future 
optimization of this molecule and design of future inhibitors. 
Due to the high sequence identity (74%) between Mycobacterium marinum (Mm) 
and Mt T6PP, the molecular structure of T6PP from Mt and the model organism Mm was 
studied in an attempt to understand the substrate binding determinants of MtT6PP. Toward 
this goal, the structure of MmT6PP complexed with the magnesium ion cofactor was 
determined to 1.9 Å resolution.  
Additionally, T6PP from Salmonella typhimurium (St) presents a potentially 
valuable model for structure-based ligand design as it does not possess an N-terminal 
elaboration, and therefore represents the “minimal catalytic unit”. Although the sequence 
identity between StT6PP and Bm and Mt T6PP is low (16% and 28% respectively), the 
catalytic efficiencies for these orthologs are within five fold against T6P [16] showing a 
conserved function. Here we present the X-ray crystallographic structure of apo StT6PP, 
refined to 1.89 Å resolution. In addition, structures of StT6PP complexes with magnesium 
cofactor and the substrate mimic trehalose 6-sulfate (T6S), the product trehalose and the 
inhibitory probe OGS were refined to 1.79, 2.05 and 2.24 Å resolution, respectively. 
Overall, the T6PP structures provide insight into the binding interactions of the phosphoryl 
and glucosyl subsites of the active site. The binding determinants of the T6PP family were 
identified as residues Glu123, Lys125, and Glu167 in the proximal glucosyl subsite and 
corroborate findings by Lui et al. that the proximal glucosyl moiety is important for binding 
ligands.  
  
3.2 Materials and Methods 
3.2.1 StT6PP Expression and Purification  
Competent BL21 (DE3) E. coli cells (New England Biolabs) were transformed with 
the pET15b (TEV) vector containing the gene encoding StT6PP [16]. For expression of 
native protein, flask cultures of LB medium with 100 μg/mL carbenicillin were used. For 
selenomethionine (SeMet)-incorporated protein, a modified M9 media was used in place 
of LB [18]. One colony was inoculated into 10 mL of LB and grown for 18 hours at 37 °C 
to produce seed cultures. Flasks containing 1 L media were inoculated with 1 mL seed 
culture and grown to OD600 = 0.6-0.8. Then, recombinant protein expression was induced 
by treating cells with 1 mM IPTG for 16 hours at 16 °C. Cells were pelleted by 
centrigugation for 10 minutes at 4000 x g and stored at -80°C.  
For lysis, cells were homogenized in 3 mL buffer per gram of cell pellet. The lysis 
buffer consisted of 25 mM CHES pH 9.5, 10 mM NaCl, 5 mM MgCl2, 10 mM imidazole, 
10 μg/ml DNase I (Sigma) and 1 protease inhibitor cocktail tablet (Sigma S8830) per 100 
mL buffer. Cells were lysed via a single pass through a microfluidizer (Microfluidics 
Model #M110P) at 18,000 PSI. Lysate was centrifuged at 100,000 x g and the supernatant 
was applied to a HisTrap HP column (GE Healthcare Life Science) using an ÄKTA FPLC 
(GE Healthcare Life Science). The column was washed with five column volumes of lysis 
buffer prior to elution of bound protein with a linear gradient of buffer consisting of 25 
mM CHES pH 9.5, 10 mM NaCl, 5 mM MgCl2 and 500 mM imidazole. The N-terminal 
His6-tag was removed from the protein with TEV protease [19] using a 1:50 ratio of TEV: 
StT6PP while dialyzing the proteins overnight against a solution of 25 mM Tris pH 8.0, 50 
mM NaCl, 5 mM DTT, and 0.5 mM EDTA at 21 °C. TEV protease, His6-tag, and any 
uncleaved StT6PP were removed with a HisTrap HP column. The resulting cleaved StT6PP 
was dialyzed into buffer comprised of 25 mM CHES pH 9.5, 10 mM NaCl, 5 mM MgCl2 
and concentrated to 40 mg/mL using an Amicon Ultra centrifugal filter unit (Millipore). 
Protein purity and monodispersity was increased by including size-exclusion 
chromatography (GE Heathcare Life Sciences HiPrep 26/60 S100) to remove aggregates. 
However, 70% of the protein was lost during this step- even after optimizing the buffer to 
consist of 100 mM CHES 9.5, 100 mM NaCl, 5 mM MgCl2. The protein was stored in 100 
μl aliquots in buffer plus 2.5% glycerol at -80 °C. SeMet-incorporated StT6PP was purified 
following the same procedure, with the exception that 5 mM DTT was added to all buffers.  
 
3.2.2 MmT6PP Purification  
Frozen cell pellets of E. coli BL21 (DE3) transformed with a pET15b (TEV) 
plasmid containing the otsb2 gene from M. marinum were generously provided by Drs. 
Zhiru Li and Clotilde Carlow at New England Biolabs, Inc. Cells (30 g) were thawed and 
resuspended in 100 mL lysis buffer containing 25 mM Bis-Tris pH 6.5, 5 mM MgCl2, and 
10 mM of NaCl with 1 mg DNAase and a protease inhibitor cocktail tablet (Sigma S8830). 
Cellular lysis and purification were executed as described for StT6PP using an elution 
buffer for nickel-affinity chromatography containing 5 mM Bis-Tris pH 6.5, 5 mM MgCl2, 
10 mM, and 500 mM imidazole. The protein was stored in lysis buffer at 15 mg/mL. During 
some purifications an additional step removed aggregates using a sizing column (GE 
Heathcare Life Sciences HiPrep 26/60 S100). 
 
3.2.3 Purification and Crystallization Attempts of Bm, Ce, and Mt T6PP 
The genes for Bm (D59), Ce, and Mt T6PP were cloned into pET15b (TEV) vectors 
and transformed into E. coli BL21 (DE3) cells. Cells were grown, lysed, and purified using 
nickel-affinity chromatography as described for StT6PP. The lysis buffer consisted of 50 
mM Tris pH 7.5, 500 mM NaCl, 5 mM MgCl2 20 mM imidazole and 1 mM EDTA. For 
elution, the imidazole concentration was increased to 500 mM.  
BmT6PP expresses and purifies in high quantities (1.5 mg/g cell pellet) and remains 
stable and active at 4 °C for several days. Attempts at crystallization yielded needles that 
that diffracted to low resolution. Moreover, the crystals had the same unit cell and space 
group as that of the structure determined by Farelli et al. indicating the enzyme was in the 
same cap-open conformation [10]. This conformer is not desirable as it does not yield a 
view of the catalytically competent state. CeT6PP also expresses and purifies with high 
yields. The enzyme was less that 25% polydisperse according to dynamic light scattering 
(DLS) measurements. However, initial high-throughput crystallization trials did not yield 
diffracting crystals. Efforts were focused on the optimization of the diffracting StT6PP 
crystals.  
MtT6PP can be expressed in BL21 cells and purified via affinity chromatography. 
The resulting enzyme is unstable and quickly forms aggregates. Differential scanning 
fluorimetry indicates the thermal stability is best in a buffer consisting of 50 mM imidazole 
and 5% glycerol. However, the protein was still unstable and aggregation prone. Circular 
dichroism was attempted to understand if the structure of N-teminal domain differed from 
that of BmT6PP. However, buffer interference prevented quality data collection and buffer 
exchange yielded aggregated protein. As the MmT6PP was more stable in solution, 
crystallization efforts were focused on that target. 
 
3.2.4 StT6PP Crystallization 
Initial sparse matrix crystallization screens (Hampton Research and Microlytic) 
were set up at a protein concentration of 40 mg/ml with a final volume of 2 μl in sitting-
drop microplates (Corning 3552) and incubated at 17 °C. Initial crystal hits which grew 
within 14 days from conditions containing PEG 3350 and lithium citrate were starbursts of 
rods. The resulting crystals were optimized into three-dimensional spears 200 x 40 x 40 
microns in dimension via vapor diffusion with hanging-drop geometry at 17 °C, with drops 
consisting of 2 μl reservoir solution (12-16% PEG 3350, 350-450 mM lithium citrate, 0-
40 mM MES, MOPS, TAPS pH 7.5), 1.5 -2 μl protein solution at 40 mg/ml, and 0.5 μl 
seed solution (1:103-1:105 dilution of original seed stock) prepared using Seed Bead™ Kit 
(Hampton Research). The crystal growth condition utilized to collect data for the high-
resolution unliganded structure also contained 2 μl water in the drop to slow equilibration. 
The well comprised 500 μl reservoir solution. Crystals grew in three days. All crystals were 
cryoprotected using 10% ethylene glycol and flash cooled in liquid nitrogen.   
The StT6PP/T6S complex was determined from a crystal grown in the presence of 
10 mM MgCl2. The crystal was soaked in a solution of 20% PEG 3350, 500 mM lithium 
citrate, 50 mM MgCl2, 10% ethylene glycol and 5 mM trehalose 6-sulfate for 2 hours. The 
crystal used to collect the StT6PP/trehalose complex was also grown in the presence of 10 
mM MgCl2 then soaked for 30 minutes in 35% PEG 3350, 166 mM lithium citrate, 166 
mM MgCl2, 10% ethylene glycol and 50 mM trehalose. The StT6PP/OGS complex was 
determined from a crystal grown in reservoir solution containing 30 mM MgCl2 and the 
resulting crystal was soaked with 1 mM OGS in a soaking solution comprised of 18% PEG 
3350, 400 mM lithium citrate, 40 mM MgCl2, and 10% ethylene glycol for 24 hours. 
Crystal soaked at lower concentrations of MgCl2 (0-50 mM) and high concentrations of 
lithium citrate (350-500 mM) in the cryoprotectant/soaking solution led to structures with 
the Mg2+ missing or bound with low occupancy. Lowering the citrate concentration (which 
can chelate metals) and increasing the MgCl2 concentration was necessary to acquire 
structures with full occupancy of the Mg2+ binding site.  
 
3.2.5 StT6PP Data Collection, Structure Solution and Refinement 
The native and trehalose-bound data sets were collected at the Advanced Photon 
Source (APS) on the Northeastern Collaborative Access Team beamline 24-ID-E. Data 
were collected under a stream of nitrogen gas at 100 K using a CCD-based ADSC Quantum 
315 detector. Data were processed via Rapid Automated Processing of Data (RAPD), 
which utilizes X-ray Detector Software (XDS). The SeMet derivative and OGS-bound data 
sets were collected at Stanford Synchrotron Radiation Lightsource (SSRL) on beamline 
14-1. Data were collected under a stream of nitrogen gas at 100 K using a MARmosaic 325 
CCD detector. Data were processed using HKL 2000 [20]. The data set for the StT6PP/T6S 
complex was collected at National Synchrotron Light Source (NSLS) II on the Highly 
Automated Macromolecular Crystallography Beamline (AMX) 17-ID-1. Data were 
collected under nitrogen gas flow at 100 K using an Eiger 9M detector and automatically 
processed using fast_dp, which utilizes XDS. Initial electron density maps were calculated 
via multiple-wavelength anomalous dispersion (MAD) from the SeMet data sets phasing 
with Phenix AutoSol [21] from eight anomalously scattering selenium sites (out of ten 
possible selenium sites) and is consistent with the two molecules per asymmetric unit 
calculated from the unit cell volume and estimated solvent content. Phenix Autobuild [21] 
was used to build residues 1-246 of the 267 amino-acid protein. The lack of density for the 
final 21 residues corroborates the inability to locate two of the ten possible anomalously 
scattering sites because Met253 is located in this segment. The model was refined against 
the electron density map using XYZ coordinates, real-space and group B-factors. 
Subsequent rounds included individual B-factor refinement, simulated annealing and the 
addition of water molecules.  
The resulting SeMet-substituted structure, refined to 2.48 Å resolution was used as 
a molecular replacement model for the native and OGS-bound data sets in Phenix Phaser 
[21]. The native structure was refined to 1.89 Å using the following strategies with non-
crystallographic symmetry restraints: XYZ coordinates, real-space, individual and group 
B-factors, and translation-libration-screw (TLS) parameters. Models were manually 
manipulated between refinement rounds with the molecular graphics program Coot [22].  
The native structure was used as the model for molecular replacement for phasing 
the data for StT6PP/trehalose and StT6PP/T6S complexes. The liganded models were 
refined similarly to the native model, with the addition of Mg2+ after waters were added. 
Then the Fo-Fc difference electron density map was used to place the ligand using Phenix 
LigandFit [21]. Data collection and refinement statistics are presented Table 3.1 and Table 
3.2. 
 
 Table 3.1 Data Collection Statistics of S. typhimurium T6PP Structures 
 SeMet-substituted Native T6S Trehalose OGS 
 Peak Inflection Remote      
PDB ID    6EBF 6EBI 6EBH 6EBJ 
Wavelengths 
(Å) 
0.9791 0.9793 0.9537 0.9791 0.9791 0.9791 1.378 
Space group P1211   P1211 P1211 P1211 P1211 
Unit cell 
(a, b, c, Å) 
46.2, 52.6, 108.1  46.0, 52.4, 105.6  46.6, 52.6, 107.6  46.8, 53.0, 108.8   46.2, 52.4, 108.6  
Unit Cell 
angles (°) 
b = 99.99   b = 98.45  b = 99.88  b = 100.6  b = 108.6  
Solvent 
content (%) 
42.9   41.4 43.2 44.2 45.6 
Vm (Å3/Dalton) 2.15   2.10 2.16 2.20 2.26 
Molecules per 
ASU 
2   2 2 2 2 
Resolution 
(Outer Shell) 
25.0-2.55 
(2.59-2.55) 
25.0-2.53 
(2.57-2.53) 
25.0-2.48 
(2.52-2.48) 
104.6-1.89  
(1.92-1.89) 
29.34-1.79 
(1.84-1.79) 
106.90 -2.05 
(2.11-2.05) 
50.0-2.24  
(2.28-2.24) 
No. of total/ 
unique 
reflections 
98325/ 
16724 
98624/ 
16725 
95447/ 
18025 
335890/39938 163952/47959 117234/32534 97659/24547 
I/σ  29.0 (7.31) 29.2 (7.11) 21.7 (3.21) 14.9 (2.9) 15.1 (1.9) 9.4 (1.2) 22.5 (2.90) 
Completeness  99.2 (87.4) 97.0 (42.7) 97.9 (64.1) 99.6 (99.9) 98.7 (90.3) 98.6 (88.8) 99.3 (90.6) 
Multiplicity  5.9 (5.1) 5.9 (4.9) 5.3 (4.0) 8.4 (7.9) 3.4 (3.0) 3.6 (3.6) 4.0 (3.1) 
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 Rmerge  0.115 (0.259) 0.113 (0.246) 0.120 (0.351) 0.109 (0.755) 0.044 (0.499) 0.076 (0.755) 0.107 (0.422) 
CC 1/2 0.992 (0.953) 0.992 (0.959) 0.992 (0.893) 0.998 (0.777) 0.998 (0.847) 0.997 (0.577) 0.978 (0.840) 
Beamline SSRL 14-1   APS 24 -ID-E NSLS II 17-ID-1 APS 24-ID-E SSRL 14-1 
Figure of Merit 
(%) 
41.0       
Practical 
resolution 
limit of 
anomalous 
signal (Å) 
3.0       
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 Table 3.2 Data Refinement Statistics of S. typhimurium T6PP Structures 
  Native T6S Trehalose OGS 
Resolution range (Å) 104.4-1.89 (1.95-1.89) 29.34-1.79 (1.83-1.79) 53.45-2.05 (2.10-2.05) 37.4-2.24 (2.30-2.24) 
Unique reflections 39919 47945 32483 24524 
Test set 1707 2342 2016 2011 
Rwork 0.187 (0.259) 0.199 (0.382) 0.214 (0.352) 0.198 (0.242) 
Rfree 0.215 (0.276) 0.241 (0.384) 0.251 (0.351) 0.223 (0.296) 
Total waters 440 297 142 283 
Wilson B 24.5 25.2 40.4 37.5 
Mean B value (Å
2
) 
Protein 
Water 
Magnesium  
Ligand 
34.4 
34.3 
35.2 
----- 
----- 
40.8 
41.0 
37.3 
41.1 
43.9 
48.4 
48.4 
46.1 
38.4 
55.2 
43.0 
43.0 
41.7 
46.8 
50.1 
RMSD 
   Bond lengths(Å
2
) 
   Bond angles (°) 
 
0.0024 
0.703 
 
0.010 
1.062 
 
0.002 
0.606 
 
0.002 
0.562 
Ramachandran Analysis (%) 
   Favored 
   Allowed 
 
96.9 
3.1 
 
97.1 
2.9 
 
95.7 
4.3 
 
96.5 
3.5 
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3.2.6 MmT6PP Crystallization, Data Collection, and Structure Determination 
M. marinum T6PP at 10 mg/mL was crystallized in 38% TacsimateTM at pH 7.0. 
Crystals were grown at 290 K via hanging drop vapor diffusion for more than 1 year and 
diffracted to 1.97 Å. Data set was collected at APS beamline 24-ID-E under nitrogen gas 
flow at 100 K using Dectris Pilatus 6M detector and processed using RAPD. The MtT6PP 
(PDB ID: 5GVX) model was divided into 3 domains, N-terminus (residues 1-120), core 
(120-225, 301-390) and cap (226-300) for a multi-component molecular replacement 
model. Phenix Phaser was used to generate a molecular replacement solution which was 
built in PHENIX AutoBuild (Shan et al., 2016). Manual loop building and refinement were 
performed with Coot and Phenix Refine was used to refine the model against the electron 
density map using simulated annealing, XYZ coordinates, real-space, individual B-factors 
and group B-factors. The Mg2+2+ cofactor and water molecules were added when the Rfree 
was below 0.30. The final model consisted of residues 2-91, 104-159, 168-387 (out of 390 
residues). Data collection and refinement statistics are listed in   
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Table 3.3.  
Another crystal of MmT6PP was grown using 15 mg/mL protein and well solution 
comprising 0.1 M sodium formate, pH 5.75 and 8% w/v PEG Smear Medium (Molecular 
Dimensions) via hanging-drop vapor diffusion. A data set was collected at NSLS II on 
beamline AMX 17-ID-1 using an Eiger 9M detector under nitrogen gas flow at 100 K. Data 
were automatically processed using fast_dp to 1.79 Å with unit-cell dimensions a = 46.2, 
b = 52.7, c = 106.4 Å and β = 99.0 in space group P 1 2 1. Molecular replacement attempts 
using Mm and Mt T6PP models were unsuccessful. The change in space group and the 
difficulty phasing indicates that the conformation may differ from that of available 
structures. Thus, the Mm and Mt T6PP model was divided into three domains and used as 
molecular replacement models individually, in tandem, and together. Again, molecular 
replacement was unsuccessful. Next, the cap and core domains of MmT6PP were 
positioned in “closed” conformations by overlaying the domains onto Af, Bm, Mt and St 
T6PP models. Using the models with a closed HAD domain also did not yield a solution. 
Therefore, SeMet substituted MmT6PP was prepared and crystallization was attempted. 
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Table 3.3 Data Collection and Refinement Statistics of M. marinum T6PP Structure 
Collection Statistics 
Wavelengths (Å) 0.979 
Space group P 21 21 21  
Unit cell dimensions (Å) 36.6 x 97.3 x 102.7 
Solvent content (%) 41 
Vm (Å3/Dalton) 2.08 
Molecules per ASU 1 
Resolution 
(Outer Shell) 
19.88-1.97  
(2.04-1.97) 
No. of total/unique reflections 87370/26386 
I/σ  18.7 (2.0) 
Completeness  98.6 (99.4) 
Multiplicity  3.3 (3.3) 
Rmerge  0.052 (0.632) 
CC 1/2 0.981 (0.720) 
Beamline APS 24-ID-E 
Refinement Statistics 
Resolution range (Å) 19.88-1.97 
Unique reflections 24645 
Test set 1627 
Rwork 0.208 
Rfree 0.255 
Total waters 264 
Wilson B 21.8 
Mean B value (Å2) 
Protein 
Water 
Magnesium  
30.1 
29.8 
33.0 
32.6 
RMSD 
   Bond lengths(Å2) 
   Bond angles (°) 
 
0.006 
1.09 
Ramachandran Analysis (%) 
   Favored 
   Allowed 
   Outliers 
 
95.6 
3.9 
0.6 
PDB ID 6DGW 
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3.2.7 Bioinformatic and Structural Comparison T6PP Orthologs  
Root mean square deviation (RMSD) of the a-carbons were scores the PDB 
Calculate Structure Alignment tool [23]. Multiple sequence alignments were generated 
using Clustal Omega [24]. For the N-terminal domain analysis, 80 sequences of T6PP from 
bacteria, fungi, plants, insects and nematodes were included. The average distance 
phylogenetic tree was calculated using BLOSUM62 [25] and visualized in Jalview [26]. 
For conservation analysis of active-site residues, the sequences from B.m, C.e, Cn, Af, Ca, 
Ta, St, Mt, and Mm T6PP were aligned. Sequences identities were extracted from the 
multiple sequence alignment and visualization of the multiple sequence alignment utilized 
ESPript 3.0 [27]. Molecular graphics were performed using UCSF Chimera [28] unless 
otherwise noted. UCSF Chimera was also used to determine hydrogen bonds (Find Hbond 
[29]) or van der Waals interactions (Find Contacts) made between enzyme residues and 
ligand. The size of the active-site cavity was measured with Voidoo [30], while tunnels 
to/from the active site were determine via Caver [31].  
 
 
 
Figure 3.2 Sequence alignment of T6PP orthologs from all domains of life. 
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sp|Q9HIW7|OTSBH_Tacidophilum/1-229  ........................................                                                                                                                                                                
tr|Q059G6|Q059G6_Cneofromans/1-987  ........................................                                                                                                                                                                
tr|Q4WWF5|Q4WWF5_Afumigatus/1-949   ........................................                                                                                                                                                                
tr|Q5AI14|Q5AI14_Calbicans/-533-354 LANSVSSERSKHAVSKAVSLRKKASQEKEIVKEDPTNGAK                                                                                                                                                                
sp|A8NS89|GOB1_Bmalayi/1-492        ........................................                                                                                                                                                                
sp|Q9XTQ5|GOB1_Celegans/1-468       ........................................                                                                                                                                                                
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3.3 T6PP Structure  
3.3.1 Structure of MmT6PP 
Due to the high sequence identity (75%) between Mm and Mt T6PP, we 
investigated the molecular structure of T6PP from the model organism Mm in order to 
characterize the molecular architecture of T6PP from mycobacterial species. Although a 
structure of MtT6PP was published [11], the conformation was in a cap-open state. 
Therefore, we aimed to determine the structure of MmT6PP in a cap-closed, catalytically 
competent, conformation.  
The structure of MmT6PP was refined to a resolution of 1.97 Å using the structure 
of MtT6PP (PDB ID 5GVX) as a molecular replacement model. Residues 2-387 (out of 
390 residues) were refined with gaps in the chain from residues 92-103 and 160-167. The 
structure consists of three domains, N-terminal domain (1-120), core domain (145-224, 
305-390), and cap domain (225-304) (Figure 3.3). Both the core domain and the N-terminal 
domain are Rossmannoid folds with parallel β-strands and flanking α-helices made up of 
β/α/β units. Mg2+ was resolved with coordinate bonds to core residues Asp150 (Dn), 
Asp333, and Asp 337, and a water molecule.  
The structure of MmT6PP was superimposed with the structure of MtT6PP with an 
RMSD value of 3.9 Å (Figure 3.3) (the individual domains of Mm and Mt T6PP are highly 
similar with RMSD values of 1.6 Å, 1.1 Å, and 0.70 Å for the N-terminal, core and cap 
domains, respectively). The overall RMSD value is large compared to that of the individual 
domains because the orthologs are in different conformations. The MmT6PP is in a 
conformation with a cap that is 30° more open with respect to the core domain than that of 
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MtT6PP. Therefore, like many other unliganded T6PP structures, the active site is exposed 
to solvent and may not bind ligands. Hence, this crystal form is not suitable for obtaining 
information about the substrate-binding determinants. Future efforts should aim to obtain 
other crystal forms.  
 
Figure 3.3 Mycobacterium T6PP structures. MmT6PP (pink) is superimposed with MtT6PP 
(cyan). Structures are shown as ribbons with the magnesium ion as lime green sphere and 
the coordinating residues shown as sticks. 
 
3.3.2 T6PP N-terminal Domain 
Some T6PPs include a domain at the N-terminus of the HAD phosphatase catalytic 
core domain [10, 11, 14]. The sequence of N-terminal domain of T6PP is not conserved 
amongst various species and the function is unknown. Therefore, I aimed to understand the 
evolutionary origin of the N-terminal domain to provide insight into its function. To do so, 
the structures of the N-terminal domain from Bm, Ca, and Mt T6PP were analyzed to find 
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similar folds in extant organisms (the MmT6PP N-terminal domain was omitted as Mm and 
Mt are similar with 65% sequence identity and an RMSD of 1.6 Å).  
The N-terminal domain of CaT6PP is large, consisting of 534 residues. Due to its 
size, the structures of the N-terminal domain and HAD domain were determined separately 
for CaT6PP [14]. The ability to individually express, purify and crystallize each domain 
indicates the domains are not co-dependent for stability. The N-terminal domain can be 
further divided into the N- and C-terminus domains, each consisting of a Rossmann fold 
[14]. The N-terminal domain of CaT6PP shares 32% sequence identity and is similar in 
structure to the preceding enzyme in trehalose biosynthesis, T6PS (1.9 Å RMSD score) 
(Figure 3.4C). Despite the high sequence and structural similarity, the N-terminal domain 
lacks key residues involved in UDP-binding and has no detectable glycosyltransferase 
activity [14]. It is not known if this domain has catalytic activity with other substrates. 
These observations suggest that a progenitor existed with the genes encoding T6PS and 
T6PP fused together. This fused domain architecture is seen in Drosophila melanogaster 
T6PP in which the N-terminal domain belongs to the T6PS fold family and retains T6PS 
activity [32].  
MtT6PP has an N-terminal domain that it is smaller (120 amino acids) than that of 
CaT6PP and comprises a single Rossmann fold [11]. As the CaT6PP N-terminal domain 
comprises two Rossmann folds and is similar to CaT6PS, we first hypothesized the 
MtT6PP N-terminal domain is a vestige of a T6PS-T6PP fusion. However, a DALI server 
search indicates the N-terminal domain is similar to hydrolases in the HADSF [11]. This 
led to a second hypothesis that the N-terminal domain is a vestige of a duplication of the 
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HAD domain. To determine if the N-terminal domain is more similar to T6PS or to the 
core domain of T6PP, the sequences and structures were aligned. As the Mycobacterial 
thermoresistible (Mtherm) T6PS has been structurally characterized [PDB ID: 5K5C] and 
has 80% sequence identity with MtT6PS, it was used as the T6PS model. Sequence 
alignments between the Rossmann fold of MtT6PP N-terminal domain and the Rossmann 
folds of T6PS and T6PP resulted in less than 20% identity, preventing any meaningful 
conclusions as to the evolutionary origin of the N-terminal domain. However, in evolution 
protein structure transcends sequence similarity [33]; sequence similarity indicates 
structural similarity, but structural similarity does not indicate sequence similarity causing 
proteins with low sequence similarity exhibiting structural similarity. The superimposition 
of the MtT6PP N-terminal domain with the Rossmann folds of the N- and C-terminus of 
MthermT6PS and the core of MtT6PP resulted in RMSD scores of 4.1 Å, 4.2 Å, 3.0 Å, 
respectively. The N-terminal domain of MtT6PP is most similar to the core domain of 
MtT6PP (Figure 3.4B) supporting the hypothesis that its N-terminal domain is a vestige of 
a gene duplication of T6PP.  
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Figure 3.4 T6PP N-terminal domains. A) BmT6PP N-terminal domain is shown as green 
ribbons superimposed with the MIT domain from Sulfolobus solfataricus Vps4 shown as 
white ribbons. B) MtT6PP N-terminal domain is shown in cyan superimposed with the core 
domain of MtT6PP shown as light gray ribbons. C) CaT6PP N-terminal domain is shown 
in orange superimposed with CaT6PS shown as dark gray ribbons.  
 
The N-terminal domain of BmT6PP is comprised of a three-helix bundle flanked 
on one edge by two short antiparallel beta sheets and a helical linker connecting to the core 
domain [10]. The three-helix bundle is similar to the microtubule interacting and transport 
(MIT) domain of the vacuolar protein sorting associated protein 4 (Vps4) from Sulfolobus 
acidocaldarius (Figure 3.4A) that mediates the interaction between the AAA-ATPase 
domain of Vps4 and endosomal sorting complex required for transport (ESCRT-III). 
BmT6PP is not known to associate with ESCRT-III or any protein [10]. It is plausible that 
the N-terminal domain mediates complex formation between T6PP and T6PS. A complex 
between T6PP and T6PS is observed in S. cerevisiae, however the interaction interface is 
yet to be characterized [34]. It is known that the N-terminal domain is necessary for 
structural stability of BmT6PP as truncation prevents expression of soluble protein [10]. In 
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summary, the N-terminal domain of BmT6PP helps maintain protein stability and may 
mediate a protein interaction such as that to T6PS.  
Analysis of the N-terminal domain from fungal, bacterial and helminthic T6PP 
revealed the architecture of the domain is variant amongst species. We hypothesize that the 
N-terminal domain of CaT6PP originates from a progenitor with T6PS-T6PP fusion 
(similar to that of D. melanogaster), the MtT6PP N-terminal domain evolves from a 
duplication of the HAD domain, and the BmT6PP N-terminal domain is a vestige of protein 
interaction mediation.  As these origins differ, we sought to understand the evolutionary 
events that occurred to cause the various N-terminal domains. To do so, an average distance 
phylogenetic tree was generated from a multiple sequence alignment of various T6PP 
protein sequences from bacteria, fungi, plants, insects and nematodes. The nodes cluster 
by length of the N-terminal domain and support the following proposed evolution. The 
progenitor of T6PP was either a T6PS-T6PP fusion or T6PP. From this progenitor, two 
branches emerged, one with the standalone T6PP gene (the T6PS gene evolved separately) 
and one with the T6PS-T6PP fusion. The T6PS-T6PP fusion evolved into the T6PP with 
an N-terminal domain similar to T6PS as observed in fungal species, e.g. CaT6PP. The 
stand-alone T6PP evolved to form numerous branches. Bacterial T6PPs, such as E. coli, 
Mycobacteria smegmatis, and St, and some T6PPs from Drosophila sp. continued to evolve 
without an N-terminal domain. Other T6PPs fused with a gene encoding an MIT domain 
to form the helminth T6PPs with an MIT-like N-terminus, e.g. BmT6PP. In another event, 
the T6PP encoding gene was duplicated to form the core-like N-terminal domain observed 
in Mm and Mt T6PP. T6PPs from plants are the most similar to mycobacterial T6PPs and 
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could have N-terminal domains also resulting from T6PP gene duplications. Alternatively, 
plant T6PPs may have yet another architecture for the N-terminal domain. The N-term 
domain may provide protein stability and/or may allow complex formation with T6PS and 
hence high local concentration of T6PP substrate. As the origins of diverse N-terminal 
domains vary, we hypothesize that the evolution of the N-terminal domain is convergent.  
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Figure 3.5 Phylogenetic tree of T6PP evolution. A) An average distance phylogenetic tree 
of T6PPs from bacteria, mycobacteria, fungi, plants, and invertebrates. The branch labels 
indicate the Genus, species, and uniprot ID of the T6PP. B) Theoretical tree of T6PP 
hypothesizing the origin of the N-terminal domain.  
 
3.3.3 Structure of Apo StT6PP 
The structure of StT6PP was determined using MAD phasing from a three-
wavelength data set collected from crystals of SeMet-substituted protein (see Table 3.1 and 
Table 3.2 for data collection and refinement statistics). The SeMet-StT6PP model was 
refined to 2.48 Å resolution and utilized in molecular replacement to calculate initial phases 
for a data set collected from the native enzyme, which was refined to 1.89 Å. Overall, 
StT6PP has two domains characteristic of HADSF members, a conserved core domain with 
a Rossmann-like fold (residues 1-95, 175-246) and a cap domain (residues 96-174), with 
the active site at the domain interface (Figure 3.6). The last 21 residues were not resolved. 
Amongst superfamily members, the cap domain varies in secondary structure [15]. StT6PP 
has a C2b type cap with four anti-parallel beta strands and two alpha helices. The core 
domain consists of six parallel β-sheets with five flanking α-helices. Additionally, there is 
a small loop at the C1 insertion location (residues 27-38). Although the enzyme is Mg2+ 
dependent, like all HADSF phosphohydrolases [15] and despite the fact that 5 mM MgCl2 
was maintained throughout enzyme purification and crystallization, there is no electron 
density observed for the Mg2+ in the active site. This phenomenon is not common but has 
been observed previously for HADSF members where the cofactor affinity is low. The 
occupancy of Mg2+ was enhanced by the addition of ligand in the phosphoryl-binding site 
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which contributes coordinate bonds [35]. StT6PP crystallizes with two molecules in the 
asymmetric unit. The two chains do not differ in tertiary structure (RMSD = 0.58 Å), but 
the average B-factors differ substantially (24.8 Å and 43.7 Å for chains A and B, 
respectively). This difference could be due to an additional crystal contact made by the 
core of chain A with the cap of chain B, that is not present in chain B (Figure 3.7). As the 
corresponding electron density is more clearly defined, the analyses herein use chain A.  
 
Figure 3.6 Structure of StT6PP. StT6PP (shown as ribbon diagram) contains two domains, 
a core and cap, with a loop at the C1 insert location. 
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Figure 3.7 Crystal lattice of StT6PP. Asymmetric unit and symmetry mates are displayed 
as Cα chains. Chain A is purple, Chain B is gold. Chain A makes crystal contacts with six 
molecules; one at the exterior cap interface, four around the center of the protein and one 
between the core of chain A and cap of chain B. Chain B also makes interactions with a 
symmetry mate at the exterior of the cap domain and four symmetry molecules around the 
center of the protein, but not with “bottom” of the core. Image generated in Coot [22].  
 
The structure of apo StT6PP is similar to that of other unliganded, Mg2+-bound 
T6PP phosphatase domains from Af [14], Bm [10], Ta [13], Pa [12] and Mt [11]. Alignment 
of the core and cap domains of Af and St T6PP results in RMSD values of 2.0 Å for the 
core and 2.0 Å for the cap. Similarly, alignment of StT6PP domains with Bm and Ta T6PP 
yields RMSD values of 2.3 and 1.7 Å for the core and 2.6 and 1.6 Å for the cap, 
respectively. Bacterial T6PP structures are also similar (RMSD values of 1.7 Å, 1.3 Å, 3.2 
Å, and 2.9 Å for Mt core, Mt cap, Pa core and Pa cap, respectively). Thus, T6PPs analyzed 
to date have the same tertiary structure despite the fairly low sequence identity with StT6PP 
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(26% with Af, 16% with Bm, 26% with Ta, 28% with Mt, and 15% with Pa). This similarity 
of the overall fold indicates that StT6PP, which lacks the N-terminal elaboration present in 
some orthologs, could be a representative model for inhibitor development. 
As described in section 3.3.1 Structure of MmT6PP for MmT6PP, the cap domains 
are structurally similar in all T6PP members; however, the position relative to the core 
varies amongst determined structures. The position of the cap domain of StT6PP is similar 
to that observed in Ta and Pa T6PP. Compared to unliganded AfT6PP structure, the StT6PP 
cap is rotated toward the core by 50.7° (Figure 3.8C). Similarly, the StT6PP cap is rotated 
toward the core domain, compared to that of the unliganded Bm and Mt T6PP, by 65.4° 
and 23.4°, respectively (Figure 3.8 A and B). Comparison of the Af and Bm T6PP structures 
reveals that the cap rotates in opposing directions leading to an overall 123.0° difference 
with a 9.0 Å translation along the rotational axis (overall acting as a screw axis). The 
various positions of the caps in the crystal structures highlights the flexibility of the T6PP 
cap domains in solution.  
 
Figure 3.8 Conformation comparison of T6PP orthologs in crystallo. StT6PP (purple) is 
superimposed with A) Bm (green), B) Mt (cyan), and C) Af (orange) T6PP. Molecular 
models are depicted as ribbon diagrams with Mg2+ shown as lime sphere.  
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In HADSF members, the flexibility of the cap enables substrate binding by opening 
the active site to ligands and bulk solvent. However, catalysis occurs in a cap closed 
conformation when solvent is excluded, binding interactions to the substrate are optimized, 
and the catalytic residues are positioned around the phosphate group [1]. Thus, to obtain 
information about the active-site binding interactions for structure-based inhibitor design, 
it is necessary to analyze the liganded enzyme in a cap-closed conformation. Comparison 
of apo StT6PP to other C2 type HADSF members in cap-closed conformations (PDB IDs: 
1U2T, 1YMQ, 3R4C) indicates the apo StT6PP structure is in a cap closed conformation. 
In crystallo, it has 198 Å3 cavity between the core and cap domains and multiple solvent 
channels leading to the active site of StT6PP. The This crystal form is especially amenable 
to the study of liganded complexes, because the ligand may be soaked into preformed 
crystals via solvent channels (ligands < 500 Daltons in molecular weight can travel through 
solvent channels). The ligand can bind in the active site cavity of the enzyme in a 
catalytically competent conformation enabling structure determination of the ligand 
complex. 
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3.4 T6PP Active Site Binding Determinants 
3.4.1 StT6PP Complex with T6S  
The cap closed conformation of StT6PP in crystals allowed for the soaking of the 
substrate mimic, trehalose 6-sulfate (T6S) into the active site of a catalytically competent 
conformer. As the unliganded structure showed no observable electron density for Mg2+ 
despite the protein buffer containing 5 mM MgCl2, crystals were grown with 10 mM MgCl2 
added to the well solution. Crystals were incubated for two hours with 5 mM T6S in a 
solution comprising 20% PEG 3350 (increased from 12% in reservoir solution), 10% 
ethylene glycol for cryoprotection, and 50 mM MgCl2. Data for StT6PP in complex with 
T6S were collected to 1.79 Å. The coordinates of the apo StT6PP were used as the model 
for phasing by molecular replacement. The resulting model comprised residues 1-246 (of 
267), the Mg2+ cofactor and one T6S molecule bound per enzyme monomer. 
The apo and T6S-complexed StT6PP models have a RMSD of 0.4 Å (although this 
value may be biased as the phases result from molecular replacement) indicating no major 
structural changes upon ligand binding. In phosphatases of the HADSF, the Mg2+ is 
coordinated by loops I and IV. In StT6PP, residues 20-22 comprise loop I and residues 
197-202 comprise loop IV. Based on knowledge of other HADSF members, Mg2+ would 
be coordinated by the nucleophilic Asp20 side chain, the backbone oxygen of Asp22 
(Asp22 C=O), and two Asp residues from loop IV which conforms to the GDXXXD motif 
[1]. However, during refinement, the placement of Mg2+ into electron density was difficult 
and ambiguous. The electron density is oblong with the highest concentration of density 
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3.7 Å from Asp22 C=O which is longer than typical magnesium coordinate bonds (~2.1 
Å). With Mg2+ placed in the electron density contoured at highest sigma levels, positive 
electron density appears between Mg2+ and Asp22 C=O. Alternatively, refinement of a 
water molecule in this same location results in positive electron density surrounding the 
water molecule indicating the water molecule has too few electrons to account for the 
density and a heavier atom should be placed in the position. As this position is too long for 
a Mg2+ coordinate bond to Asp22 C=O, we attempted to place Mg2+ 2.1 Å from Asp22 C=O 
with a water molecule bridging the interaction with an Asp on loop IV. After refinement, 
the resulting electron density encompassed neither atom. We conclude the electron density 
appears to be the averaged electron density from a) Mg2+ ~2.0 Å from Asp22 C=O with a 
water to make a bridging coordinate bond to Asp202 and b) a water molecule. We 
hypothesize the low occupancy of Mg2+ is due to chelation by the 450 mM citrate in the 
crystallization condition. Since no single model fully explains the data, the best model 
places Mg2+ in position with a long coordinate bond (3.7 Å) to Asp22 C=O (Figure 3.9).  
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Figure 3.9 Active site of StT6PP/T6S complex. Residues (purple) and T6S (gray) are 
displayed as sticks. Magnesium ion is shown as lime green sphere and coordinate bonds 
are shown as dashed lines with bond lengths shown in Å. The 2Fo-Fc electron density for 
magnesium is displayed as mesh while unmodeled Fo-Fc density is shown as a white 
surface. Electron density maps are contoured at 2s.   
 
The active site of StT6PP can be divided into three subsites for substrate binding:  
the phosphate binding site, the binding site for the glucosyl moiety proximal to the 
phosphate (proximal subsite), and the binding site for the glucosyl moiety distal to the 
phosphate (distal subsite). 
The phosphate binding site is conserved throughout the HADSF and consists of 
four loops that contribute hydrogen bonds to the phosphate group [36]. In StT6PP the loops 
are also conserved and contribute hydrogen bonds from the following residues: loop I - 
Asp20 main chain and Asp22 side chain, loop II - Ser60 side chain and Gly61 main chain, 
loop III - Lys175 side chain, loop IV - Asp199 side chain. However, in the StT6PP/T6S 
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complex, the sulfate group of T6S is shifted away from loop I (6.7 Å from the closest 
sulfonyl oxygen to backbone nitrogen of Asp22) preventing the sulfonyl group from 
making direct hydrogen bonds to the enzyme (Figure 3.14). Instead, all interactions 
between the sulfate group and the enzyme are mediated through waters. As this is 
uncharacteristic of the HADSF, we posit that the phosphate mimic in this structure is 
improperly oriented compared to the canonical phosphoryl binding orientation. In the 
HADSF, Mg2+ typically provides coordinate bonds to position the phosphoryl group with 
respect to loops I-IV. As the Mg2+ has low occupancy in the StT6PP/T6S complex, the 
sulfate group may experience electrostatic repulsion by the charged residues of loop I that 
typically ligand Mg2+ altering the sulfate group orientation. Therefore, the binding 
determinants of the phosphoryl binding site may not be obtained from this structure.  
Although the phosphoryl group generally anchors the substrate into the active site 
in HADSF phosphatases, the substrate leaving group makes interactions that confer 
specificity [36]. Understanding the specificity determinants is especially important for 
designing inhibitors selective for the target. In T6PP, the specificity determinants for 
trehalose can be separated into two glucosyl subsites, proximal and distal to the phosphate 
binding site. The proximal glucosyl ring is mainly stabilized by hydrogen bonds from 
residues in the cap domain (Figure 3.10). The C3 hydroxyl participates in two hydrogen 
bonds (2.6 and 3.1 Å) with the side chain of Glu123 and a 3.1 Å hydrogen bond to the side 
chain of Lys125. The C4 hydroxyl makes a 2.9 Å hydrogen bond with the side chain of 
Glu167. The oxygen of the pyranose ring forms a hydrogen bond with a water molecule 
(H2O1) that is hydrogen bonded to the side chain of Asp22 in the core. Additionally, the 
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oxygen of C6 is hydrogen bonded to H2O2 which has an extensive network of hydrogen 
bonds (Asp199 side chain, Lys163 backbone C=O, a sulfonyl oxygen and the C2 hydroxyl 
of distal glucosyl ring of T6S). Additional hydrophobic interactions are observed between 
the hexose ring and methylene chain of Arg62 and carbons of His132. 
The distal glucosyl moiety is also stabilized through hydrophilic and hydrophobic 
interactions (Figure 3.10). The C2 hydroxyl forms a hydrogen bond with the backbone 
C=O of the cap residue Lys163 (3.0 Å) and H2O2 (vide supra). The C3 hydroxyl also 
makes a hydrogen bond to a water (H2O3) that bridges to the His132 side chain and the 
backbone C=O of Cys164. Additionally, Arg134 side chain makes two hydrogen bonds 
(2.9 and 3.1 Å) with the C3 hydroxyl. The C4 and C6 hydroxyl groups interact with the 
backbone of the C1 loop at Lys29 (2.9 Å to C=O and 3.0 to NH, respectively). The C-6 
hydroxyl makes an additional hydrogen bond with H2O4 bridging to the backbone C=O of 
Glu27 in the C1 loop and the side chain of Asp22. The C6 carbon makes van der Waals 
interactions with Pro32 and Val35 of the C1 loop.  
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Figure 3.10 Active-site interactions between StT6PP and T6S. Water molecules are shown 
as blue circles, hydrogen bonds are shown as dashed lines, and residues making van der 
Waals interactions are shown in red.  
 
Overall, StT6PP utilizes many hydrogen bonds to orient the substrate mimic, 
trehalose 6-sulfate in the active site. The employment of polar amino acids to form 
hydrogen bonds with hydroxyl groups of sugars to confer specificity has been noted in 
other sugar binding proteins by Rao et al [37]. The most common amino acids in such 
carbohydrate binding sites are Arg, Asp, and Glu [38] while glucose binding sites also 
utilize Asn and Gln for hydrogen bonding [39]. The trehalose binding site of StT6PP 
contains two Glu residues and one Arg residue. Galactose binding proteins commonly 
utilize stacking of an aromatic ring with the pyranose ring to orient carbohydrates [40]. 
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Some glucose binding sites also utilize this mode of interaction, but T6PP does not contain 
aromatic residues planar to the glucose rings of trehalose. Instead, aliphatic hydrophobic 
residues on the C1 loop or in the cap domain form van der Waals interactions with the 
glucosyl moieties. 
 
3.4.2 StT6PP complex with trehalose 
The product, trehalose, was also soaked into a crystal of StT6PP. The crystal was 
soaked with high concentrations of trehalose (50 mM) to promote ligand binding in a 
solution also containing 35% PEG 3350 (increased 19% from reservoir solution), 166 mM 
lithium citrate, 166 mM MgCl2 and 10% ethylene glycol. The lithium citrate was decreased 
while magnesium chloride concentration was increased compared to the StT6PP/T6S 
complex conditions to prevent magnesium chelation and promote Mg2+ binding in the 
active site. The data were phased using the apo StT6PP model in molecular replacement 
and the structure refined to 2.05 Å resolution. 
The overall structure of the StT6PP/trehalose complex is in the same conformation 
as apo St6PP as shown by the low RMSD score of 0.7 Å between the models. The high 
magnesium chloride concentration did afford Mg2+ binding in the canonical magnesium 
binding site of HADSF members. The Mg2+ maintains a trigonal bipyramidal coordination 
state through coordinate bonds to loop I, loop IV, and 2 water molecules. Mg2+ is 
coordinated by Asp20 side chain (2.1 Å) and Asp22 C=O oxygen (2.0 Å) on loop I. On 
loop IV, Asp 198 side chain makes a 2.1 Å coordinate bond with Mg2+ and Asp202 forms 
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hydrogen bonds to a bridging water molecule (2.7 Å) that is 2.0 Å from Mg2+- as predicted 
from the Mg2+ density seen in StT6PP/T6S. The additional two water molecules in this 
structure compared to the StT6PP/T6S structure maintain 2.0 Å and 2.1 Å coordinate bonds 
to Mg2+. 
 
Figure 3.11 Active site of StT6PP/trehalose complex. Residues (purple) and trehalose 
(navy) are displayed as sticks. Magnesium ion is shown as lime green sphere and 
coordinate bonds are shown as dashed lines. The 2Fo-Fc electron density for magnesium 
is displayed as mesh contoured at 2s. 
 
The trehalose molecule has full occupancy in the StT6PP/trehalose complex. It is 
curious that 50 mM trehalose provided > 90% binding in crystallo given that in solution 
10 mM trehalose provides no inhibition (< 10% binding) of StT6PP-catalyzed hydrolysis 
of T6P (KI >10 mM, see Chapter 4). These values are inconsistent with hyperbolic ligand 
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binding characterized by 10% - 90% ligand binding over two orders of magnitude ligand 
concentration; StT6PP shows 10% - 90% ligand binding over a 5-fold trehalose 
concentration change. We propose the difference in binding is due to the differences of the 
enzyme in solution and in crystallo. In crystallo, the cap is maintained in a closed 
conformation, and thus the energy needed to close the cap has been accounted for. In 
solution, ligand binding promotes cap closure. Assuming hyperbolic binding of trehalose, 
the dissociation constant (KD) can roughly be estimated in crystallo and in solution at 5 
mM and 100 mM, respectively. The 20-fold change in KD equates to an energetic cost of 
7.4 kJ/mol to close the cap domain for ligand binding. Compared to the energetic cost of 
molecular motors like F-ATPase and kinesin (-64 kJ/mol and -31 kJ/mol, respectively) [41, 
42], the energetic cost of StT6PP cap closure is small. This is logical as StT6PP is a smaller 
protein and the domain shift a ~50° hinge closure, whereas F-ATPase and kinesin are large 
and have more complex domain shifts. For example, ATP hydrolysis drives the Fo and F1 
subunits of F-ATPase to rotate 120° around a central shaft. Indeed, the energy of cap 
closure is comparable to the formation of a single hydrogen bond [43].  
As with the StT6PP/T6S structure, there are many hydrogen bonds to the glucose 
moieties of trehalose (Figure 3.12). The C3 and C4 hydroxyls of the proximal glucose 
moiety form hydrogen bonds to the side chains of residues Glu123, Lys125, and Glu167 
and the C6 hydroxyl maintains a hydrogen bond with a bridging water, H2O1 to Asp199 
(this bridging water molecule does not have the same hydrogen bonding network observed 
in StT6PP/T6S- hydrogen bonds are not made to the distal glucose C2 hydroxyl, or Lys163 
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C=O. Instead, polar interactions are seen to Cl- ion and a water molecule). Additionally, 
the C2 hydroxyl hydrogen of trehalose forms hydrogen bonds to Glu66 side chain through 
a stabilized water molecule (3.0 Å), H202 (forms hydrogen bonds with both carbonyl 
oxygens of Glu66 (2.7 and 3.1 Å), Glu123 side chain (2.7 Å), the C3 hydroxyl of trehalose 
(3.4 Å) and another water molecule H2O3 (3.2 Å)). In addition to the interactions with 
Glu123 and Lys125, the C3 hydroxyl makes hydrogen bonds to 2 water molecules, H2O2 
(vide supra) and H2O3 (both 3.4 Å). H2O3 is positioned by hydrogen bonds to the Glu123 
side chain (2.8 Å), Glu66 side chain (2.4 Å), Ser63 NH (3.4 Å) and H2O2 (3.2 Å). The C6 
hydroxyl also makes a hydrogen bond to Glu167 side chain (2.8 Å) and another water 
molecule H2O4 (2.8 Å) with an extensive hydrogen bonding network (Glu167 side chain 
(3.3 Å), His82 side chain (3.3 Å), Gln160 C=O (3.1 Å), and H2O1 (3.2 Å)). As with the 
T6S bound complex, hydrophobic interactions between the proximal hexose ring and 
methylene chain of Arg62 and carbons of His132 are seen in the trehalose complex. For 
the distal glucose moiety, all interactions described in the StT6PP/T6S complex are also 
seen in the StT6PP/trehalose complex.  
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Figure 3.12 Active-site interactions between StT6PP and trehalose. Water molecules are 
shown as blue circles, chloride ion is shown as a yellow circle, hydrogen bonds are shown 
as dashed lines, and residues making van der Waals interactions are shown in red. 
 
3.4.3 StT6PP complex with OGS 
In addition to the substrate mimic T6S, the inhibitory probe, OGS was utilized to 
assess the consequences of substituting various moieties of the substrate—in this case, the 
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distal glucosyl group. Crystals of StT6PP were soaked in a solution containing 1 mM OGS 
and 40 mM MgCl2 and the liganded structure was determined to 2.24 Å resolution, with 
phases determined via molecular replacement using the model from SeMet-substituted 
StT6PP. The apo and OGS-liganded structures are very similar with an overall RMSD of 
0.42 Å (this number may be an underestimate due to bias from use of SeMet coordinates 
in molecular replacement). As discussed for the StT6PP/T6S complex, the density at the 
magnesium-binding site appears oblong due to the partial occupancy of Mg2+/water, as 
judged by the electron density, B-factors, and length of coordinate bonds. The Mg2+ 
occupies the same position in StT6PP/OGS model as that in the StT6PP/T6S complex. 
In this instance, the low occupancy of Mg2+ did not alter the binding site of the 
sulfate moiety of OGS from the typical phosphate binding site in the HADSF (Figure 3.14). 
Two oxygens of the sulfuryl group are observed to be coordinated to the Mg2+ (2.3 and 3.1 
Å). Additionally, the sulfate group makes direct hydrogen bonds with residue side chains 
in loops I (3.0 Å to backbone NH of Asp22 and 3.2 Å to backbone NH of Leu 21), II (Ser60 
side chain (2.6 Å) and Gly61 NH (2.8 Å)) and III (Lys175 side chain (2.9 Å)). A bridging 
water molecule creates interactions with residues in loop IV (Asp 198 and Asp 199 side 
chains) and Asp22 backbone C=O on loop I (Figure 3.13).  
As the proximal glucose moiety has not been replaced in OGS, the sugar makes 
some of the same interactions as in the proximal binding site of the T6S and trehalose 
bound structures. That is, the C3 hydroxyl hydrogen bonds with the side chain of Glu123 
and Lys125 (3.1 and 3.2 Å, respectively) and the carbon ring maintains van der Waals 
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interactions with the methylene chain of Arg62 and carbons of His132. Like the 
StT6PP/trehalose complex, the glucose moiety has shifted to create hydrogen bonds 
between the C2 hydroxyl through a bridging water to the side chains of Glu123 and Glu66. 
However, the C4 hydroxyl makes a 3.4 Å hydrogen bond with only the side chain of 
Lys125 (not Glu167 as seen in the StT6PP/T6S complex or both as seen in 
StT6PP/trehalose complex). 
The phenyl ring of OGS is observed in the distal subsite of T6PP. The position of 
the ring is rotated by 82° compared to the glucose in the distal subsite in the StT6PP/T6S 
complex and makes van der Waals interactions with Val165 in the cap domain and Ile28 
in the C1 insert. Ile28 also interacts with the octyl moiety of OGS along with Pro30 side 
chain and Lys29 backbone. The aliphatic methylene chain of Arg134 makes favorable van 
der Waals interactions with the octyl moiety of OGS with the guanidinium oriented toward 
the solvent. 
 110 
 
Figure 3.13 Active-site interactions between StT6PP and OGS. Water molecules are shown 
as blue circles, hydrogen bonds are shown as dashed lines, and residues making van der 
Waals interactions are shown in red. 
 
3.4.4 T6PP family utilizes the same binding determinants  
The substrate bound form of T6PP has been determined for the Mt ortholog [11] 
and for the catalytically inactive nucleophilic Asp to Asn variant of the phosphatase domain 
of CnT6PP [14]. Additionally, a complex of CaT6PP with a mimic of the phosphoenzyme, 
BeF3-, and product, trehalose, was determined [14]. Together, these structures and the 
structures of StT6PP complexes enable evaluation of the following questions:  Does T6PP 
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bind substrate in similar binding pockets amongst bacterial species and in various domains 
of life? What residues determine substrate position and specificity? Are they the same 
amongst all T6PPs? Which residues vary? Can we leverage knowledge about the substrate 
binding determinants to create one inhibitor of T6PP in multiple disease-causing 
organisms?  
 
Overall binding position of substrate.  
Mt and St T6PP share 31% sequence identity and their structures have high 
structural similarity (RMSD of 1.7 Å and 1.6 Å between the core and cap domains, 
respectively). St and Cn T6PP share a sequence identity of 28% and high structural 
similarity is observed between the liganded structures with an overall RMSD value of 2.1 
Å. The substrate analog complexes of Ca and St T6PP are similar with an RMSD of 2.1 Å 
for cap and core (despite low sequence identity of 27%). Superposition of the core domain 
of the complexes MtT6PP/T6P, CaT6PP/trehalose/BeF3, CnT6PP/T6P, StT6PP/trehalose, 
StT6PP/T6S, and StT6PP/OGS leads to the superposition of the ligands and many side 
chains (Figure 3.14, for clarity, only the latter four complexes are shown with the side 
chains of StT6PP). Particularly, the position of the proximal glucose is unchanged in all 
complexes. The positioning of the moiety in the distal glucose subsite is more variable. In 
the complexes CnT6PP/T6P, MtT6PP/T6P, and StT6PP/OGS the phosphoryl moiety or 
mimic retains the same hydrogen-bonding pattern to strictly conserved residues in loops I-
IV. From this overlay, it is apparent the sulfonyl group in the StT6PP/T6P is an outlier.  
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Figure 3.14 Conservation of T6PP active site. The core domain of T6PP complexes 
StT6PP/T6S (gray), StT6PP/trehalose (navy), StT6PP/OGS (brown), and CnT6PP/T6P 
(peach) were overlayed. Residues side chains of the StT6PP/trehalose complex are depicted 
as sticks colored by sequence conservation.  
 
Retained interactions and conservation of the proximal and distal subsites  
Proximal subsite 
Due to the partially open cap conformation of MtT6PP, interactions between 
residues in the cap and substrate cannot be examined. However, liganded structures of Cn 
and Ca T6PP are in a cap-closed conformer. In the complexes CnT6PP/T6P and 
CaT6PP/trehalose/BeF3-, the proximal glucosyl moiety of T6P forms a hydrogen bonds 
with two glutamates and a lysine corresponding to Glu123, Lys125 and Glu167 in StT6PP. 
The proximal C3 hydroxyl of T6P in the CnT6PP structure makes an additional hydrogen 
bond to Thr138. The trehalose C4 hydroxyl makes an additional hydrogen bond to His87 
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of CaT6PP (does not correspond to His132 in StT6PP). The proximal glucose moiety in 
CnT6PP/trehalose/BeF3- and CaT6PP/T6P complexes also retains hydrophobic 
interactions with the methylene side chain of an arginine corresponding to Arg62 in 
StT6PP. Overall the retained interactions between five structures at the proximal glucosyl 
binding site are hydrogens bonds to two glutamates (exception: StT6PP/OGS only interacts 
with Glu123) and a lysine. Additionally, all structures make van der Waals interactions 
with the methylene side chain of an arginine. We analyzed the conservation of the 
interacting residues using select sequences from all domains of life (Figure 3.2). Residues 
corresponding to Glu23, Lys125, and Glu167 in StT6PP are highly conserved (nematodes 
replace Glu123 with Gln). Arg62 is conserved in bacteria, archaea and fungi, but not 
nematodes (replaced with a serine). Based on the retained interactions and sequence 
conservation, it can be concluded that formation of hydrogen bonds with the Glu/Lys/Glu 
motif is necessary for substrate specificity and binding. The importance of the Glu/Lys/Glu 
motif for binding ligands explains the inability to replace the proximal glucosyl group with 
a phenyl ring during the design of OGS.  
 
Distal subsite  
As with the StT6PP/T6S structure, the C4 and C6 hydroxyls of the distal glucose in 
MtT6PP/T6P, CnT6PP/T6P and CaT6PP/trehalose/BeF3- complexes make hydrogen bonds 
with backbone residues in the C1 loop. The retained interactions include the position of an 
ordered water to bridge a hydrogen bond to the C1 loop (this water also bridges a hydrogen 
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bond to the acid/base aspartate side chain). Additionally, van der Waals interactions with 
Pro32 and various hydrophobic residues are seen in all liganded complexes.  
The C1 loop is a novel structural feature of the HADSF observed only in the T6PP 
family. The conformation of the C1 loop is maintained amongst all structurally 
characterized orthologs of T6PP to date (both liganded and unliganded), yet the primary 
sequence is not conserved among T6PPs. As the hydrogen bond interactions between the 
distal glucose and the C1 loop involve only main chain atoms, there is a lack of 
evolutionary constraint on the side chains leading to variability of the sequence.  
In StT6PP/T6S complex, the distal glucose also makes hydrogen bonds with the 
following cap residues: Arg134 side chain, Lys163 mainchain, and His132 through a 
bridging water. In the CnT6PP/T6P and CaT6PP/trehalose/BeF3- complexes these 
hydrogen bonds are also observed with the corresponding residues. Additionally, the C2 
hydroxyl forms a hydrogen bond with Asn178, however this residue is only conserved in 
fungal T6PPs. Arg134 is positioned toward the active site in T6PP complexes with 
substrate and substrate-mimics (StT6PP/T6S, StT6PP/trehalose, CnT6PP/T6P and 
CaT6PP/Tre/BeF3-). The residue is conserved in bacteria and fungi but varies to other 
nitrogen-containing residues in nematodes (Lys and His in Bm and Ce T6PP, respectively). 
In the archaeon, TaT6PP, the corresponding residue is a glycine. In the StT6PP/OGS 
structure Arg134 has “swung-out” to position the guanidinium toward solvent and the octyl 
tail of OGS makes favorable van der Waals interactions with the methylene chain. The 
Lys163 is not highly conserved, but the positioning of the backbone is more important for 
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ligand binding. His132 is conserved amongst bacteria, fungi and archaea, but not 
nematodes.  
Overall, the distal subsite is more variable than the proximal subsite—no residues 
interacting with the distal glucose are strictly conserved amongst all domains of life. This 
could be the cause of the variability of the distal glucose positioning in various T6PP 
structures. As the distal subsite does not provide specific interactions, we predict it is used 
to increase affinity for the substrate via hydrogen bonds to the backbone and van der Waals 
interactions with hydrophobic side chains. For future efforts to rationally design inhibitor 
of T6PP, interactions in this site could be used to increase affinity and medicinal chemical 
properties. 
 
Comparison of T6PP and SPP 
Sucrose-6f-phosphate phosphatase (SPP) catalyzes the dephosphorylation of the 
disaccharide, sucrose-6f-phosphate and represents the HADSF member with the most 
similar substrate to T6PP. Although the sequence identity (13%) is low between StT6PP 
and SPP (like many HADSF members), the core and cap domains have similar folds 
(RMSD values of 3.0 and 2.8 Å, respectively) [44]. The core and cap domains of SPP are 
mobile with respect to each other like T6PP (as indicated by crystal forms in the open and 
closed conformation). SPP lacks the C1 loop and has a binding cleft that binds substrate 
opposed to the binding cavity observed in T6PP. SPP utilizes the sucrose moiety to exclude 
water during catalysis. The difference between the active sites leads to SPP and T6PP 
utilizing dissimilar determinants to bind substrate. While T6PP orients the substrate in the 
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active site via the proximal glucose and phosphate, SPP forms hydrogen bonds to the 
phosphate and distal glucose to orient the substrate for catalysis. The comparison of the 
binding modes of SPP and T6PP indicates the T6PP binds substrate in a unique manner 
compared to other HADSF members.  
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3.5 Conclusions 
The structures of Mm and St T6PP were determined in cap-open and cap-closed 
conformations, respectively. The cap-closed conformation of StT6PP allowed for structure 
determination in the presence of substrate mimic- T6S, product- trehalose and an inhibitory 
probe- OGS. The cap-closed conformation of StT6PP is an energetically favorable 
conformation that increases ligand binding due to proximally prepositioning the cap and 
core domains. The liganded structures confirmed the binding site for T6PP in bacterial 
species positions substrate similarly to that seen in fungal T6PPs [14]. The trehalose moiety 
is oriented with numerous hydrogen bonds from the cap domain and the backbone of the 
C1 loop. Specifically, the highly conserved Glu/Lys/Glu cap motif confers specificity for 
the proximal glucose of T6P.  
As the substrate specificity determinants are conserved in the T6PP family, it is 
possible that a broad spectrum antibacterial, antifungal and antihelminth therapeutic can 
be developed. Efforts to design OGS determined a molecule must target the phosphate 
binding site and the proximal glucosyl subsite. We furthered this understanding by 
determining that interactions with the Glu/Lys/Glu motif in the proximal subsite are 
required for ligand binding. As the phosphate binding site is a critical site in all HADSF 
members to anchor the ligand in the active site, it is important that therapeutics utilize 
hydrogen bonds with the Glu/Lys/Glu motif for specificity. Hydrophobic interactions at 
the distal subsite may be used to increase affinity. However, as this subsite is variable, the 
potency of a single therapeutic may differ against diverse pathogenic species.  
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This research not only assists the future development of therapeutics against human 
illness, it supports our knowledge of the HADSF. Here we present the second example of 
a disaccharide-binding HADSF member (the first was SPP [44]). T6PP confers specificity 
for substrate via the phosphate and proximal glucosyl subsites. T6PP also utilizes a novel 
structural motif, the C1 loop, to bind the distal glucosyl moiety. With every HADSF 
member structure, the understanding of how this superfamily catalyzes phosphoryl transfer 
from assorted substrates to water grows. With more structural information, we will 
continue to gain understanding of molecular binding interactions in the HADSF.  
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 SUBSTRATE SPECIFICITY AND SMALL MOLECULE INHIBITION OF T6PP 
Abstract 
T6PP, a therapeutic target for lymphatic filariasis and tuberculosis catalyzes the 
dephosphorylation of T6P to trehalose. As a potential therapeutic target, T6PP poses 
unique challenges in specificity because therapeutics must not inhibit phosphatases that 
serve essential functions in the cell. Additionally, current phosphate mimics are charged 
moieties unfavorable for therapeutics. In an effort to discover new phosphate mimics, Seth 
McDonald (undergraduate researcher, Allen laboratory) computationally screened small 
molecule functional groups or fragments for binding to the HADSF phosphoryl-binding 
subsite of the active site. Tetrazole was identified as a potential ligand and tested as a 
phosphate mimic by via inhibition of T6PP-catalyzed dephosphorylation by trehalose 6-
tetrazole. Additionally, two inhibitors of Brugia malayi T6PP, Cephalosporin C, and 
Closantel, were discovered by screening the Johns Hopkins University Clinical Compound 
library. Computational docking of Cephalosporin C into StT6PP indicated a hydrogen-
bonding network that differed from that observed with substrate or product. Thus, new 
analogs of Cephalosporin C were designed with an optimized 5,6-indole scaffold to 
incorporate substituents that form hydrogen bonds with binding determinants conserved 
among T6PP orthologs. Initial inhibitors based on this scaffold show promise for further 
development. From the same library, Closantel was determined to act as a slow-binding 
inhibitor. To further enhance inhibitor potency, a library of Closantel analogs was 
synthesized in the Janda laboratory at The Scripps Research Institute (La Jolla, CA) and 
tested for inhibition relative to Closantel; two of these Closantel analogs showed increased 
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potency. Future efforts will focus on incorporation of tetrazole into the Closantel scaffolds 
and the structural characterization of the inhibitors’ binding poses in the T6PP active site 
to further inform therapeutic design.  
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4.1 Introduction 
Lymphatic filariasis is a painful and disfiguring disease leading to lymphoedema 
of limbs and hydrocele caused by blockages in the lymph system by parasitic nematodes 
such as Brugia malayi (Bm), Wuchereria bancrofti and Brugia timori. The microfilariae, 
or infantile nematodes, are transferred from human to human via mosquitos. Hence, 
tropical and subtropical areas have an estimated 120 million infected and almost 40 million 
disabled individuals. Current treatment comprises annual dosing of albendazole and 
ivermectin or diethylcarbamazine to the entire at-risk population [1]. However, these drugs 
only target microfilariae, but not the adult nematodes, and have adverse side effects like 
headache, stomach pain, and nausea [2]. As the adult nematodes can live in the human host 
for up to 7 years, patients from mostly under-resourced countries require treatment for at 
least 5 years. There is an urgent need to develop new therapeutics that target both the 
microfilariae and adult nematodes, which could decrease both disability and treatment 
duration.  
Tuberculosis is an infection of Mycobacterium tuberculosis (Mt) in the lungs that 
leads to coughing, fever, loss of lung function and weight loss. It is one of the top ten causes 
of death world-wide with 95% of cases occurring in developing countries. Most patients 
are adults, but children, the elderly, and people infected with HIV are especially 
susceptible. Tuberculosis is treated with a rigorous six-month antibiotic course [3], and is 
becoming more antibiotic resistant; in 2016, greater than 5.8% of tuberculosis incidences 
developed antibiotic resistance [3]. Additional challenges to target Mt include the ability 
of Mt to enter a low activity persistent state in which antibiotics that target actively dividing 
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cells are ineffectual [4] and low cell permeability of small molecules due to the formation 
of Mt biofilms and the additional layer in the bacterial cell wall consisting of mycolic acids 
and polysaccharides [5]. Improved treatments for tuberculosis are required to shorten 
treatment time and decrease the deaths caused by this disease.  
Although lymphatic filariasis and tuberculosis are caused by different organisms, 
these organisms share the biosynthetic pathway of the sugar trehalose [6]. Mycobacteria 
and nematodes utilize the enzymes trehalose-6-phosphate synthase and trehalose-6-
phosphate phosphatase (T6PP) to synthesize trehalose through the intermediate trehalose 
6-phosphate (T6P) [7, 8]; humans do not utilize or synthesize trehalose. It has been shown 
that the build-up of T6P is toxic and decreases the viability and virulence of Caenorhabditis 
elegans (Ce; a model nematode system) and Mt [7, 9, 10]. Therefore T6PP is a therapeutic 
target for lymphatic filariasis and tuberculosis and we aim to design specific therapeutics 
for T6PP.  
T6PP is a phosphatase that catalyzes the dephosphorylation of T6P to generate 
trehalose. Phosphatases are ubiquitous in nature and catalyze reactions in numerous 
important cellular pathways [11]. Traditionally, phosphatases have not been targeted for 
therapeutic intervention with great success due to the detrimental effects of small-
molecules non-specifically binding to phosphatases essential for cellular function. 
Additionally, the negative charge of the phosphate group imparts significant binding 
energy in the enzyme-substrate complex [11] and is not easily mimicked by cell permeable 
groups. Current phosphate mimics including sulfate, tungstate, vanadate, aluminum 
trifluoride and beryllium trifluoride are useful biochemical tools to gain insight into the 
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catalytic mechanism of phosphatases, but are not ideal substituents for therapeutic 
molecules. Therefore, substituents that mimic phosphates without the incorporation of 
heavy metals or a charge are desired.  
In this Chapter, I discuss the use of small molecules to inhibit T6PP from the 
parasitic nematode Bm, the bacterium Mt, and their models Ce, Mycobacterium marinum 
(Mm) and Salmonella typhimurium (St). The identification of inhibitors with in vitro 
activity will aid future efforts to create specific therapeutics for lymphatic filariasis and 
tuberculosis.  
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4.2 Methods 
4.2.1 Phosphatase Assays 
To study the T6PP reaction, two assays that monitor the production of inorganic 
phosphate were used, the BIOMOL® Green assay and the EnzChek™ phosphate assay. The 
general methods are discussed in the following sections. 
BIOMOL Green Assay 
The BIOMOL Green assay is a colorimetric, discontinuous assay used to detect 
PO43-. It may be used with a minimum reaction volume of 40 µL and reactions are quenched 
with 100 µL of BIOMOL Green reagent. This reagent contains malachite green chloride 
(N,N,N′,N′-tetramethyl-4,4′-diaminotriphenylcarbenium chloride) (Figure 4.1A), 
molybdate, and 1 M NaOH. In the presence of PO43-, malachite green chloride and 
molybdate form a complex with a maximum absorbance at 620 nm. In Nunc MaxiSorp™ 
clear, flat-bottom 96-well plates, the BIOMOL Green assay has a background absorbance 
of ~0.05 absorbance units. The linear range of the assay extends from 2-60 µM PO43- with 
a slope of 0.00704 Abs620/µM PO43- (Figure 4.1B). 
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Figure 4.1 BIOMOL Green Assay. A) Structure of malachite green chloride. B) Typical 
standard curve of BIOMOL green assay. Error bars indicate standard deviation of triplicate 
measurements. 
 
The BIOMOL Green assay was used to study the steady-state kinetics of T6PP and 
to analyze the inhibition of the T6PP reaction via small-molecule inhibitors. Each 
experiment started by determining the optimal concentration of enzyme. As enzyme 
stability and activity may vary slightly with each aliquot of stored protein, this must be 
determined daily. Generally, 20 µL enzyme is 2-fold serial diluted into a kinetics buffer 
containing 100 mM Tris pH 7.5, 50 mM NaCl, 5 mM MgCl2 and 0.1mg/mL BSA. The 
reaction is started by the addition of 20 µL of T6P at 1-5 mM and quenched with BIOMOL 
Green reagent after 5-10 minutes. Reagent color is developed for 30 minutes and the 
absorbance is measured at 620 nm. For inhibition kinetics, an optimal enzyme 
concentration is at the maximum of the linear range (Abs620 @ 0.45) to subsequently 
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visualize the decrease in activity. To test inhibition, the volume of enzyme was decrease to 
15 µL to account for 5 µL of inhibitor; 20 µL of T6P was added to start the reaction. For 
steady-state kinetics, the optimal enzyme concentration is in the middle of the linear range. 
Generally, 2-50 nM T6PP was used. Controls include testing the substrate solution, purified 
protein, kinetics buffer, and inhibitor solution for the presence of PO43- or interference with 
the BIOMOL Green reagent. If small amounts (less than 10 µM) of PO43- were present, it 
was subtracted as background absorbance. 
 
EnzChek Phosphate Assay 
The EnzChek Phosphate assay is a continuous, coupled, spectrophotometric assay 
used to detect PO43-. In the presence of PO43-, the enzyme purine nucleoside phosphorylase 
(PNP) catalyzes the cleavage of the nucleoside 2-amino-6-mercapto-7-methylpurine 
riboside (MESG) forming ribose 1-phosphate and 2-amino-6-mercapto-7-methylpurine 
(Figure 4.2A). The accumulation of purine is measured in real time spectrophotometrically 
by its absorbance at 360 nm. I optimized the assay to be used in Corning® UV-transparent 
96-well plates with a reaction volume of 200 µL. MESG has substantial background 
absorbance of ~ 0.3 absorbance units and the linear range of the assay extends from 5-100 
µM PO43- with a slope of 0.00651 Abs360/µM PO43- (Figure 4.2B).  
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Figure 4.2 EnzChek Phosphate Assay. A) The PO43--coupled reaction of MESG cleavage 
by PNP. B) Typical standard curve for EnzChek phosphate assay. Error bars indicate 
standard deviation of triplicate measurements. 
 
Each reaction contained 48 µL water, 10 µL 20X EnzChek buffer (1.0 M Tris pH 
7.5, 20 mM MgCl2, and 2 mM sodium azide), 40 µL 1 mM MESG, 2 µL 100 U/mL PNP 
(former components herein referred to as EnzChek cocktail), 6-10 µL T6PP, 0-4 µL 
inhibitor, and 90 µL T6P. All components except T6P were incubated for 10 minutes to 
reach equilibration. Addition of T6P started the reaction and absorbance at 360 nm was 
monitored every 10-30 seconds for 5-10 minutes. As was done for the BIOMOL Green 
assay, the concentration of enzyme was optimized daily. The optimal enzyme 
concentration maintained the initial reaction velocity (showed linear absorbance over the 
time course) and reached the maximum of the linear range of the assay (~0.95 absorbance 
units) at the end of the measured time. Generally, 20-500 nM enzyme was used. Substrate 
solution, purified protein, kinetics buffer, and inhibitor solution were tested for the 
presence of contaminating PO43- and/or interference with the absorbance. Additionally, 
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control experiments were performed to ensure inhibitors designed against T6PP activity 
did not inhibit PNP activity.  
 
4.2.2 Steady-state Kinetics 
Steady-state kinetic constants were measured for Bm, Mt, Mm, and St T6PP. Kinetic 
constants were determined for Mt and Mm T6PP using the BIOMOL Green assay. For 
MtT6PP, 20 nM enzyme was incubated with 0.16-10 mM T6P for 0, 5, 10, 15, and 20 
minutes. For MmT6PP, 4 nM enzyme was incubated with 0.016-4.0 mM T6P for 0, 4, 8, 
12, 16, and 20 minutes. The Enzcheck phosphate assay was used to monitor PO43- release 
from Bm and St T6PP-catalyzed hydrolysis of T6P. For BmT6PP, 65 nM enzyme in 
EnzChek cocktail was mixed with 0.014-7.2 mM T6P. Absorbance was measured every 
30 seconds for 10 minutes. For StT6PP, accumulation of purine was measured every 10 
seconds for 10 minutes using 30 nM enzyme in EnzChek cocktail with 0.059-7.6 mM T6P. 
Absorbance measurements were performed with a SpectraMax M5 plate reader. Initial 
reaction velocities (!") were determined by linear regression. Data were fit using GraphPad 
Prism 6 using Equation 4.1: 
Equation 4.1 
!" = !$%&[(]*+ + [(] 
where !$%& is the maximum velocity, [S] is the total concentration of T6P and *+ is the 
Michaelis-Menten constant. The turnover number (-.%/) was calculated using Equation 
4.2: 
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Equation 4.2 -.%/ = !$%&[0]  
where [E] is the concentration of T6PP.  
 
4.2.3 Inhibition Kinetics 
Inhibitor Spot Tests and Screening 
T6PP inhibition by small molecules was initially probed using a spot test. A spot 
test used the BIOMOL Green assay to test a single reaction at a constant T6P and inhibitor 
concentration to evaluate if the molecule inhibits T6PP. Generally, the concentration of 
T6P was 2-5	x *+. If testing a novel inhibitor, the activity was tested at > 1 mM inhibitor. 
If comparing the inhibition of analogs to the original inhibitor, inhibitor concentrations 
were near the half maximal inhibition concentration (IC50).  
Trehalose and SO43- were tested as inhibitors of T6PP. 60 nM BmT6PP and 5 nM 
StT6PP were incubated with 10 mM trehalose and 2.5 mM T6P for 5 minutes. Reactions 
were quenched with BIOMOL Green reagent, developed for 30 minutes and absorbance 
determined at 620 nm on a SpectraMax M5 plate reader. The previous reaction was 
repeated using 10 mM SO43- and 25 nM BmT6PP. To evaluate the inhibition of other 
phosphate mimics, 30 nM StT6PP was incubated with 5 mM phosphate mimic for 1 hour 
to establish equilibrium. The reaction was initiated with 1 mM T6P and quenched after 5 
minutes. The CephC analogs were tested for inhibitory effect on 10 nM BmT6PP in the 
presence of 2.5 mM T6P for 5 minutes at 10 µM CephC analog. For the Closantel analogs, 
 136 
75 nM BmT6PP was incubated for 1 hour with 10 µM Closantel analogs prior to a 10-
minute reaction with 1 mM T6P.  
 
Determining Half Maximal Inhibitory Concentrations 
To estimate inhibition of T6PP by small molecules, IC50 values were measured 
using the BIOMOL Green assay. Generally, inhibitors were diluted serially by 2-fold. T6P 
at 2-5 x *+ was added to the inhibitors and the reaction was initiated with the addition of 
T6PP. The reaction was quenched after 5-10 minutes, BIOMOL Green reagent was 
developed for 30 minutes and the absorbance at 620 nm was read on a SpectraMax M5 
plate reader. The absorbance was plotted against the log of inhibitor concentration ([I]). 
IC50 was calculated in GraphPad Prism 6 using Equation 4.3: 
Equation 4.3 
Abs567 = Bottom+ (Top− Bottom)1 + 10([CDE[F]GCDE(FHIJ))∗LMNN	ONDPQ 
where Top and Bottom are the plateaus of the curve and Hill slope is the slope factor. Hill 
slope is constrained to one unless otherwise noted. Not all dose-response curves were 
complete with plateaus on each end of the curve due to limitations in solubility and 
availability of inhibitors. In these instances, the Top and Bottom were constrained to the 
no inhibitor and no enzyme and/or substrate controls, respectively.  
 
Determining Inhibition Constants 
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The steady-state inhibition constant (*R) was determined for BmT6PP with the 
inhibitors CephC and 5,6-indole-tetrazole. Initial reaction velocities were measured with 
the EnzChek phosphate assay as a function of T6P concentration and inhibitor 
concentration (I). For CephC, 125 nM BmT6PP catalyzed 0.088-11.25 mM T6P in the 
presence of 0, 0.25, 0.50, 1.0 and 2.0 µM CephC zinc salt. For 5,6-indole-tetrazole, 65 nM 
BmT6PP catalyzed 0.014-7.2 mM T6P in the presence of 0, 15, 30 and 50 µM 5,6-indole-
tetrazole. Initial rates were fit via linear regression and plotted against T6P concentration. 
Date were fit to Equation 4.4: 
Equation 4.4 
!" = !$%&[(]*$(1 + [S]*R 	) + [(] 
with a global fit of !$%&	and *$. Data were collected for the inhibition of 40 nM MmT6PP 
by 50 µM CephC zinc salt at 56, 84 and 225 µM T6P. The incomplete hyperbolic binding 
curve was fit to Equation 4.4 to estimate the *R. An estimate of *R was also determined for 
trehalose 6-tetrazole by measuring !" of 450 nM BmT6PP with 1.8 mM T6P in the absence 
and presence of 800 µM trehalose 6-tetrazole. Data were fit to Equation 4.5: 
Equation 4.5 
1 − !T!" = [S][S] + *R(1 + [(]*+	) 
where !T is the inhibited initial velocity.  
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4.2.4 Structural Characterization of Inhibitor Binding 
Dynamic Light Scattering 
Dynamic light scattering (DLS) is a technique used to measure the size and 
uniformity of particles in solution. It detects small quantities of protein aggregates and 
changes to the uniformity of proteins. Therefore, DLS was used to measure effects of 
inhibitors on T6PP stability. 1 mg/mL BmT6PP was mixed with equimolar inhibitor in a 
10 µL volume. Ten acquisitions (5 seconds each) of light scattering data were collected 
and averaged to measure particle sizes.   
 
Crystallography Trials 
To characterize the binding position of inhibitors, the three-dimensional x-ray 
crystallographic structure of T6PP in complex with inhibitors was pursued. Most attempts 
were focused on soaking inhibitors into preformed crystals of StT6PP. Protein expression, 
purification and crystallization were performed as described in Chapter 3. As we were able 
to obtain structures of the cap-closed conformation of StT6PP complexed with the small 
molecules T6S, trehalose, and OGS by crystal soaking, it follows that other small 
molecules complexes can be determined by this method as well. Numerous trials were 
executed to obtain liganded complexes of StT6PP by soaking of the following molecules 
into crystals:  T6P, glucose, Closantel, CloA3, CephC, 5-methyl-1H-tetrazole, 1-methyl-
1H-tetrazole, 5-phenyl-1H-tetrazole, 5-(4-nitrophenyl)-1H-tetrazole, trehalose 6-tetrazole, 
5,6-indole-tetrazole, and 4-n-octylphenyl-2-(3-(flurosulfonyl) benzoylamino)-2-deoxy α-
D-glucopyranoside-6-sulfate (OFBGS). A summary of the data sets collected is shown in 
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Table 4.1. Exhaustive efforts to optimize soaking conditions for Closantel and CephC were 
undertaken. First, inhibitor concentrations were increased to saturation and the length of 
soaking was increased up to 30 days. To increase inhibitor solubility various inhibitor 
solvents were tried according to Hassel et al. [12] and the Cryosol™ manual. Crystals were 
cross-linked with glutaraldehyde to enhance the ability of the crystals to tolerate higher 
solvent concentrations. Additionally, crystals were soaked at 37 °C to increase enzyme 
motion in crystallo to facilitate ligand binding. Concurrently, co-crystallization attempts 
were initiated. Sparse-matrix high-throughput screening of crystallographic conditions 
were performed with MmT6PP/Closantel, MmT6PP/CephC, MmT6PP/OFBGS, 
MtT6PP/OFBGS, StT6PP/Closantel, StT6PP/CephC, StT6PP/OFBGS, 
BmT6PP/Closantel, and BmT6PP/OGS. No crystal hits yielded reproducible crystals or 
diffraction quality crystals. 
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Table 4.1 Data sets of StT6PP soaked with small molecules 
 
 
Inhibitor Docking 
In lieu of experimental structural data, inhibitor docking was performed using the 
Autodock Vina extension in UCSD Chimera [13, 14]. The structure of StT6PP bound to 
T6S was used as the model to ensure that active-site residues were oriented as in the 
Michaelis complex. T6S was deleted from the model prior to docking and the Autodock 
Vina algorithm was used to remove water molecules and metal ions. Hydrogen bonds were 
predicted by the Find H-bond feature in UCSD Chimera. Graphic displays were also 
generated in USCD Chimera.  
 
  
Ligand # of Soaked Data Sets  
Closantel 44 
ClosA3 16 
CephC 39 
5,6-indole tetrazole 3 
Tetrazoles (various) 9 
OFBGS 2 
T6P 2 
Glucose  1 
Glucose with VO43- 1 
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4.3 Steady-State Kinetics of T6PP  
The catalytic efficiencies of T6PP orthologs were determined to confirm previously 
published data and ensure all T6PP orthologs are comparable. To do so, the steady-state 
parameters, kcat and KM, were determined using initial reaction velocities (Figure 4.3). The 
KM values determined were higher (up to 6-fold) than published values but kcat values are 
within 10-fold of those published ( 
Table 4.2) (respectively, published kcat and KM values for BmT6PP: 28 s-1, 260 µM 
[9]; MtT6PP: 10 s-1, 500 µM [15, 16]; StT6PP: 6 s-1, 310 µM [15]). T6PP exhibits low 
affinity towards substrate with KM values up to 1.9 mM. MmT6PP shows the highest 
affinity with a KM of 0.18 mM. KM values can approximate affinity in this instance, because 
we are comparing values of the same reaction and expect the rate-limiting step (generally 
the hydrolysis of the phospho-enzyme in the HADSF [17]) amongst orthologs to be 
consistent. The turnover number amongst these species is similar and within 15-fold of one 
another (although this value seems large, the Allen Lab has observed kcat can vary an order 
of magnitude between individual experiments due to protein preparation and experimental 
error). Overall, the catalytic efficiency of T6PP is consistent across orthologs. Together, 
the kinetic constants, catalytic efficiencies and structural similarity (see Chapter 3) of T6PP 
orthologs indicate structure-function results from one ortholog may be extrapolated to 
others.  
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Figure 4.3 Initial velocities of T6PP-catalyzed hydrolysis of T6P vs T6P concentration. 
The reactions contained 65 nM Bm, 20 nM Mt, 4 nM Mm, or 30 nM St T6PP with T6P 
(0.014 - 10 mM) in a Tris buffer at pH 7.5 containing at least 1 mM MgCl2. Reactions 
were performed at 25 °C and were initiated with the addition of substrate. The 
concentration of phosphate generated over time was measured using the EnzChek 
Phosphate or BIOMOL Green assays.  
 
Table 4.2 Steady-state kinetic constants for T6PP-catalyzed hydrolysis of T6P.  
T6PP ortholog kcat (s-1) KM (mM) kcat/KM (M-1s-1) 
Bm 2.8 ± 0.0056 1.1 ± 0.0066 2.6 x 103 
Mt 40 ± 0.94 0.80 ± 0.087 5.0 x 104 
Mm 31 ± 0.41 0.18 ± 0.0070 1.7 x 105 
St 17 ± 0.048 1.9 ± 0.012 9.2 x 103 
 
Although T6P does not bind to T6PP with high affinity, knowledge of the 
contribution of the trehalose and phosphate moieties to substrate binding would allow 
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rational design of inhibitors. We hypothesized that either the phosphate or trehalose moeity 
would provide more energy towards substrate binding than the other moiety. If this 
hypothesis is true, we could focus our inhibitor design efforts to target the most important 
subsite. Therefore, trehalose and the phosphate mimic, sulfate, were tested as inhibitors of 
the T6PP reaction. Sulfate was used in lieu of phosphate to measure binding at the 
phosphate binding site because the available experimental assays produce signal correlated 
to the concentration of inorganic phosphate. In Bm and St T6PP, concentrations of 10 mM 
trehalose or sulfate did not cause an observable decrease in activity, therefore, 
conservatively the KI for these compounds can be estimated at greater than 10 mM. The 
high inhibition constants of T6PP by trehalose and sulfate indicate that neither the trehalose 
nor the phosphate moiety contribute the majority of the substrate binding energy. However, 
trehalose 6-sulfate does inhibit T6PP activity in the mid-micromolar range [15]. So, we 
propose there is a synergistic effect of the trehalose and phosphate groups that enhances 
binding. Moving forward, inhibitors of T6PP should include moieties that bind in the 
trehalose and phosphate subsites.   
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4.4 Tetrazole as a Phosphate Mimic 
4.4.1 Bioinformatic Discovery of Phosphate Mimics  
To discover phosphate mimics, we computationally screened fragment libraries to 
search for molecules with similar properties to phosphate. First a composite active site of 
HADSF members was generated. The core domain of 11 representative HADSF members 
with all cap types was superimposed and the positions of the hydrogen bond donors were 
averaged. In addition, the active site of histidine protein phosphatase SixA from E. coli was 
used to generate a second model. SixA represents a second superfamily of phosphatases 
that was used to prevent data bias toward only the HADSF, and to attest the results are 
generalizable to other phosphatase families. The histidine protein phosphatase superfamily 
was chosen in particular because it is similar to the HADSF in that is contains a Rossman 
fold core domain and a modular cap domain. Both active sites were used to generate models 
in Avogadro [18] that placed hydrogen bond acceptor atoms in position to mimic 
phosphate. Then the Zinc [19], Zenobia, and ChemBridge fragment libraries were screened 
using Open Eye ROCS for compounds that matched the chemical, electrostatic, and 
structural properties of the model. This computational screening was performed by Seth 
McDonald while he visited from Ripon College during his 2016 summer research 
undergraduate experience. Data was manually parsed to find an uncharged phosphoryl 
mimic. The functional groups tetrazole, 1,3,5-triazine, trifluoromethoxymethane, N-
methylmethanesulfonamide, and 1,1-dimethoxypropane reoccurred in the highest-ranking 
fragments (Figure 4.4).  
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Figure 4.4 Functional groups computationally identified as phosphate mimics. 
 
4.4.2 Experimental Analysis of Phosphate Mimics 
The computationally identified phosphate mimics 1,3,5-triazine, N-
methylmethanesulfonamide, 1-methyl-1H-tetrazole, 5-phenyl-1H-terazole, and 4-(5-
nitrophenyl)-1H-tetrazole were acquired from commercial sources and tested at 5 mM for 
inhibitory effects on StT6PP (Figure 4.5A). 1,1-dimethoxypropane and 
trifluoromethoxymethane were not pursued due to their similarity to carboxylic acid and 
beryllium trifluoride, respectively, which are known phosphate mimics. N-
methylmethanesulfonamide and 1-methyl-1H-tetrazole showed negligible inhibition while 
1,3,5-triazine inhibited 49 ± 5 % of T6PP activity. 5-phenyl-1H-tetrazole and 4-(5-
nitrophenyl)-1H-tetrazole showed the most inhibition, inhibiting 72 ± 3 % and 71 ± 6 % of 
T6PP activity, respectively. The inhibition of StT6PP by the 5-phenyl-1H-tetrazole 
containing compounds was further characterized in a dose-response experiment (Figure 
4.5B). Both compounds exhibited an all-or-none response indicating the inhibition was not 
hyperbolic. As tetrazole has been shown to chelate divalent metals [20], the inhibition of 
BmT6PP in the presence of 5, 10, or 25 mM MgCl2 and 10 mM 5-phenyl-1H-tetrazole was 
tested. At all concentrations of MgCl2, BmT6PP was catalytically inactive. The addition of 
Mg2+ was unable to recover activity indicating that Mg2+ chelation was not the cause of 
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inhibition. Another possibility was the destabilization of T6PP in the presence of inhibitor. 
To test for destabilization, equimolar BmT6PP and 5-phenyl-1H-tetrazole or 4-(5-
nitrophenyl)-1H-tetrazole were tested for aggregation using DLS. The no inhibitor control 
showed 2% of BmT6PP in solution was aggregated and 98% of protein was only 9.5% 
polydisperse. Both 5-phenyl-1H-tetrazole or 4-(5-nitrophenyl)-1H-tetrazole caused 
aggregation to approximately 30% of BmT6PP in solution (measured by percent mass with 
radii > 100 nm). The remaining protein was more than 30% polydisperse (Figure 4.5C). 
The high polydispersity and increase in aggregation indicate that the enzyme is unstable 
and unfolding in the presence of 5-phenyl-1H-tetrazole containing compounds. Therefore, 
the mechanism of inhibition of 5-phenyl-1H-tetrazole and 4-(5-nitrophenyl)-1H-tetrazole 
is considered to be via unfolding and destabilizing T6PP. 
After the initial screening of all the phosphatase mimics and the indication that 
tetrazole containing molecules inhibit T6PP (prior to understanding the mechanism of 
inhibition), our collaborator in the Janda Lab at Scripps Research Institute, Lucy Lin 
synthesized a substrate mimic by replacing phosphate with tetrazole at carbon 6 to generate 
trehalose 6-tetrazole. DLS was used to determine if trehalose 6-tetrazole caused 
aggregation of T6PP. BmT6PP at 23 µM was incubated with 1 mM trehalose 6-tetrazole 
for 1 hour at 4 °C prior to collecting DLS measurements (Figure 4.5). The results show 
that trehalose 6-tetrazole does not cause BmT6PP aggregation as 100% of the mass has a 
radius of 4.4 nm (correlating to an approximate molecular weight of 108.6 kDa) with a 
polydispersity of 11.7%. At 800 µM, trehalose 6-tetrazole inhibits the initial velocity of 
BmT6PP with 1.8 mM T6P by 56% (Figure 4.5D). The initial velocities of BmT6PP- 
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catalyzed dephosphorylation of T6P are not linear, which was consistently observed when 
utilizing the Enzchek Phosphate assay. Normally, nonlinear velocities indicate greater than 
15% of substrate has been depleted or that product is inhibiting the reaction. However, 
product does not inhibit T6PP (see Section 4.3 Steady-State Kinetics of T6PP) and only 80 
µM of the 1.8 mM T6P (< 5%) was converted to product. Assuming competitive inhibition 
and using Equation 4.5, the KI of BmT6PP by trehalose 6-tetrazole is estimated to be 188 
µM, which is comparable to the KI of T6S at 82 µM. Given the structural similarity to 
trehalose 6-phosphate and trehalose 6-sulfate, it is probable that tetrazole is binding in the 
phosphate binding site. Future experiments will measure the KI of trehalose 6-tetrazole for 
T6PP by measuring the rate of T6PP-catalyzed T6P hydrolysis at various substrate 
concentrations in the presence of 0.5 x, 1 x, and 2 x KI trehalose 6-tetrazole. These data will 
be analyzed to verify the assumption of competitive binding. 
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Figure 4.5 Inhibition of T6PP-catalyzed hydrolysis of T6P by phosphate mimics. A) Spot 
tests of potential phosphate mimics. Phosphate mimics at 5 mM were incubated with 30 
nM StT6PP for 1 hour prior to the initiation of a 5-minute reaction with 1 mM T6P. The 
phosphate concentration was measured and normalized to the no inhibitor control. Error 
bars represent standard deviation for four replicates. B) Dose-response of StT6PP with 5-
phenyl-1H-terazole and 4-(5-nitrophenyl)-1H-tetrazole (0.390 – 20 mM) in a 5-minute 
reaction with 1 mM T6P. Error bars represent standard deviation of duplicate 
measurements. C) DLS data of BmT6PP in the presence of equimolar 5-phenyl 1H-terazole 
and 4-(5-nitrophenyl)-1H-tetrazole or 1 mM trehalose 6-tetrazole (~5xKI). Enzyme was 
incubated with inhibitor for 1 hour prior to data collection. D) Initial reaction velocities of 
BmT6PP with 1.8 mM T6P in the absence and presence of 800 µM trehalose 6-tetrazole. 
All reactions were performed at 25 °C in a buffer containing Tris pH 7.5 and greater than 
1 mM MgCl2. 
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4.4.3 Docking Studies of Tetrazole-Containing Compounds in T6PP 
Tetrazole and trehalose 6-tetrazole were computationally docked into the active site 
of StT6PP Figure 4.6). Tetrazole binds in the phosphate binding site and makes hydrogen 
bonds to loops I, II and III that are conserved in the HADSF. The first and fourth nitrogen 
form hydrogen bonds with the backbone C=O of Asp22 and the backbone NH of Gly61. 
Additionally, the second nitrogen makes hydrogen bonds with the side chain of Lys175. 
Trehalose 6-tetrazole docks into the same position as T6S, wherein the tetrazole does not 
bind in the phosphate binding site. As the sulfate moiety of T6S was not in the phosphate 
binding site in the StT6PP/T6S complex, tetrazole binding adjacent to the phosphate 
binding site may be an artifact of this structure. Trehalose 6-tetrazole was also docked into 
the apo and OGS-bound structures of StT6PP. However, the binding position of trehalose 
6-tetrazole did differ substantially. The trehalose moiety remained in the same position and 
the tetrazole moiety was not positioned into the phosphate binding site. The positioning of 
the tetrazole moiety outside the phosphate binding site could be an artifact of the docking 
algorithm. Experimental structural information of T6PP in complex with Mg2+ and 
trehalose 6-tetrazole is necessary.  
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Figure 4.6 A) Tetrazole and B) trehalose 6-tetrazole docked into the active site of StT6PP. 
StT6PP is displayed as a purple ribbon diagram with key residues shown as sticks. 
Tetrazole is shown as grey sticks, trehalose 6-tetrazole is shown as green sticks. Panel B 
shows T6S as purple sticks for comparison. 
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4.5 Inhibition of T6PP with CephC: A Cautionary Tale 
4.5.1 T6PP Inhibition by CephC 
CephC (Figure 4.9A) was identified as an inhibitor of BmT6PP from the Johns 
Hopkins University Clinical Compound Library (1600 molecules). Steady-state inhibition 
kinetics of Bm and Mm T6PP were performed in the presence of the commercially available 
CephC zinc salt (Figure 4.7). Data show CephC zinc salt decreases the apparent KM of 
BmT6PP but causes no change in vmax. These results are consistent with competitive 
inhibition and CephC inhibits T6PP with KI of 1.0 ±  5.2 x 10-5 µM for BmT6PP and an 
estimated KI of 68 µM for MmT6PP. The KI for MmT6PP was estimated using initial rates 
in the presence of 50 µM CephC and 56.25 µM and 225 µM T6P and Equation 4.5.  
 
Figure 4.7. Initial reaction velocities of A) BmT6PP- and B) MmT6PP-catalyzed 
hydrolysis of T6P vs T6P concentration in the presence of CephC. Reactions were 
performed at 25 °C in a Tris buffer at pH 7.5 containing at least 1 mM MgCl2. The 
concentration of phosphate generated over time was measured using the EnzChek 
Phosphate assays. A) Reactions initially contained at 125 nM BmT6PP, CephC (0, 0.25, 
0.50, 1.0 or 2.0 µM) and T6P (0.088-11.25 mM). Error bars represent duplicate 
measurements. B) Reactions initially contained 40 nM MmT6PP, CephC (0 or 50 µM) and 
T6P (28-225 µM). Data represent a single measurement. 
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4.5.2 Docking Studies 
CephC was docked into the active site of StT6PP to gain insight into the binding 
position of the inhibitor (Figure 4.8A). The b-lactam and thiopyran rings are positioned in 
the distal glucose binding site. The carboxylic acid and carboxylic ester substituents form 
hydrogen bonds with Arg134. The amino group of CephC is positioned by computation in 
the phosphate binding site and forms hydrogen bonds with conserved loops 1 and 2. There 
do not appear to be any interactions with the conserved Glu/Lys/Glu motif at the proximal 
subsite. Therefore, we speculate inhibitor affinity and specificity could be increased by 
creating interactions with the Glu/Lys/Glu motif.  
 
Figure 4.8 A) CephC (green sticks) and B) 5,6-indole-tetrazole (gold sticks) 
computationally docked into the StT6PP active site. StT6PP is shown as purple ribbons 
with key residues displayed as sticks and the Mg2+ shown as lime green sphere. Predicted 
hydrogen bonds are shown as cyan lines.  
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4.5.3 Optimization of CephC Scaffold 
First, six scaffolds based on CephC were designed to remove the b-lactam ring 
(Figure 4.9A). As b-lactam rings are highly reactive, we aimed to remove this system to 
enhance the tractability and facilitate synthesis of derivatives. The proposed scaffolds with 
substituents similar to CephC were computationally docked into the StT6PP structure and 
ranked according to the predicted binding energy and number of interactions with the 
Glu/Lys/Glu motif. The 5,6-indole scaffold was predicted to bind with the lowest energy 
at -9.2 kcal/mol and forms hydrogen bonds to Lys125 side chain, loops 1 and 4, Arg134 
side chain, and the backbone of the C1 loop. This scaffold was further modified to replace 
the amino group with the phosphate mimic tetrazole. The length of the linker between the 
amide group and tetrazole was optimized to three carbons via docking studies (herein the 
tetrazole modified 5,6-indole scaffold will be referred to as 5,6-indole-tetrazole). The 
tetrazole moiety of 5,6-indole-tetrazole is predicted to form hydrogen bonds with loops 1 
and 2 (Figure 4.8B). The initial velocities of BmT6PP-catalyzed hydrolysis of T6P were 
measured in the presence of 0, 15, 30 and 50 µM 5,6-indole-tetrazole (Figure 4.9B). Initial 
velocities measured with 30 µM and 50 µM inhibitor were similar skewing the global fit 
of the data to overestimate the KI. Data shows that varying the inhibitor concentration 
varies the apparent KM values but consistent vmax values are seen, indicating 5,6,-indole-
tetrazole is a competitive inhibitor. The KI for BmT6PP by 5,6-indole-tetrazole was 
determined to be 22 ± 0.3 µM. As some molecules with tetrazole were shown to cause 
BmT6PP aggregation, DLS measurement were collected with 23 µM BmT6PP in the 
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presence of 110 µM (~5 x KI) 5,6-indole-tetrazole (Figure 4.9C). Control and inhibited 
BmT6PP do not contain aggregates.   
 
Figure 4.9 New scaffolds based on CephC. A) Structures of Cephalosporin C and six 
proposed scaffolds to mimic Cephalosporin C. B) Steady-state inhibition of BmT6PP-
catalyzed hydrolysis of T6P by 5,6-indole-tetrazole. Reactions initially contained 65 nM 
BmT6PP, 5,6-indole-tetrazole (0, 15, 30 or 50 µM) and T6P (0.014 – 7.2 mM). Reactions 
were performed at 25 °C in a Tris buffer at pH 7.5 containing 1 mM MgCl2. Inorganic 
phosphate production was monitored over time using the Enzchek Phosphate assay. C) 
DLS data for BmT6PP in the absence and presence of 110 µM 5,6-indole-tetrazole. 
  
 
Additionally, a series of 24 CephC analogs was synthesized to probe the structure-
activity relationship of the amino substituent. Analogs maintained the CephC scaffold with 
carboxylic acid and carboxylic ester substituents but varied the amino substituent (Figure 
4.10). At an inhibitor concentration of 10 µM CephC analogs (10 x KI of CephC) as 
measured with 2.5 mM T6P substrate there was negligible inhibition of BmT6PP for all 
analogs. As some of the CephC analogs such as LL-03-162 D and LL-03-178 are merely 
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missing a methylene or amino group, it was surprising that they had no inhibitory effect. 
These data led us to doubt the validity of CephC as an inhibitor.  
 
Figure 4.10 Cephalosporin C analogs.  
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4.5.4 Divalent Cation Inhibition 
The results from the CephC analog screen were puzzling as many of the analogs 
were very similar to CephC. As T6PP is a magnesium dependent enzyme and CephC is 
sold as a zinc salt, the inhibition could be due to zinc competition with the Mg2+ cofactor. 
However, the coordination chemistry of Zn2+ and Mg2+ binding sites varies with Mg2+ 
preferentially coordinated by carboxylic acid containing residues and Zn2+ by histidine and 
cysteine [21]. As the T6PP Mg2+ binding site is composed of four aspartate residues, the 
likelihood of inhibition by Zn2+ seemed low. Moreover, CephC zinc salt inhibits T6PP in 
the low micromolar range which is indicative of specific binding. Nonetheless, inhibition 
of St and Bm T6PP was tested in the presence of ZnCl2 (Figure 4.11). In the presence of 
ZnCl2 concentrations greater than 125 µM, the BIOMOL green assay exhibited high 
background absorbance. At 125 µM ZnCl2, Bm and St T6PP were inhibited by 100% and 
by ~50%, respectively. It should be noted that all metal inhibition assays were conducted 
with a final concentration of MgCl2 equal to 1.9 mM. So, we conclude it is the Zn2+ that 
inhibits T6PP in CephC zinc salt, not the organic portion of CephC. The inhibition of 
BmT6PP was further analyzed via dose-response curves in the presence of other divalent 
cations. MgCl2 and LiCl were used as positive controls. All divalent cations showed 
inhibition. Preliminary dose response curves indicate divalent metals have IC50 in the 
following order: Cd2+ < Zn2+ < Cu2+ < Ni2+ < Co2+ < Ca2+ (Figure 4.11B). The preliminary 
data indicates Cd2+ and Zn2+ inhibit with low nanomolar IC50 values signifying tight binding 
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of the cations. This tight binding has not previously been seen in HADSF members and is 
intriguing assuming that the cations are competitive inhibitors of T6PP at the Mg2+ binding 
site. The affinities of T6PP for cations generally follow the Irving-Williams series of 
transition metal complexes (Mg2+ and Ca2+ (weakest binding) < Mn2+ < Fe2+ < Co2+ < Ni2+ 
< Cu2+ > Zn2+) with the exception of the inversion of Zn2+ and Cu2+. The inversion of Zn2+ 
and Cu2+ affinities may be a result of inaccuracies in the preliminary data. However, it is 
known that magnesium-binding proteins often preferentially bind zinc [22]. Cells prevent 
the mismetallation of magnesium-binding proteins by tightly controlling the zinc 
concentration via metal efflux, metal influx and metal sequestration [22, 23]. An alternative 
hypothesis is that the divalent metals may have an alternative binding site. Additional 
studies are necessary to characterize the binding site of divalent metals and understand 
their mode of inhibition of T6PP.  
 
Figure 4.11 Inhibition of T6PP by cations. A) Dose-response curves of Bm and St T6PP in 
the presence of ZnCl2. B) Dose-response curves of BmT6PP by divalent metal chlorides. 
MgCl2 and LiCl were used as positive controls. T6PP-catalyzed hydrolysis of T6P (2.5 
mM) in the presence of cations was measured after 5-minute reaction time. Error bars 
represent duplicate measurements.   
-8 -6 -4 -2
0.0
0.2
0.4
0.6
Log [ZnCl2] (M)
Ab
so
rb
an
ce
 a
t 6
20
 n
m
Bm
St
-8 -6 -4 -2
0.0
0.2
0.4
0.6
Log [metal] (M)
Ab
so
rb
an
ce
 a
t 6
20
 n
m
CaCl2
CdCl2
CoCl2
CuCl2
LiCl
NiCl2
MgCl2
ZnCl2
A B
 158 
4.6 Inhibition of T6PP with Closantel 
4.6.1 Kinetic Analysis  
Closantel was also identified as an inhibitor of BmT6PP via screening of the Johns 
Hopkins Clinical Compounds Library. Closantel is a nonpolar molecule with low solubility 
in aqueous solutions. Therefore, many attempts at collecting kinetic data were unsuccessful 
or required high concentrations of organic solvent in the reaction. Notably, BmT6PP shows 
a mild increase in activity in the presence of 25% DMSO (tested via the BIOMOL Green 
and Enzchek assays) and StT6PP maintains thermal stability in the presence 25% DMSO 
(determined via differential scanning fluorimetry). Hence, it is assumed up to 25% DMSO 
does not affect our measurements, but all experiments include a control reaction containing 
DMSO. 
First, a dose-response curve was acquired with BmT6PP in the presence of 0.089-
125 µM Closantel (25% DMSO at the highest Closantel concentration. Note: future 
experiments should use a constant DMSO concentration) and 1 mM T6P. A plot of 
response vs log [Closantel] shows decreased activity with inhibitor concentrations varying 
over four orders of magnitude, indicating non-hyperbolic binding (Figure 4.12A). 
However, the IC50 value can be estimated to be approximately 5 µM. Experiments aimed 
at determining the inhibition of Ce and Mm T6PP by Closantel also showed non-hyperbolic 
dependence on concentration; dose-response curves have Hill slopes of -1.9 and -6.7, 
respectively (Figure 4.12 C and D). The IC50 values for Ce and Mm are estimated at 15 and 
6 µM. Later experiments using the sodium salt of Closantel also showed a steep hill slope 
of -2.2 ; the IC50 is estimated near 5 µM for this set of experiments (Figure 4.12B).  
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Figure 4.12 Dose-response curves of T6PP-catalyzed hydrolysis of T6P in the presence of 
Closantel. T6PP and Closantel were incubated for 1 hour prior to initiating the reaction 
with T6P. A) BmT6PP (75 nM) inhibition by Closantel(0.089-15 µM) after 10 minutes in 
the presence of 1 mM T6P. B) BmT6PP (30 nM) inhibition by Closantel sodium salt (0.39-
25 µM) after 5 minutes in the presence of 2.5 mM T6P. C) CeT6PP (10 nM) inhibition by 
Closantel (2.0-125 µM) after 5 min in the presence of 1 mM T6P. D) MmT6PP (15 nM) 
inhibition by Closantel (0.78-100 µM) after 10 minutes in the presence of 1 mM T6P. Error 
bars represent duplicate measurements.  
 
As the dose-response curves indicate non-hyperbolic bonding, I first tested whether 
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equilibrium within the one-hour incubation prior to testing. Experiments using Bm, Ce, and 
Mm T6PP were performed over two-hour times courses. T6PP was incubated at room 
temperature with DMSO or Closantel for 5, 30, 60, 90 and 120 minutes. BmT6PP was also 
incubated for 180 and 240 minutes. BmT6PP shows no activity in the DMSO controls 
indicating the stock enzyme was not stable at 4 °C for four hours (experimental time points 
were performed in reverse order to initiate and quench T6PP activity simultaneously). Ce 
and Mm T6PP show a decrease in activity over time in the presence of Closantel (Figure 
4.13). CeT6PP is inhibited faster at higher Closantel concentrations than lower Closantel 
concentrations. The lag exhibited at the 30-minute time point for CeT6PP in the presence 
of 5 µM Closantel is an artifact, as this point (as well as the positive control) is above the 
linear range of the BIOMOL Green assay. These results are consistent with slow binding 
inhibition. Slow binding inhibitors show two rates when measuring inhibition, an initial 
rate (vi) and a steady-state rate (vs) with a rate constant (kobs) that describes the transition 
from vi to vs. In the time course for CeT6PP, the amount of product (PO43-) produced by 
T6PP in the same amount of time continues to decrease with longer incubations with 
Closantel indicating that vs has not been reached after two hours. For the Closantel 
concentration series with MmT6PP, increasing inhibitor concentrations do not exhibit 
increased inhibition, which is inconsistent with slow biding inhibition. Additionally, the 
inhibitory response is subtle. Experiments should be repeated with higher Closantel 
concentrations. 
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Attempts at determining the equilibration time between T6PP and Closantel were 
unsuccessful as T6PP is not stable at room temperature for several hours. Future efforts are 
planned to optimize protein stability utilizing osmolytes such as glycerol or sarcosine and 
decreasing the incubation and reaction temperature. As Closantel binds very slowly but is 
potent, necessitating low concentration of inhibitor, the experiment must be optimized for 
inhibitor concentration, equilibration time, and enzyme stability in order to determine the 
inhibited steady-state velocity. Additionally, to determine the KI, the vs and vi must be 
recorded. Hence, the continuous Enzchek phosphate assay should be utilized. Furthermore, 
it must be confirmed that Closantel is a reversible inhibitor not an irreversible inactivator. 
This information can be obtained by incubating T6PP with Closantel and testing the 
activity before and after dialyzing the enzyme/inhibitor complex in fresh buffer.   
 
Figure 4.13 Slow binding inhibition of Closantel with T6PP A) CeT6PP (40 nM) and B) 
MmT6PP (60 nM) were incubated with Closantel (1.25- 10 µM) for up to 2 hours at 25 °C. 
Reactions were simultaneously initiated by the addition of 1 mM T6P and quenched after 
5 minutes with BIOMOL Green reagent.  
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4.6.2 Closantel Analogs 
The inhibitor structure-activity relationship of Closantel was investigated using a 
series of 27 Closantel analogs. BmT6PP (75 nM) and analogs (10 μM) were incubated for 
one hour prior to testing the activity of BmT6PP with 1 mM T6P. The Closantel control 
showed 47% inhibition. Analogs 3 and 7 (CloA3 and CloA7) showed more than 70% 
inhibition. In CloA3 and CloA7 the linkage between rings B and C is changed from a 
cyano-substituted methine to an ether linkage. The ether linkage was incorporated in many 
analogs (1-9, 25-31) and generally did not affect affinity. Additionally, the chloro- and 
methyl-substituents are removed from ring B and the chloro-substituent of ring C is 
modified to a methyl (CloA3) or removed (CloA7). The inhibition of CloA3 and CloA7 
was further characterized by a dose-response curve. The binding of both analogs is 
hyperbolic with IC50 values of 57 ± 1 µM and 64 ± 1 µM. respectively. Although these IC50 
values are larger than the estimated Closantel IC50 value, this could be due to variations in 
slow binding characteristics. However, further investigation of the time-dependency of 
CloA3 and CloA7 is required.  
 
 163 
 
Figure 4.14 Inhibition of T6PP by Closantel analogs. A) Phosphatase activity of BmT6PP 
(75 nM) in the presence of 10 µM Closantel or Closantel analog. B) Dose-response curve 
of CloA3 and CloA7. BmT6PP was incubated with inhibitors for 1 hour prior to the 
initiation of a 10-minute reaction by addition of 1 mM T6P. Error bars represent the 
standard deviation of duplicates.  
 
Additionally, structure-activity trends can be identified by this screen. Removal of 
substituents on ring A lead to molecules that show little potency (analogs 25-31). However, 
the iodine moeties can be modified to hydroxyl groups (analogs 23 and 24) or chlorines (4, 
31-35) with only small decreases in affinity. 
 
Table 4.3 Closantel Analogs. Closantel is shown in the top left corner. Rings are labeled 
A, B and C for identification.  
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The steady-state kinetics of T6PP were confirmed for Bm, Mt and St T6PP and 
determined for MmT6PP. T6PP has low affinity for T6P in the 100-1000 µM range and a 
catalytic efficiency near 104 M-1s-1. The affinity for substrate is due to synergy of binding 
the trehalose and phosphate moieties. Therefore, inhibitors of T6PP must have a bidentate 
binding motif.  
Current phosphate mimics are generally charged and are unfavorable substituents 
for therapeutic purposes. Tetrazole, an uncharged 5-membered heterocycle, was identified 
as a phosphate mimic via computational screening of fragment libraries into phosphatase 
active sites. Tetrazole is a common carboxylate mimic incorporated into pharmaceuticals, 
e.g. losartan and candesartan. Replacement of the phosphate group on T6P with a tetrazole 
yielded an inhibitor with an estimated inhibition constant similar to that of T6S. As T6PP 
binding to T6P requires synergy between the trehalose and phosphate binding sites, the 
inhibition of trehalose 6-tetrazole suggests trehalose and tetrazole are binding in the active 
site. Tetrazole will be incorporated onto future inhibitors.  
Two inhibitors of BmT6PP were identified from the Johns Hopkins University 
Clinical Compound Library, CephC and Closantel. After determining the inhibition 
constant of CephC for BmT6PP to be single digit micromolar, a series of compounds with 
the CephC scaffold and similar, but more tractable, scaffolds of CephC were synthesized. 
Although the scaffolds designed based on CephC docking showed inhibition, the molecules 
with the original CephC scaffold did not. As commercially available CephC is a zinc salt, 
inhibition by zinc ions was tested and determined to be the mechanism of inhibition for 
CephC zinc salt. However, prior to gaining the knowledge that zinc, not CephC, inhibits 
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T6PP, a molecule based on the CephC scaffold was designed. This molecule, 5,6-indole-
tetrazole, also incorporated a tetrazole moiety and was determined to have a KI for BmT6PP 
of 20 µM. Although experimental data guided the design of 5,6-indole-tetrazole, the CephC 
inhibition data was flawed and it appears we have de novo created an inhibitor. Future 
efforts will aim to further optimize the affinity for T6PP.  
Closantel was determined to be a slow-binding inhibitor with an IC50 in the single 
digit micromolar range. Attempts to understand the steady-state binding were undermined 
by the instability of the enzyme over time. Future work will aim to stabilize the enzyme 
and determine its inhibition constant and characterize the slow-binding mechanism. 
Closantel analogs were also screened for their inhibitory effects on T6PP. Two analogs, 
CloA3 and CloA7 appeared to have greater potency than Closantel. However, the IC50 
values were greater than that of Closantel. The difference could be due to variable slow-
binding features. Additional studies will aim to characterize the inhibition and slow binding 
characteristics of CloA3 and CloA7.  
Table 4.4 Summary of small-molecule inhibition of BmT6PP catalyzed hydrolysis of T6P 
Trehalose KI > 10 mM  
Sulfate KI > 10 mM 
Trehalose 6-tetrazole KI ~ 188 µM 
CephC zinc salt KI 1.0 ± 5.2 x 10-5 µM  
5,6-indole-tetrazole KI 22 ± 0.3 µM 
ZnCl2 IC50 < 100 nM 
Closantel  IC50 ~5 µM 
CloA3 IC50 57 ± 1 µM  
CloA7 IC50 64 ± 1 µM 
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Overall, small molecules with various scaffolds were used to inhibit T6PP. Lead 
candidates include 5,6-indole-tetrazole, Closantel, CloA3 and CloA7. Tetrazole is 
proposed as a phosphate mimic and will be incorporated into lead candidate scaffolds. 
Future efforts aim to experimentally characterize the binding position of inhibitors so 
substituents can be rationally placed to increase specificity and affinity for T6PP. These 
efforts are aimed to generate therapeutics for tuberculosis and lymphatic filariasis.  
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APPENDIX 1 EXPRESSION AND PURIFICATION OF DULLARD 
A1.1 Introduction 
A1.1.1 Haloalkanoic Acid Dehalogenase Super Family 
The haloalkanoic acid dehalogenase superfamily (HADSF) is a large enzyme 
superfamily represented in all domains of life. This superfamily was named after the 
function of the first discovered enzyme, but is a misnomer as the family is dominated by 
phosphotransferases. Thus far, activities of HAD members have been classified into 
phosphohydrolases, ATPases, phosphomutases, phosphonatases, and dehalogenases [1–4]. 
The HADSF contains a core catalytic domain comprised of a unique Rossmann-
like fold containing parallel b-strands flanked by a-helices. The active site is a concave 
surface at the C-terminal end of the central beta sheet and contains five conserved amino 
acids located on four loops that coordinate a catalytic Mg2+ to stabilize the substrate 
phosphoryl charge. In the first loop, there are residues that form one helical turn and 
comprise two aspartates (the DxDGT motif). Serine or threonine on loop 2, lysine or 
arginine on loop 3, and two or three aspartate or glutamate residues on loop 4 comprise the 
remainder of the active site [5]. 
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Figure A1.1 Examples of the HADSF. C1 and C2 cap insertion locations are shown in 
sequence schematics. The core domain is shown as blue ribbons while the cap is in yellow. 
The catalytic Mg2+ is shown as a silver sphere. Figure courtesy of Nick Silvaggi, Ph.D.  
 
HADSF members contain another domain, termed the cap domain, which provides 
substrate specificity and desolvation of the active site. There are three cap types, C0, C1, 
and C2, which are used to structurally group HADSF members. C0 and C1 caps are inserted 
after the first beta strand of the Rossmann fold, specifically in the b-hairpin turn. C2 caps 
are inserted after the third beta-strand [6] (Figure 1). C0 caps are minimal, often containing 
only a loop or two short beta strands; C1 caps are a-helical; C2 caps contain both a-helices 
and b-sheets. C2 caps are further characterized into C2a and C2b due to the parallel or 
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antiparallel b-sheet architecture, respectively. The C1 and C2 caps have a flexible linker 
between the cap and core allows a rigid-body motion between the two domains [7].  
 
A1.1.2 Lipin  
The lipin family is part of the HADSF and found in many species from yeast to 
humans. In humans, three lipin isoforms have been identified (lipin1-3). Lipin1 is the best 
characterized and is 890 amino acids in length. There are two known domains at the N- 
and C-termini, termed the N-Lip (residues 1-114) and C-Lip (674-830) domains, 
respectively [8]. The C-Lip domain which comprises the HADSF domain that catalyzes 
the dephosphorylation of phosphatidic acid (PA) to form diacylglycerol (DAG) [9]. The 
intervening sequence between the domains is hypothesized to be unstructured. However, 
throughout the sequence, there are a few motifs of interest that regulate lipin function. 
There are two sumoylation sites (IKEE and IKHE) at residues 565 and 595 [10]. As 
sumoylation is linked to nuclear localization and transcriptional activation/repression, it is 
inferred that lipin moves through the nuclear membrane. Lipin is able to access the nucleus 
through nuclear pore complexes due to the nuclear localization sequence at residue 154. 
Once inside the nucleus, lipin interacts with PGC1-α, a transcriptional activator, to express 
PPARα, via the LXXIL motif in the HADSF domain [11].   
Because lipin is a transcriptional coactivator that regulates the expression of genes 
involved in lipid metabolism and converts PA to DAG during the penultimate step to 
triacylglycerol synthesis, it is an important protein for cellular function. Therefore, 
disruption of the activity of this protein can lead to metabolic disorders. In mice, it has been 
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shown that a lipin deficiency leads to “fatty liver dystrophy.” In neonatal mice, the disease 
causes an enlarged liver, hypertriglyceridemia, a decreased lipoprotein lipase activity in 
adipocytes and altered gene expression in the liver for proteins involved in lipid 
metabolism [12]. In adult mice, fatty liver dystrophy leads to impaired movement due to 
underdeveloped nerve cells [13] and the lack of functional adipocytes [14]. Additionally, 
lipin deficiency in mice leads to a build-up of glucose in adipose and skeletal muscle tissues 
leading to insulin resistance [15]. Conversely, overexpression of lipin can lead to obesity 
[16].   
 
 
Figure A1.2 Lipin Pathways. Dullard regulates Lipin during the metabolism of 
triacylglycerol (TAG). Lipin also acts as a transcriptional coactivator for genes involved in 
lipid metabolism.  PA, phosphatidic acid; DAG, diacylglycerol. 
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A1.1.3 Dullard  
Dullard is another member of the HADSF. It is responsible for the regulation of 
lipin by dephosphorylation. Phosphorylated lipin is still active on PA in vitro, but in vivo 
cells without dullard show the same phenotype as those lacking lipin [17]. Therefore, if 
lipin is phosphorylated it prevents the protein from accessing the endoplasmic reticulum 
and nuclear membranes, hence its substrates; thus lipin is inactive [18]. 
Although, the structure of dullard is unknown, genome sequencing and protein 
characterization have revealed pieces of its function and structure. First, there is a helix 
predicted from primary sequence to be a transmembrane helix at the N-terminus of dullard. 
This leads to the conclusion that it is a membrane associated protein. Additionally, Harris 
et al. discovered that pSer106 of lipin1 is the major site of insulin-stimulated 
phosphorylation [19]. Then, Wu et al. determined that dullard preferentially 
dephosphorylates pSer106 of lipin1 [20]. Together, these results give evidence that the 
HADSF domain of dullard regulates lipin1 through dephosphorylation of Ser106.   
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Figure A1.3 Homology model of dullard based on the structure of Scp1 (PDB code: 1TA0; 
45% sequence identity). The C0 type cap is highlighted in magenta and the conserved HAD 
domain is in blue. 
 
A1.1.4 Aims 
As lipin is an important protein for proper organismal function, we seek to find the 
molecular structures of lipin, dullard, and their complex. This will further elucidate the 
intricacies of recognition between lipin, dullard, and the membrane.  
Overall, this research will aid the understanding of the interactions of lipin and 
dullard, their respective substrates, and their cellular environment. activities The 
experiments in this aim are designed to address how Dullard recognizes a specific 
phosphorylation site on lipin1 and how it catalyzes the hydrolysis of the phosphoSer at this 
site. We focused on determining the X-ray crystal structure of Dullard and peptide liganded 
Dullard to interpret the findings from the biochemical studies. The experiments in this 
appendix were designed to address how Dullard recognizes a specific phosphorylation site 
on lipin1 and how it catalyzes the hydrolysis of the phosphoSer at this site. We are focused 
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on determining the X-ray crystal structure of Dullard and peptide liganded Dullard to 
interpret the findings from the biochemical studies. 
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A1.2 Methods and Results 
Experiments were aimed at finding conditions and constructs of dullard for reliable 
expression and purification to ultimately yield diffraction quality crystals. Substantive 
efforts were made to identify constructs and expression conditions to produce soluble 
protein as well as the production of dullard bearing the transmembrane helical region (TM). 
In order to express dullard, numerous approaches were taken including:  1) utilizing 
orthologs from Homo sapiens, C. elegans and Nemostella vectensis, 2) designing 
constructs with and without the transmembrane helix (TM), 3) altering the construct to 
include solubility tags (GB1, MBP and SUMO), 4) altering the expression strain (BL21, 
SoluBL21, arctic express, LMG194, and OverExpress C41 and C43 with and without 
pLysS), 5) varying the expression conditions (time, temperature and autoinduction). 
Seventeen systems were successful in overexpressing dullard (Table A1.1). Once the 
protein was expressed, we sought to obtain pure, untagged, stable protein. Since all 
expressed constructs contain a His-tag, affinity chromatography was the preferred 
purification method. However, dullard was unstable once the cells were lysed. Methods to 
obtain folded protein included 1) refolding 2) buffer optimization using a thermofluor 
screen 3) detergent extraction from the membrane. First, I focused on purifying full-length 
H. sapiens dullard with a His-tag (pDEST17) from SoluBL21 cells. However, it was 
determined that I was purifying an endogenous SoluBL21 protein of similar size. I was 
able to consistently purify SUMO-tagged full-length N. vectensis dullard from the 
membrane into the detergent dodecylphosphocholine. Although pure, dynamic light 
scattering showed the enzyme was 33% polydispersed (note that the high polydispersity 
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could be due to the variations in the number of detergent molecules surrounding the 
protein). We aim for a polydispersity of less than 25% prior to crystallization, the enzyme 
needed to be further stabilized. We attempted to remove the SUMO tag via an engineered 
TEV cleavage site and utilizing SUMO protease, but the detergent interfered. We also 
attempted to screen buffer optimization via thermofluor assay. The assay showed a high 
background signal indication the transmembrane helix was binding the dye or the protein 
was already unfolded. Hence, circular dichroism was attempted to determine the percent 
of unfolded residues. However, buffer interference prevented clean spectra from being 
determined and attempts at switching buffers yielded aggregated protein. As 
crystallographic studies using this construct seemed unlikely to succeed, we attempted 
kinetic studies. Unfortunately, this detergent interfered with the malachite green assay to 
determine phosphatase activity. Attempts to switch to a more economical and assay-
compatible detergent also yielded protein aggregation. Unfortunately, it appears this 
protein construct is not amenable to crystallographic or kinetic studies. 
In summary, SUMO-tagged full-length dullard from N. vectensis expressed in 
many several cell lines, was solubilized in detergent from the membrane fraction of cell 
lysate, and purified without contaminants.  
 
 
 Table A1.1 Conditions for dullard purification. 
Organism Construct Vector	 Cell	Line	 Expression*	 Soluble	 Purification	 Tag	Separation	
H. sapiens 46-244 pTH34	 Arctic Express moderate yes contaminants  
  	 Overexpress C43 low	 no	 	  
 1-244 pDEST17	 SoluBL21 moderate	 yes	 yes unsuccessful 
  pSUMO	 Arctic Express none	 	   
  	 LMG184 none	 	   
  	 OverExpress C41 low	 no   
  	 OverExpress C41 pLysS low	 no   
  	 OverExpress C43 pLysS none	 	   
  	 OverExpressC43 none	 	   
  	 SoluBL21 low	 no   
  pTH34	 Arctic Express none	 	   
  	 LMG184 none	 	   
  	 OverExpress C41 none	 	   
  	 OverExpress C41 pLysS none	 	   
  	 OverExpress C43 pLysS none	 	   
  	 OverExpressC43 none	 	   
  	 SoluBL21 none	 	   
N. vectensis 43-253 pDEST17	 BL21	 none	 -	 	  
  	 SoluBL21	 low	 yes	(10%)	 	  
  pSUMO	 Artic	Express	 moderate	 yes	(20%)	 unsuccessful  
  	 BL21	 moderate	 no	 	  
  	 SoluBL21	 low	 yes	(60%)	 contaminants  unsuccessful 180 
   pTH-34	 BL21	 moderate	 no	 	  
  	 SoluBL21	 low	 yes	(10%)	 	  
  	 Artic	Express	 high	 yes	(90%)	 unsuccessful  
 1-253 pSUMO	 Arctic Express none	 	   
  	 LMG184 none	 	   
  	 OverExpress C41 low	 yes**   
  	 OverExpress C41 pLysS low	 yes**   
  	 OverExpress C43 pLysS none	 	   
  	 OverExpressC43 none	 	   
  	 SoluBL21 low	 yes** yes unsuccessful 
  pTH34	 Arctic Express none	 	   
  	 LMG185 none	 	   
  	 OverExpress C41 none	 	   
  	 OverExpress C41 pLysS none	 	   
  	 OverExpress C43 pLysS none	 	   
  	 OverExpressC43 none	 	   
  	 SoluBL21 none	 	   
C. elegans 54-276 pMBP	 SoluBL21	 low yes contaminants  
* Protein expression was tested in most cell lines using IPTG induction 37 °C for 3 hours, 15 °C for 16 hours and autoinduction 
at 10 °C and 37 °C.  
** Protein was solubilized in detergent from membrane fraction of cell lysate. 
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APPENDIX 2 CRYSTALLIZATION OF PGLD/INHIBITOR COMPLEX: AN OPTICAL ILLUSION 
A2.1 Introduction 
The sugar N,N’-diacetylbacillosamine (diNAcBac) is utilized exclusively in 
bacteria as the reducing end of glycoproteins, the core of lipopolysaccharides, and in 
capsular polysaccharides [1]. DiNAcBAc is synthesized as the nucleotide activated sugar 
from UDP-N-acetylglucosamine (GlcNac) utilizing a dehydratase, aminotransferase, and 
acetyltransferase. In C. jejuni, these enzymes are denoted as PglF, PglE, and PglD, 
respectively [1]. It has been shown that PglD gene knockdown variants decrease protein 
glycosylation in vitro and bacterial colonization in vivo [2]. Hence, PglD is a target for 
small-molecule inhibition.  
To aid in inhibitor design, PglD has been biochemically and structurally 
characterized. PglD catalyzes the N-acetylation of UDP-2-acetamido-4-amino-2,4,6-
trideoxy-R-D-glucopyranose (UDP-4-amino-sugar) using acetyl Coenzyme A (AcCoA) as 
the acetyl donor to form diNacBac and Coenzyme A (CoA). Apparent steady state-
parameters of PglD for UDP-4-amino-sugar are KM = 410 µM, kcat = 8050 s-1 and kcat/ KM 
= 2.0 x 107 M-1s-1 [3]. PglD binds AcCoA with slightly higher affinity, KM = 194 µM, than 
UDP-4-amino-sugar, but, as expected the kcat and kcat/ KM do not differ from those for 
AcCoA at 1100 s-1 and 5.5 x 107 M-1s-1 [4]. Structures have been determined in the presence 
of UDP-4-amino-sugar and AcCoA to 2.3 Å and 1.8 Å resolution. PglD is a biological 
trimer with an N-terminal a/b domain and a C-terminal left-handed b-helix (LbH) domain. 
The AcCoA binding site is located at the interface of the subunits between the LbH 
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domains. The UDP-4-amino-sugar binding site extends from the acetyl group of AcCoA 
at the interface of the a/b and LbH domains [5]. 
Inhibitors of PglD were identified in the Imperiali lab at MIT using small molecule 
and fragment high-throughput screening. Lead molecules were optimized to generate 
potent (IC50 values in nanomolar range), competitive inhibitors of AcCoA. The crystal 
structure of PglD bound to an inhibitor with an IC50 of 2.2 µM, 5-methyl-4-(methylamino)-
2-phenethylthieno[2,3-d]pyrimidine-6-carboxylic acid (I17) was determined to 1.94 Å 
resolution [6]. This scaffold was optimized in the Imperiali lab to decrease the IC50 to 15 
nM by substituting the carboxylic acid for a tetrazole, introducing an amine group to the 
methyl substituent and incorporating a nitrogen into the phenyl substituent (herein the 
optimized inhibitor will be referred to as Itet). I aimed to determine the structure of PglD 
in complex with Itet.  
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A2.2 Materials and Methods: Crystallization, Data Collection, Structure Solution 
and Refinement 
Initial crystallization conditions that produced rod-shaped crystals were identified 
from the Hauptmann Woodward Institute Standard Protein Screen [7] (Figure 1). The 
condition comprised 200 nL PglD/inhibitor solution (6 mg/mL PglD and 0.55 mM 
inhibitor) with 200 nL well solution containing 50 mM HEPES pH 6.8, 15% PEG 3350, 
and Silver Bullets reagent 25 (Hampton Research) (0.25% w/v benzamidine hydrochloride, 
0.25% w/v L-carnitine hydrochloride, 0.25% w/v L-cystine, 0.25% w/v L-ornithine 
hydrochloride, 0.02 M HEPES sodium pH 6.8) under paraffin oil. Crystals were optimized 
via hanging-drop vapor diffusion at 17 °C to obtain final conditions with well solution of 
26% PEG3350 and 50 mM HEPES pH 7.0 (500 μL total well volume); the drop was set 
up with 2 µL of 6 mg/mL protein/0.55 mM Itet, 2 µL well solution, and 2 µL Silver Bullets 
25. Crystals were passed through paratone prior to cryo-cooling in liquid nitrogen.  
Data were collected on an Eiger-16M Pixel Array detector at the Advanced Photon 
Source (APS) on the Northeastern Collaborative Access Team (NECAT) beamline 24-ID-
E at 12.66 keV (0.979 Å). The data collection strategy was guided by Rapid Automated 
Processing of Data (RAPD) and consisted of exposing 180° data at an oscillation range of 
0.4° with a detector distance of 340 mm. Data were indexed and integrated using X-ray 
Detector Software (XDS) [8], with subsequent scaling and merging via Aimless in the 
program suite CCP4 [9]. Molecular replacement utilizing the coordinates of the protomer 
of PglD PDB ID 5T2Y with water and ligands removed was performed using Phaser in 
Phenix [10] and resulted in an initial model with an LLG of 6036 and TFZ of 51.3. 
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Refinement of the model against the electron density was performed in Phenix Refine with 
XYZ coordinate and real-space refinement, and group and individual B-factor refinement. 
To de-bias data, simulated annealing was performed prior to addition of waters. The 
inhibitor was placed in the Fo-Fc difference electron density map using LigandFit in 
Phenix with an overall CC of 0.685 when Rwork/Rfree were 0.192/0.224. Ligand restraints were 
created in Phenix Elbow and manually edited in REEL [11]. Models were manipulated 
manually in Coot [12] between refinements. Final data collection and refinement statistics 
are presented in Table 1.  
 
Figure A2.1 Initial crystal of C. jejuni PglD from Hauptmann Woodward Institute standard 
protein screen condition comprising 50 mM HEPES pH 6.8, 15% PEG 3350, and Silver 
Bullets reagent 25. 
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Table A2.1 X-ray Data Collection and Refinement Statistics 
Data Set Statistics 
Wavelengths (Å)  0.979 
Space group  P63 
Unit cell dimensions (Å)  a=b=106, c=46.9 
Solvent content (%)  65.5 
Vm (Å3/Dalton)  3.56 
Molecules per ASU  1 
No. of total/unique reflections  162131/16225 
Resolution (Outer Shell)  91.39-2.16 (2.23-2.17) 
I/σ   9.5 (1.8) 
Completeness   100.0 (100.0) 
Multiplicity   10 (8.9) 
Rmerge   0.150 (1.30) 
CC ½  0.998 (0.706) 
Refinement Statistics 
Resolution range (Å)  41.71 – 2.16 (2.22 – 2.16) 
Unique reflections  16189 
Test set  1613 (10%) 
Rwork  0.181 (0.239) 
Rfree  0.210 (0.289) 
Total Waters  98 
Wilson B-factor  35.4 
Mean B factor (Å2) 
     Protein 
     Solvent 
     Inhibitor 
 
 
38.4 
44.2 
55.7 
RMSD         
     Bond length (Å) 
     Bond angle (°) 
 0.005 
0.735 
Ramachandran Analysis (%) 
     Favored 
     Allowed 
 
 
 
96.9 
3.11  
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A2.3 Results and Conclusions 
 
A2.3.1 Overall Structure 
The crystallographic asymmetric unit of the PglD complex determined in this study 
consists of a single subunit exhibiting an N-terminal Rossmann fold (residues 1-71) and a 
C-terminal LbH domain (residues 76-195).  The biological unit of PglD is a trimer and can 
be displayed using symmetry mates (Figure A2.2). This suggests that each subunit in the 
biological assembly is highly similar to the other monomers.  
 
Figure A2.2 Trimer of PglD bound to inhibitor. Monomers are shown as ribbons, colored 
in cyan, light blue and purple. Itet molecules are shown as sticks.  
 
A2.3.2 The Bait- Placement of the Inhibitor 
Itet was fit into the Fo-Fc electron density map and placed between two monomers 
of PglD in the AcCoA binding site (Figure A2.3). Superposition of this structure with that 
from PglD in complex with I17 (PDB 5T2Y) resulted in an RMSD score of 0.36 and caused 
the Itet to overlay with the inhibitor  from the published complex in the same location and 
with similar orientation (Figure A2.4), indicating the overall binding location was correct. 
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The tetrazole, core, and pyridine are well defined by density with an overall B-factor of 
55.7 for the ligand (surrounding residues B-factor range 32.6-45.3) (Figure A2.5).  
 
Figure A2.3 The inhibitor binding site. Inhibitor is modeled in the 2Fo-Fc density map 
contoured at 2σ shown as gray mesh. The two monomers of PglD are displayed as sticks 
with carbons colored cyan and light blue. Inhibitor is displayed as gray sticks. 
 
 
Figure A2.4 Overlay of Itet (gray) and I17 (green) displayed as sticks.  
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Figure A2.5 Inhibitor colored by B-factor with Fo-Fc density omit map contoured to 2σ 
shown as gray mesh.  
 
There is unmodeled electron density opposite the pyridine ring (Figure A2.6). 
Attempts to model the density include rotating the inhibitor by 180° and refining. This 
model was unsatisfactory because neither R-group was placed into density. Additionally, 
all components of the crystallization cocktail were also modeled into this density. No 
ligand produced an overall CC greater than 0.8, nor was a singular ligand’s fit significantly 
better than the others. We concluded that a mixture of molecules from the crystallization 
milieu are bound here and therefore had left region this region unmodeled. There is a 
smaller region of unmodeled density near the tetrazole that had also been left unmodeled.  
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Figure A2.6 Unmodeled density near Itet. PglD residues and inhibitor are displayed as 
sticks in the 2Fo-Fc electron density map contoured at 2.0σ shown as grey mesh. The Fo-
Fc electron density map contoured at 2.6σ is shown as a green surface.   
 
A2.3.3 Inhibitor Binding  
The inhibitor as refined is positioned between monomers of PglD. Hence, 3 
inhibitors bind to the homotrimer. The ligand is stabilized by hydrogen bonds from one 
monomer and van der Waals interactions from the other monomer. The tetrazole ring forms 
hydrogen bonds to Ser136 (3.1 Å) and the backbone amine of Ile155 (3.1 Å). Additionally, 
Phe152 and tetrazole create a T-shape pi stacking interaction with an angle of 73.4° and 
distance of 3.5 Å. The sulfur and a nitrogen from the thienopyrimidine core form hydrogen 
bonds to the amine of Gly173 (3.78 and 3.3 Å, respectively). The nitrogen of the pyridine 
makes hydrogen bonds to the hydroxyl of Gly173 and amine of Gly189 through a water 
molecule (Figure A2.7A). Val188 and Gly172 contribute hydrophobic interactions from 
this monomer. Four residues from the other monomer contribute hydrophobic interactions, 
including Val160, Pro161, Ile178, and Pro191 (Figure A2.7B).  
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A.      B. 
         
 
Figure A2.7 Interactions between PglD and Itet. Residues and inhibitor are displayed as 
sticks with PglD carbons colored cyan and light blue for each monomer and inhibitor 
colored gray. Hydrogen bonds displayed as orange lines. In B, van der Waals interactions 
displayed as gray lines.  
 
A2.3.4 Comparison of inhibitor interactions to 17  
As previously shown in Figure A2.4, the Itet and I17 bind in the same location. 
However, the IC50 of Itet is approximately 150-fold lower than that of I17. The inhibitor 
maintains all the interactions seen with I17 (Figure A2.8) and generates new interactions 
with PglD. The additional hydrogen bond mediated through a water and the T-shaped pi 
stacking in the PglD/Itet complex could account for the increased affinity.  
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Figure A2.8 Interactions between PglD and I17. PDB 5T2Y modeled as sticks. Monomers 
are colored in cyan and light blue with I17 colored dark green. H-bonds and hydrophobic 
interactions are displayed as orange and gray lines, respectively.  
 
A2.3.5 The Switch- PglD/CoA Complex 
As shown in section  
A2.3.2 The Bait- Placement of the Inhibitor, the model of Itet did not account for 
all of the electron density at the AcCoA biding site. Therefore, the substrate, AcCoA was 
modeled into the Fo-Fc map. AcCoA was placed into the AcCoA active site with an overall 
CC of 0.745 and it fit into the electron density well. Therefore, we establish substrate or 
product is bound to the enzyme. Protein from the purification preparation used to 
crystallize the complex was analyzed by HPLC for the presence of substrate/product; ~ 
40% of protein molecules were bound to CoA product. It is unexpected to observe CoA 
bound to PglD because 1) CoA was not added during purification thus PglD co-purified 
with product bound in the active site and 2) the KM for AcCoA is >10,000-fold greater than 
the IC50 for Itet and the corresponding product would be expected to bind with low affinity. 
A B 
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The low concentration of CoA purified with PglD should have been competitively 
displaced by the high concentration (2 x molar concentration of PglD at 275 µM) of Itet. 
The occupancy of CoA was refined to determine if some molecules could contain Itet. 
However, the occupancy was high at 0.84 indicating that only molecules bound to CoA 
were introduced into the crystal lattice. The structure of the PglD/CoA complex has 
previously been published by Rangarajan et al. [13].  
 
Figure A2.9 CoA modeled into electron density. CoA is displayed as pink sticks in the 
2Fo-Fc electron density map contoured at 2.0σ shown as grey mesh. 
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A2.4 Current Progress and Future Directions 
Progress has been made to optimize the purification of PglD to ensure the enzyme 
is CoA-free. Co-crystallization is ongoing with efforts focused on reproducing crystals 
from published conditions. Additionally, crystals using CoA-free enzyme have been 
reproduced in the conditions described in section A2.2 Materials and Methods: 
Crystallization, Data Collection, Structure Solution and Refinement. Several conditions 
from the Hampton Index high-throughput screen were also identified and efforts to 
reproduce them are underway. The crystallographic structure of PglD and Itet will provide 
valuable insight as to why the introduction of several nitrogen-containing substituents 
caused a 150-fold decrease in activity compared to I17. 
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